



(51) International Patent Classification:

C12N 15/113 (2010.01) C07H 21/02 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2020/049056

(22) International Filing Date:

02 September 2020 (02.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/895,217 03 September 2019 (03.09.2019) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: TU, Ho-Chou; 675 West Kendall Street, Henri
A. Termeer Square, Cambridge, MA 02142 (US).

MCININCH, James; 675 West Kendall Street, Henri A.
Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: LU, David; Lando & Anastasi, LLP, 60 State Street,
23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

(57) Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.



COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

Related Applications

5 This application claims priority to U.S. provisional application number 62/895,217, filed on September 3, 2019. The entire content of each of the foregoing application is hereby incorporated herein by reference.

Sequence Listing

10 The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on August 27, 2020, is named A2038-7232WO_SL.txt and is 221,086 bytes in size.

Field of the Disclosure

15 The disclosure relates to the specific inhibition of the expression of the LECT2 gene.

Background

20 Amyloidosis is a group of diseases characterized by deposition of insoluble fibrous protein aggregates, called amyloids, in organs or tissues. Amyloids can form from mutant or wild type proteins. One system of nomenclature for amyloid diseases uses an abbreviation for the protein that forms amyloid deposits, preceded by the letter "A." Thus, for example, ALECT2 is the abbreviation for an amyloidosis involving deposit of amyloids formed from leukocyte cell derived chemotactic factor-2 (ALECT2).

25 LECT2 amyloidosis (ALECT2) is one of the most recently discovered types of amyloidosis. LECT2 amyloidosis has been observed in individuals with renal or hepatic amyloidosis. This form of amyloidosis can present with nephrotic syndrome or with liver involvement (*e.g.*, hepatitis, *e.g.*, chronic hepatitis). It may be particularly prevalent in Mexican Americans and/or individuals who are homozygous for the G allele encoding valine at position
30 40 in the mature LECT2 protein (or at position 58 in the unprocessed protein). Treatments for LECT2 amyloidosis are limited, and new treatments are needed.

SUMMARY

The present disclosure describes methods and iRNA compositions for modulating the expression of a LECT2 gene. In certain embodiments, expression of a LECT2 gene is reduced or inhibited using a LECT2-specific iRNA. Such inhibition can be useful in treating disorders
5 related to LECT2 expression, such as amyloidosis, *e.g.* a LECT2 amyloidosis (ALECT2).

Accordingly, described herein are compositions and methods that effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of the LECT2 gene, such as in a cell or in a subject (*e.g.*, in a mammal, such as a human subject). Also described are compositions and methods for treating a disorder related to expression of a LECT2 gene, such as
10 a LECT2 amyloidosis.

In some embodiments, the LECT2 amyloidosis is a renal amyloidosis. In some embodiments, the LECT2 amyloidosis involves amyloid deposition in the kidney. In some embodiments, LECT2 amyloidosis is associated with renal disease (*e.g.*, nephrotic syndrome). In some embodiments, the amyloidosis is associated with proteinuria. In some embodiments,
15 proteinuria is absent. In some embodiments, the LECT2 amyloidosis is a hepatic amyloidosis. In some embodiments, the LECT2 amyloidosis involves amyloid deposition in the liver. In some embodiments, the LECT2 amyloidosis is associated with inflammation in the liver (*e.g.*, hepatitis, *e.g.*, chronic hepatitis). In some embodiments, the methods described herein are effective to inhibit amyloid deposition (*e.g.*, by preventing amyloid deposition or reducing
20 amyloid deposition, *e.g.*, by reducing size, number, or extent of amyloid deposits) or symptoms associated with amyloid deposition.

As used herein, the term “iRNA,” “RNAi,” “iRNA agent,” “RNAi agent,” or “iRNA molecule,” refers to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript, *e.g.*, via an RNA-induced silencing
25 complex (RISC) pathway. In one embodiment, an iRNA as described herein inhibits LECT2 expression in a cell or mammal.

The iRNAs (*e.g.*, dsRNAs) included in the compositions featured herein include an RNA strand (the antisense strand) having a region, *e.g.*, a region that is 30 nucleotides or less,
30 generally 19-24 nucleotides in length, that is substantially complementary to at least part of an mRNA transcript of a LECT2 gene (*e.g.*, a mouse or human LECT2 gene) (also referred to

herein as a “LECT2-specific iRNA”). In some embodiments, the LECT2 mRNA transcript is a human LECT2 mRNA transcript, *e.g.*, SEQ ID NO: 1. In some embodiments, the LECT2 mRNA transcript has a A to G substitution at nucleotide position 373 of SEQ ID NO: 1. In some embodiments, the mRNA transcript encodes valine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein). In some embodiments, the mRNA transcript encodes isoleucine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein).

In some embodiments, the iRNA (*e.g.*, dsRNA) described herein comprises an antisense strand having a region that is substantially complementary to a region of a human LECT2 mRNA. In some embodiments, the human LECT2 mRNA has the sequence of NM_002302.2 (SEQ ID NO: 1). In some embodiments, the human LECT2 mRNA has a A to G substitution at nucleotide position 373 of SEQ ID NO: 1.

In other embodiments, an iRNA encompasses a dsRNA having an RNA strand (the antisense strand) having a region that is substantially complementary to a portion of a LECT2 mRNA. In one embodiment, the iRNA encompasses a dsRNA having an RNA strand (the antisense strand) having a region that is substantially complementary to a portion of a LECT2 mRNA, *e.g.*, a human LECT2 mRNA (*e.g.*, a human LECT2 mRNA as provided in NM_002302.2 (SEQ ID NO: 1) or having a A to G substitution at nucleotide position 373 of SEQ ID NO: 1).

In one embodiment, an iRNA for inhibiting expression of a LECT2 gene includes at least two sequences that are complementary to each other. The iRNA includes a sense strand having a first sequence and an antisense strand having a second sequence. The antisense strand includes a nucleotide sequence that is substantially complementary to at least part of an mRNA encoding a LECT2 transcript, and the region of complementarity is 30 nucleotides or less, and at least 15 nucleotides in length. Generally, the iRNA is 19 to 24 nucleotides in length.

In some embodiments, the iRNA is 19-21 nucleotides in length. In some embodiments, the iRNA is 19-21 nucleotides in length and is in a lipid formulation, *e.g.* a lipid nanoparticle (LNP) formulation (*e.g.*, an LNP11 formulation). In one embodiment, the iRNA targeting LECT2 is formulated in a stable nucleic acid lipid particle (SNALP).

In some embodiments, the iRNA is 21-23 nucleotides in length. In some embodiments, the iRNA is 21-23 nucleotides in length and is in the form of a conjugate, *e.g.*, conjugated to one or more GalNAc derivatives as described herein.

5 In some embodiments the iRNA is from about 15 to about 25 nucleotides in length, and in other embodiments the iRNA is from about 25 to about 30 nucleotides in length. An iRNA targeting LECT2, upon contact with a cell expressing LECT2, inhibits the expression of a LECT2 gene (*e.g.*, by at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%) when assayed by a method known
10 in the art or as described herein.

In one embodiment, an iRNA (*e.g.*, a dsRNA) featured herein comprises or consists of a first sequence of a dsRNA that is selected from the group consisting of the sense sequences of Tables 2A-2B, 3A-3B, 6, or 7 and a second sequence that is selected from the group consisting of the corresponding antisense sequences of Tables 2A-2B, 3A-3B, 6, or 7, or a pharmaceutically
15 acceptable salt thereof.

In some embodiments, an iRNA (*e.g.*, dsRNA) featured herein comprises or consists of a sense and/or antisense sequence selected from those provided in Tables 2A-2B, 3A-3B, 6, or 7, or a pharmaceutically acceptable salt thereof. In some embodiments, an iRNA (*e.g.*, dsRNA) featured herein comprises or consists of a sense and/or antisense sequence selected from those of
20 AD-454781, AD-133461, AD-454746, AD-86459, or AD-86460 as disclosed herein in the Examples. In some embodiments, the iRNA (*e.g.*, dsRNA) has sense and/or antisense sequences selected from those of AD-454781, AD-133461, or AD-454746. In some embodiments, the iRNA (*e.g.*, dsRNA) has the sense and/or antisense sequences AD-454781.

The iRNA molecules featured herein can include naturally occurring nucleotides or can
25 include at least one modified nucleotide, including, but not limited to a 2'-O-methyl modified nucleotide, a nucleotide having a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative. Alternatively, the modified nucleotide may be chosen from the group of: a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an acyclic nucleotide, an abasic nucleotide, a glycol nucleotide, 2'-amino-modified nucleotide,
30 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. Such a modified sequence can be based, *e.g.*, on a first sequence of said

iRNA selected from the group consisting of the sense sequences of Table 2A, 3A, or 6, and a second sequence selected from the group consisting of the corresponding antisense sequences of Table 2A, 3A, or 6.

In one embodiment, an iRNA (e.g., a dsRNA) featured herein comprises a sense strand
5 comprising a sequence selected from the group consisting of SEQ ID NO: 143, SEQ ID NO: 29, or SEQ ID NO: 23. In one embodiment, an iRNA (e.g., a dsRNA) featured herein comprises an antisense strand comprising a sequence selected from the group consisting of SEQ ID NO: 144, SEQ ID NO: 30, or SEQ ID NO: 24. In one embodiment, the iRNA (e.g., a dsRNA) comprises a sense strand comprising the sequence of SEQ ID NO: 143. In one embodiment, the iRNA (e.g.,
10 a dsRNA) comprises an antisense strand comprising the sequence of SEQ ID NO: 144.

In one embodiment, an iRNA (e.g., a dsRNA) featured herein comprises a sense strand comprising a sequence selected from the group consisting of SEQ ID NO: 370, SEQ ID NO: 294, or SEQ ID NO: 290. In one embodiment, an iRNA (e.g., a dsRNA) featured herein comprises an antisense strand comprising a sequence selected from the group consisting of SEQ
15 ID NO: 371, SEQ ID NO: 295, or SEQ ID NO: 291. In one embodiment, the iRNA (e.g., a dsRNA) comprises a sense strand comprising the sequence of SEQ ID NO: 370. In one embodiment, the iRNA (e.g., a dsRNA) comprises an antisense strand comprising the sequence of SEQ ID NO: 371.

In one embodiment, an iRNA as described herein targets a wildtype LECT2 RNA
20 transcript variant, and in another embodiment, the iRNA targets a mutant transcript (e.g., a LECT2 RNA carrying an allelic variant). For example, an iRNA featured in the disclosure can target a polymorphic variant, such as a single nucleotide polymorphism (SNP), of LECT2.


In some embodiments, the iRNA (e.g., dsRNA) targets (e.g., reduces) mRNA that encodes valine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed
25 protein). In some embodiments, the iRNA (e.g., dsRNA) targets (e.g., reduces) mRNA that encodes isoleucine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein). In another embodiment, the iRNA (e.g., dsRNA) targets (e.g., reduces) both mRNA that encodes valine and mRNA that encodes isoleucine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein).

In another embodiment, the iRNA targets both a wildtype and a mutant LECT2 transcript. In yet another embodiment, the iRNA targets a particular transcript variant of LECT2. In yet another embodiment, the iRNA agent targets multiple transcript variants.


In one embodiment, an iRNA featured in the disclosure targets a non-coding region of a LECT2 RNA transcript, such as the 5' or 3' untranslated region of a transcript.

In some embodiments, an iRNA as described herein is in the form of a conjugate, *e.g.*, a carbohydrate conjugate, which may serve as a targeting moiety and/or ligand, as described herein. In one embodiment, the conjugate is attached to the 3' end of the sense strand of the dsRNA. In some embodiments, the conjugate is attached via a linker, *e.g.*, via a bivalent or trivalent branched linker.

In some embodiments, the conjugate comprises one or more N-acetylgalactosamine (GalNAc) derivatives. Such a conjugate is also referred to herein as a GalNAc conjugate. In some embodiments, the conjugate targets the RNAi agent (*e.g.*, dsRNA) to a particular cell, *e.g.*, a liver cell, *e.g.*, a hepatocyte. The GalNAc derivatives can be attached via a linker, *e.g.*, a bivalent or trivalent branched linker. In particular embodiments, the conjugate is




In some embodiments, the RNAi agent is attached to the carbohydrate conjugate via a linker, *e.g.*, a linker as shown in the following schematic, wherein X is O or S



In some embodiments, X is O. In some embodiments, X is S.

In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below.



In some embodiments, the RNAi agent is conjugated to a ligand that targets the RNAi (*e.g.*, dsRNA) to a desired organ (*e.g.*, the liver) or to a particular cell type (*e.g.*, hepatocytes). In some embodiments, the RNAi agent is conjugated to a ligand (*e.g.*, a GalNAc ligand, *e.g.*, L96) that targets the RNAi agent (*e.g.*, dsRNA) to the liver.

In an aspect provided herein is a pharmaceutical composition for inhibiting the expression of a LECT2 gene in an organism, generally a human subject. The composition typically includes one or more of the iRNAs described herein and a pharmaceutically acceptable carrier or delivery vehicle. In one embodiment, the composition is used for treating a disorder related to LECT2 expression, *e.g.*, amyloidosis, *e.g.*, LECT2 amyloidosis.

In one aspect, an iRNA provided herein is a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand 15-30 base pairs in length and the antisense strand is complementary to at least

15 nucleotides of a target sequence for a duplex disclosed in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7, or a pharmaceutically acceptable salt thereof.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of a target sequence for a duplex disclosed in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7. In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of a target sequence for a duplex disclosed in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of a target sequence for a duplex disclosed in Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of a target sequence for a duplex disclosed in Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of the target sequence of the duplex AD-454781, AD-133461, AD-454746, AD-86459, or AD-86460. In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of the target sequence of the duplex AD-454781, AD-133461, AD-454746, AD-86459, or AD-86460.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of the target sequence of the duplex AD-454781, AD-133461, or AD-454746. In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of the target sequence of the duplex AD-454781, AD-133461, or AD-454746.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of the target sequence of the duplex AD-454781. In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of the target sequence of the duplex AD-454781. In some embodiments, the antisense strand is complementary to all nucleotides of the target sequence of the duplex AD-454781.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of a target sequence provided in Table 2A, 3A, or 6. In some

embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of a target sequence provided in Table 2A, 3A, or 7.

In some embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NOs: 145, 31, or 25. In some
 5 embodiments, the antisense strand is complementary to at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NO: 145. In some embodiments, the antisense strand is complementary to all nucleotides of SEQ ID NO: 145.

In a further aspect, an iRNA provided herein is a double stranded RNAi (dsRNA)
 10 comprising a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region of complementarity to a LECT2 RNA transcript, wherein each strand has about 14 to about 30 nucleotides, wherein said double stranded RNAi agent is represented by formula (III):

sense: 5' n_p - N_a -(X X X)_i- N_b -Y Y Y- N_b -(Z Z Z)_j- N_a - n_q 3'

15 antisense: 3' n_p' - N_a' -(X'X'X')_k- N_b' -Y'Y'Y'- N_b' -(Z'Z'Z')_l- N_a' - n_q' 5'

(III)

wherein:

i, j, k, and l are each independently 0 or 1;

p, p', q, and q' are each independently 0-6;

20 each N_a and N_a' independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;

each N_b and N_b' independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;

25 each n_p , n_p' , n_q , and n_q' independently represents an overhang nucleotide;

XXX, YYY, ZZZ, X'X'X', Y'Y'Y', and Z'Z'Z' each independently represent one motif of three identical modifications on three consecutive nucleotides;

modifications on N_b differ from the modification on Y and modifications on N_b' differ from the modification on Y'.

30 In some embodiments, the sense strand is conjugated to at least one ligand.

In some embodiments, i is 1; j is 1; or both i and j are 1.

In some embodiments, k is 1; l is 1; or both k and l are 1.

In some embodiments, XXX is complementary to X'X'X', YYY is complementary to Y'Y'Y', and ZZZ is complementary to Z'Z'Z'.

In some embodiments, the Y'Y'Y' motif occurs at the 11, 12 and 13 positions of the
5 antisense strand from the 5'-end.

In some embodiments, the Y' is 2'-O-methyl.

In some embodiments, the duplex region is 15-30 nucleotide pairs in length. In some
embodiments, the duplex region is 17-23 nucleotide pairs in length. In some embodiments, the
duplex region is 19-21 nucleotide pairs in length. In some embodiments, the duplex region is 21-
10 23 nucleotide pairs in length.

In some embodiments, the modifications on the nucleotides are selected from the group
consisting of a locked nucleic acid (LNA), an acyclic nucleotide, a hexitol or hexose nucleic acid
(HNA), a cyclohexene nucleic acid (CeNA), a glycol nucleic acid (GNA), 2'-methoxyethyl, 2'-
O-alkyl, 2'-O-allyl, 2'-C- allyl, 2'-fluoro, 2'-deoxy, 2'-hydroxyl, and any combination thereof.


In some embodiments, the modifications on the nucleotides are 2'-O-methyl, 2'-fluoro, or
15 both, and optionally glycol nucleic acid (GNA).

In some embodiments, the ligand comprises a carbohydrate.


In some embodiments, the ligand is attached via a linker.

In some embodiments, the linker is a bivalent or trivalent branched linker.

20 In some embodiments, the ligand is



In some embodiments, the ligand and linker are as shown in Formula XXIV:



In some embodiments, the ligand is attached to the 3' end of the sense strand.

In some embodiments, the dsRNA has (*e.g.*, comprises) a nucleotide sequence (*e.g.*, a
 5 sense and/or antisense sequence) selected from the group of sequences provided in Tables 2A-
 2B, 3A-3B, 6, or 7.

In a further aspect, an iRNA provided herein is a double-stranded ribonucleic acid
 (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and
 10 an antisense strand, the antisense strand comprising a region of complementarity to a LECT2
 RNA transcript, which antisense strand comprises at least 15 contiguous nucleotides differing by
 no more than 3 nucleotides from one of the antisense sequences listed in any one of Tables 2A-
 2B, 3A-3B, 6, or 7, or a pharmaceutically acceptable salt thereof.

In some embodiments, the antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21,
 15 22, or 23 contiguous nucleotides differing by no more than 3 nucleotides from one of the
 antisense sequences listed in any one of Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments,
 the antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides
 differing by no more than 2 nucleotides from one of the antisense sequences listed in any one of
 Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments, the antisense strand comprises at least 15,
 20 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides differing by no more than 1 nucleotide
 from one of the antisense sequences listed in any one of Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the sense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22,
 or 23 contiguous nucleotides differing by no more than 3 nucleotides from one of the antisense
 sequences listed in any one of Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments, the sense
 25 strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides differing by
 no more than 2 nucleotides from one of the antisense sequences listed in any one of Tables 2A-

2B, 3A-3B, 6, or 7. In some embodiments, the sense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides differing by no more than 1 nucleotide from one of the antisense sequences listed in any one of Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the sense and antisense sequences are selected from those of the
5 duplexes AD-454781, AD-133461, AD-454746, AD-86459, or AD-86460 as disclosed in the Examples. In some embodiments, the sense and antisense sequences are selected from those of the duplexes AD-454781, AD-133461, or AD-454746. In some embodiments, the sense and antisense sequences are those of the duplex AD-454781. In some embodiments, the sense and antisense sequences are those of a duplex disclosed herein that suppresses LECT2 mRNA
10 expression by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, e.g., as assessed using an assay disclosed in the Examples provided herein.

In some embodiments, the dsRNA comprises at least one modified nucleotide. In some embodiments, no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand of the dsRNA are unmodified nucleotides. In some
15 embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand of the dsRNA comprise a modification.

In some embodiments, at least one of the modified nucleotides is chosen from the group consisting of: a 2'-O-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid
20 bisdecylamide group.

In some embodiments, the modified nucleotide is chosen from the group consisting of: a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an acyclic nucleotide, an abasic nucleotide, a glycol nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base
25 comprising nucleotide.

In some embodiments, the dsRNA comprises a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, or both, and optionally a glycol nucleotide.

In some embodiments, the dsRNA comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or more 2'-O-methyl modified nucleotides in the sense strand. In some
30 embodiments, the dsRNA comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more 2'-O-methyl modified nucleotides in the antisense strand.

In some embodiments, the dsRNA comprises at least 1, 2, 3, 4, or more 2'-fluoro modified nucleotides in the sense strand. In some embodiments, the dsRNA comprises a 2'-fluoro modified nucleotide at position 7, position 9, position 10, position 11, or a combination thereof, of the sense strand. In some embodiments, the dsRNA comprises 2'-fluoro modified nucleotides at position 7, position 9, position 10, and position 11, of the sense strand. In some
5 embodiments, the dsRNA comprises at least 1, 2, 3, 4, 5, 6, 7, or more 2'-fluoro modified nucleotides in the antisense strand. In some embodiments, the dsRNA comprises a 2'-fluoro modified nucleotide at position 2, position 4, position 6, position 8, position 9, position 14, position 16, or a combination thereof, of the antisense strand. In some embodiments, the dsRNA
10 comprises 2'-fluoro modified nucleotides at position 2, position 14, and position 16, of the antisense strand. In some embodiments, the dsRNA comprises 2'-fluoro modified nucleotides at position 2, position 6, position 8, position 9, position 14, and position 16, of the antisense strand. In some embodiments, the dsRNA comprises 2'-fluoro modified nucleotides at position 2, position 4, position 8, position 9, position 12, position 14, and position 16, of the antisense
15 strand.

In some embodiments, the dsRNA further comprises a glycol nucleotide. In some embodiments, the glycol nucleotide is present in the antisense strand. In some embodiments, the glycol nucleotide is present at position 7 of the antisense strand.

In some embodiments, the dsRNA comprises a phosphorothioate linkage between
20 position 1 and position 2, between position 2 and position 3, or both, of the sense strand. In some embodiments, the dsRNA comprises phosphorothioate linkages between position 1 and position 2 and between position 2 and position 3 of the sense strand.

In some embodiments, the dsRNA comprises a phosphorothioate linkage between
25 position 1 and position 2, between position 2 and position 3, between position 21 and position 22, between position 22 and position 23, or a combination thereof, of the antisense strand. In some embodiments, the dsRNA comprises phosphorothioate linkages between position 1 and position 2, between position 2 and position 3, between position 21 and position 22, and between position 22 and position 23, of the antisense strand.

In some embodiments, the region of complementarity is at least 17 nucleotides in length.
30 In some embodiments, the region of complementarity is between 19 and 23 nucleotides in length. In some embodiments, the region of complementarity is 21 nucleotides in length.

In some embodiments, each strand is no more than 30 nucleotides in length. In some embodiments, each strand is between 21 nucleotides and 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length. In some embodiments, the antisense strand is 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

In some embodiments, at least one strand comprises a 3' overhang of at least 1 nucleotide. In some embodiments, at least one strand comprises a 3' overhang of at least 2 nucleotides. In some embodiments, the dsRNA comprises a blunt end. In some embodiments, the dsRNA comprises a 3' overhang and a blunt end.

In some embodiments, an iRNA (*e.g.*, a dsRNA) described herein further comprises a ligand. In some embodiments, the ligand is a GalNAc ligand. In some embodiments, the ligand targets the iRNA (*e.g.*, the dsRNA) to the liver (*e.g.*, to hepatocytes). In some embodiments, the ligand is conjugated to the 3' end of the sense strand of the dsRNA.

In some embodiments, the region of complementarity consists of an antisense sequence selected from the antisense sequences provided in Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments, the region of complementarity consists of an antisense sequence selected from that of AD-454781, AD-133461, AD-454746, AD-86459, or AD-86460 as disclosed in the Examples. In some embodiments, the region of complementarity consists of an antisense sequence selected from that of AD-454781, AD-133461, or AD-454746. In some embodiments, the region of complementarity consists of the antisense sequence of the duplex AD-454781. In some embodiments, the region of complementarity consists of an antisense sequence selected from a duplex disclosed herein, wherein the duplex suppresses LECT2 mRNA or protein expression by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85% or 90%.

In some embodiments, the dsRNA comprises a sense strand comprising or consisting of a sense strand sequence selected from Tables 2A-2B, 3A-3B, 6, or 7, and an antisense strand comprising or consisting of an antisense sequence selected from Tables 2A-2B, 3A-3B, 6, or 7. In some embodiments, the dsRNA comprises or consists of a pair of corresponding sense and antisense sequences selected from those of the duplexes disclosed in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7. In certain embodiments, the dsRNA comprises or consists of a pair of corresponding sense and antisense sequences selected from those of the duplexes disclosed in Table 2A, 3A, or 6. In certain embodiments, the dsRNA comprises or consists of a pair of corresponding sense

and antisense sequences selected from those of the duplexes disclosed in Table 2B, 3B, or 7. In certain embodiments, the dsRNA comprises or consists of a pair of corresponding sense and antisense sequences selected from those of the duplexes disclosed in Table 4A or 4B. In certain embodiments, the dsRNA comprises or consists of a pair of corresponding sense and antisense sequences selected from those of the duplexes disclosed in Table 5.

In one aspect, the disclosure provides a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the sense strand comprises the sequence and all of the modifications of csasugugCfaCfAfUfugaaaacuguL96 (SEQ ID NO: 23) and the antisense strand comprises the sequence and all of the modifications of asCfsaGfuu(Tgn)UfCfaaUfgUfgCfacaugscsg (SEQ ID NO: 24).

In one aspect, the disclosure provides a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the sense strand comprises the sequence and all of the modifications of asusggucAfgAfUfCfucaaaaauaaL96 (SEQ ID NO: 29) and the antisense strand comprises the sequence and all of the modifications of usUfsauuu(Tgn)gaagauCfuGfaccausug (SEQ ID NO: 30).

In one aspect, the disclosure provides a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the sense strand comprises the sequence and all of the modifications of gsgsucagAfuCfUfUfcaaaaauaaL96 (SEQ ID NO: 143) and the antisense strand comprises the sequence and all of the modifications of asUfsuuaUfuUfUfgaagAfuCfugaccsgsg (SEQ ID NO: 144).

In one aspect, the disclosure provides a cell containing at least one iRNA (*e.g.*, dsRNAs) disclosed herein. The cell is typically a mammalian cell, such as a human cell. In some embodiments, the cell is a liver cell (*e.g.*, a hepatocyte).

5 In one aspect, the disclosure provides a human cell (*e.g.*, a human cell described herein) comprising a reduced level of LECT2 mRNA or a level of LECT2 protein as compared to an otherwise similar untreated cell, wherein optionally the level is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.

10 In some embodiments, the human cell was produced by a process comprising contacting a human cell (*e.g.*, a human cell described herein) with the dsRNA, *e.g.*, a dsRNA described herein.

In an aspect provided herein is a pharmaceutical composition for inhibiting expression of a LECT2 gene, the composition comprising an iRNA (*e.g.*, a dsRNA) described herein.

15 In some embodiments of the pharmaceutical compositions described herein, the iRNA (*e.g.*, dsRNA) is administered in an unbuffered solution. In some embodiments, the unbuffered solution is saline or water.

20 In some embodiments of the pharmaceutical compositions described herein, the iRNA (*e.g.*, dsRNA) is administered with a buffer solution. In some embodiments, the buffer solution comprises acetate, citrate, proline, carbonate, or phosphate or any combination thereof. In some embodiments, the buffer solution is phosphate buffered saline (PBS).

In some embodiments of the pharmaceutical compositions described herein, the iRNA (*e.g.*, dsRNA) is targeted to the liver (*e.g.*, to hepatocytes).

25 In some embodiments of the pharmaceutical compositions described herein, the composition is administered intravenously. In some embodiments of the pharmaceutical compositions described herein, the composition is administered subcutaneously.

In some embodiments, a pharmaceutical composition comprises an iRNA (*e.g.*, a dsRNA) described herein that comprises a ligand (*e.g.*, a GalNAc ligand) that targets the iRNA (*e.g.*, dsRNA) to a liver cell, *e.g.*, a hepatocyte.

30 In some embodiments, a pharmaceutical composition comprises an iRNA (*e.g.*, a dsRNA) described herein that comprises a ligand (*e.g.*, a GalNAc ligand), and the

pharmaceutical composition is administered subcutaneously. In some embodiments, the ligand targets the iRNA (*e.g.*, dsRNA) to a liver cell, *e.g.*, a hepatocyte.

In certain embodiments, a pharmaceutical composition, *e.g.*, a composition described herein, includes a lipid formulation. In some embodiments, the RNAi agent is in an LNP formulation, *e.g.*, a MC3 formulation. In some embodiments, the LNP formulation targets the RNAi agent to a particular cell, *e.g.*, a liver cell (*e.g.*, a hepatocyte). In some embodiments, the lipid formulation is a LNP11 formulation. In some embodiments, the composition is administered intravenously.

In another embodiment, the pharmaceutical composition is formulated for administration according to a dosage regimen described herein, *e.g.*, not more than once every four weeks, not more than once every three weeks, not more than once every two weeks, or not more than once every week. In another embodiment, the administration of the pharmaceutical composition can be maintained for a month or longer, *e.g.*, one, two, three, or six months, or one year or longer.

In another embodiment, a composition containing an iRNA featured in the disclosure, *e.g.*, a dsRNA targeting LECT2, is administered in conjunction with a second therapy for a disorder related to LECT2 expression (*e.g.*, a LECT2 amyloidosis). An iRNA or composition comprising an iRNA provided herein can be administered before, after, or concurrent with a second therapy. In some embodiments, the iRNA is administered before the second therapy. In some embodiments, the iRNA is administered after the second therapy. In some embodiments, the iRNA is administered concurrent with the second therapy.

In some embodiments, the second therapy is a non-iRNA therapeutic agent that is effective to treat the disorder or symptoms of the disorder.

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis that affects kidney function, *e.g.*, through amyloid deposition in the kidney. In some such embodiments, the iRNA is administered in conjunction with a therapy that supports kidney function (*e.g.*, dialysis). In some embodiments, the iRNA is administered in conjunction with a diuretic, an ACE (angiotensin converting enzyme) inhibitor, an angiotensin receptor blocker, and/or dialysis, *e.g.*, to support or manage kidney function.

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis involving amyloid deposits in the liver. In some such

embodiments, the iRNA is administered in conjunction with a therapy that supports liver function.

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis, and the iRNA is administered in conjunction with
5 removal of all or part of the organ(s) affected by the amyloidosis (*e.g.*, resection of all or part of kidney or liver tissue affected by the amyloidosis). The removal is optionally conducted in conjunction with a replacement of all or part of the organ removed (*e.g.*, in conjunction with a kidney or liver organ transplant).

10 In an aspect provided herein is a method of inhibiting LECT2 expression in a cell, the method comprising: (a) introducing into the cell an iRNA (*e.g.*, a dsRNA) described herein and (b) maintaining the cell of step (a) for a time sufficient to obtain degradation of the mRNA transcript of a LECT2 gene, thereby inhibiting expression of the LECT2 gene in the cell.

15 In an aspect, provided herein is a method of inhibiting LECT2 expression in a cell (*e.g.*, a cell described herein), the method comprising: (a) contacting, *e.g.*, introducing into the cell an iRNA (*e.g.*, a dsRNA) described herein and (b) maintaining the cell of step (a) for a time sufficient to obtain to reduce levels of the LECT2 mRNA, LECT2 protein, or both of LECT2 mRNA or LECT2 protein, thereby inhibiting expression of the LECT2 gene in the cell.

20 In an aspect provided herein is a method for reducing or inhibiting the expression of a LECT2 gene in a cell (*e.g.*, a liver cell, *e.g.*, a hepatocyte). The method includes contacting the cell with a dsRNA as described herein, thereby inhibiting expression of a LECT2 gene.

“Contacting,” as used herein, includes directly contacting a cell, as well as indirectly contacting a
25 cell. For example, a cell within a subject (*e.g.*, a liver cell) may be contacted when a composition comprising an RNAi is administered (*e.g.*, intravenously or subcutaneously) to the subject.

In some embodiments, the method includes:

(a) introducing into the cell a double-stranded ribonucleic acid (dsRNA), wherein the
30 dsRNA includes at least two sequences that are complementary to each other.

The dsRNA has a sense strand having a first sequence and an antisense strand

having a second sequence; the antisense strand has a region of complementarity that is substantially complementary to at least a part of an mRNA encoding LECT2, and where the region of complementarity is 30 nucleotides or less, *e.g.*, 15-30 nucleotides in length, and generally 19-24 nucleotides in length, and where the dsRNA upon contact with a cell expressing LECT2, inhibits expression of a LECT2 gene by at least 10%, *e.g.*, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more; and

- (b) maintaining the cell of step (a) for a time sufficient to obtain degradation of the mRNA transcript of the LECT2 gene, thereby reducing or inhibiting expression of a LECT2 gene in the cell.

In some embodiments of the foregoing methods of inhibiting LECT2 expression in a cell, the cell is treated *ex vivo*, *in vitro*, or *in vivo*. In some embodiments, the cell is a hepatocyte.

In some embodiments, the cell is present in a subject in need of treatment, prevention and/or management of a disorder related to LECT2 expression.

In some embodiments, the disorder is a LECT2 amyloidosis, as described herein.

In some embodiments, the expression of LECT2 is inhibited by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, *e.g.*, as determined by a method described herein.

In some embodiments, the expression of LECT2 mRNA is inhibited by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the expression of LECT2 protein is inhibited by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.

In some embodiments, the iRNA (*e.g.*, dsRNA) has an IC_{50} in the range of 0.0005-1 nM, *e.g.*, between 0.001 and 0.2 nM, between 0.002 and 0.1 nM, between 0.005 and 0.075 nM, or between 0.01 and 0.05 nM. In some embodiments, the iRNA (*e.g.*, dsRNA) has an IC_{50} equal to or less than 0.02 nM, *e.g.*, between 0.0005 and 0.02 nM, between 0.001 and 0.02 nM, between 0.005 and 0.02 nM, or between 0.01 and 0.02 nM. In some embodiments, the iRNA (*e.g.*, dsRNA) has an IC_{50} in the range of 0.01-1 nM.

In some embodiments, the cell (*e.g.*, the hepatocyte) is a mammalian cell (*e.g.*, a human, non-human primate, or rodent cell). In one embodiment, the subject is a mammal (*e.g.*, a human) having a LECT2 amyloidosis. In one embodiment, the dsRNA introduced reduces or inhibits expression of a LECT2 gene in the cell.

5 In one embodiment, the dsRNA inhibits expression of a LECT2 gene, or inhibits amyloid deposition (*e.g.*, by preventing amyloid deposition or reducing amyloid deposition, *e.g.*, by reducing size, number, or extent of amyloid deposits). The inhibition optionally involves an inhibition of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
10 70%, 75%, 80%, 85%, 90%, 95%, or more, compared to a reference, (*e.g.*, a control that is untreated or treated with a non-targeting dsRNA (*e.g.*, a dsRNA that does not target LECT2)).

In some embodiments, inhibiting expression of LECT2 gene decreases a LECT2 protein level in a biological sample (*e.g.*, a serum sample) from the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.

15 In other aspects, the disclosure provides methods for treating pathological processes related to LECT2 expression (*e.g.*, amyloid deposition). In one embodiment, the method includes administering to a subject, *e.g.*, a patient in need of such treatment, an effective (*e.g.*, a therapeutically or prophylactically effective) amount of a dsRNA provided herein.

20 In an aspect provided herein is a method of treating and/or preventing a disorder related to LECT2 expression (*e.g.*, a LECT2 amyloidosis) comprising administering to a subject in need of such treatment a therapeutically effective amount of an iRNA (*e.g.*, a dsRNA) described herein, or a composition comprising an iRNA (*e.g.*, a dsRNA) described herein.

25 In an aspect provided herein is a method of treating a disorder related to LECT2 expression (*e.g.*, LECT2 amyloidosis) comprising administering to a subject in need of such treatment a double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand and an antisense strand 15-30 base pairs in length and the antisense strand is complementary to at least 15 contiguous nucleotides of a LECT2 mRNA transcript, *e.g.*, a
30 human LECT2 mRNA transcript, *e.g.*, SEQ ID NO: 1 or a nucleotide sequence having a A to G substitution at nucleotide position 373 of SEQ ID NO: 1. In one embodiment, the iRNA (*e.g.*,

dsRNA) targets mRNA that encodes valine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein).

In one embodiment provided herein is a method of treating a subject having a LECT2 amyloidosis, the method comprising administering to the subject a double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand and an antisense strand 15-30 base pairs in length and the antisense strand is complementary to at least 15 contiguous nucleotides of a LECT2 mRNA transcript, *e.g.*, a human LECT2 mRNA transcript, *e.g.*, SEQ ID NO: 1 or a nucleotide sequence having a A to G substitution at nucleotide position 373 of SEQ ID NO: 1. In one embodiment, the iRNA (*e.g.*, dsRNA) targets mRNA that encodes valine at position 40 in the mature LECT2 protein (or amino acid 58 in the unprocessed protein).

In some embodiments, administration of the iRNA targeting LECT2 alleviates or relieves the severity of at least one symptom of a disorder related to LECT2 expression in the patient. In some embodiments, at least one sign or symptom of a disorder related to LECT2 expression, *e.g.*, an amyloidosis, *e.g.*, LECT2 amyloidosis, comprises a measure of amyloid deposits or presence or level of LECT2 (*e.g.*, LECT2 gene, LECT2 mRNA, or LECT2 protein)).

In one embodiment, subject has a LECT2 amyloidosis. In another embodiment, the subject is at risk for developing a LECT2 amyloidosis.

In some embodiments, the subject is a human.

In some embodiments, the dsRNA or pharmaceutical composition, *e.g.*, a dsRNA or pharmaceutical composition as described herein, is administered to the subject subcutaneously or intravenously.

In some embodiments, treating comprises prevention of progression of the disorder. In some embodiments, treating comprises inhibiting or reducing the expression or activity of LECT2 in a cell, *e.g.* a hepatocyte. In some embodiments, treating results in at least a 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% mean reduction from baseline of LECT2 mRNA in the cell.

In some embodiments, the methods described herein further comprise measuring level of LECT2 (*e.g.*, LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject. In some embodiments measuring the level of LECT2 in the subject comprises measuring the level of LECT2 gene, LECT2 protein or LECT2 mRNA in a biological sample from the subject (*e.g.*, a tissue, blood, or serum sample). In some embodiments, the methods described herein further

comprise performing a blood test, an imaging test, or a liver or kidney biopsy. In some embodiments, measuring level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject is performed prior to treatment with the dsRNA agent or the pharmaceutical composition. In some embodiments, upon determination that a subject has a level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) that is greater than a reference level, the dsRNA agent or the pharmaceutical composition is administered to the subject. In some embodiments, measuring the level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject is performed after treatment with the dsRNA agent or the pharmaceutical composition.

In some embodiments, the iRNA (e.g., dsRNA) is formulated as an LNP formulation. In some embodiments, the iRNA (e.g., dsRNA) is in the form of a GalNAc conjugate. In some embodiments, the iRNA (e.g., dsRNA) is administered at a dose of 0.05-50 mg/kg.

In some embodiments, the iRNA (e.g., dsRNA) is administered at a concentration of 0.01 mg/kg-5 mg/kg bodyweight of the subject.

In some embodiments, the iRNA (e.g., dsRNA) is formulated as an LNP formulation and is administered at a dose of 0.05-5 mg/kg. In some embodiments, the iRNA (e.g., dsRNA) is formulated as an LNP formulation and is administered at a dose of 0.1 to 0.5 mg/kg.

In some embodiments, the iRNA (e.g., dsRNA) is in the form of a GalNAc conjugate and is administered at a dose of 0.5-50 mg/kg. In some embodiments, the iRNA (e.g., dsRNA) is in the form of a GalNAc conjugate and is administered at a dose of 1 to 10 mg/kg.

In some embodiments, the method inhibits expression of a LECT2 gene, or inhibits amyloid deposition (e.g., by preventing amyloid deposition or reducing amyloid deposition, e.g., by reducing size, number, or extent of amyloid deposits). The inhibition optionally involves an inhibition of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, compared to a reference (e.g., a control that is untreated or treated with a non-targeting dsRNA (e.g., a dsRNA that does not target LECT2)).

In some embodiments, the iRNA (e.g., dsRNA) has an IC_{50} in the range of 0.0005-1 nM, e.g., between 0.001 and 0.2 nM, between 0.002 and 0.1 nM, between 0.005 and 0.075 nM, or between 0.01 and 0.05 nM. In some embodiments, the iRNA (e.g., dsRNA) has an IC_{50} equal to or less than 0.02 nM, e.g., between 0.0005 and 0.02 nM, between 0.001 and 0.02 nM, between

0.005 and 0.02 nM, or between 0.01 and 0.02 nM. In some embodiments, the iRNA (*e.g.*, dsRNA) has an IC₅₀ in the range of 0.01-1 nM.

In some embodiments, a method described herein ameliorates a symptom associated with a LECT2 related disorder (*e.g.*, a LECT2 amyloidosis). In some embodiments, a method described herein inhibits expression of a LECT2 gene in the subject. In some embodiments, a method described herein inhibits amyloid deposition (*e.g.*, by preventing amyloid deposition or reducing amyloid deposition, *e.g.*, by reducing size, number, or extent of amyloid deposits).

In some embodiments, the iRNA (*e.g.*, dsRNA) or composition comprising the iRNA is administered according to a dosing regimen. In some embodiments, the iRNA (*e.g.*, dsRNA) or composition comprising the iRNA is administered repeatedly, *e.g.*, according to a dosing regimen.

In some embodiments, the iRNA (*e.g.*, dsRNA) or composition comprising the iRNA is administered subcutaneously. In some embodiments, the iRNA is in the form of a GalNAc conjugate. In some embodiments, the iRNA (*e.g.*, the dsRNA) is administered at a dose of 0.5-50 mg/kg. In some embodiments, the iRNA (*e.g.*, dsRNA) is in the form of a GalNAc conjugate and is administered at a dose of 1 to 10 mg/kg.

In an aspect provided herein is a vector encoding at least one strand of an iRNA (*e.g.*, a dsRNA) as described herein.

In an aspect provided herein is a vector encoding at least one strand of a dsRNA, wherein said dsRNA comprises a region of complementarity to at least a part of an mRNA encoding LECT2, wherein said dsRNA is 30 base pairs or less in length, and wherein said dsRNA targets said mRNA for cleavage.

In some embodiments, the region of complementarity is at least 15 nucleotides in length. In some embodiments, the region of complementarity is 19 to 23 nucleotides in length. In some embodiments, the region of complementarity is 21 to 23 nucleotides in length.

In one aspect, a vector is provided for inhibiting the expression of a LECT2 gene in a cell. In one embodiment, the vector comprises an iRNA as described herein. In one embodiment, the vector includes at least one regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of an iRNA as described herein. In one embodiment the vector comprises at least one strand of a LECT2 iRNA.

In an aspect provided herein is a cell comprising a vector as described herein.

In an aspect provided herein is a cell containing a vector for inhibiting the expression of a LECT2 gene in a cell. The vector includes a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of an iRNA described herein.

All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

The details of various embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and the drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 depicts a human LECT2 mRNA transcript sequence (Ref. Seq. NM_002302.2 GI:59806344, record dated April 17, 2013; SEQ ID NO: 1).

FIG. 2 depicts the sequences and chemistry of three exemplary LECT2 siRNAs: AD-454781, AD-133461, and AD-454746, which were designed to target regions of the LECT2 mRNA in both humans and cynomolgus monkeys. For each siRNA, “F” which is shown in green is the “2’fluoro” modification, OMe shown in black is a methoxy group, GNA shown in purple is a glycol nucleic acid, and PS refers to the phosphonothioate linkage. **FIG. 2** discloses SEQ ID NOS 897-902, respectively, in order of appearance.

FIG. 3 depicts the pharmacodynamics of the three exemplary LECT2 siRNAs in rodent AAV models. Relative levels of LECT2 mRNA in the liver and circulating LECT2 protein in the plasma (percent remaining) were quantified on day 14 post-treatment in the experimental (LECT2 siRNAs) and control (PBS) groups.

FIGS. 4A-4C show the dose-response of the three exemplary LECT2 siRNAs in suppressing LECT2 in cynomolgus monkeys relative to a PBS control. Relative levels of plasma LECT2 (plasma LECT2 protein knockdown) were quantified by normalization to pre-treatment protein levels for each individual monkey.

FIGS. 5A-5B depict the relative levels of rat (**FIG. 5A**) or mouse (**FIG. 5B**) LECT2 mRNA in the liver (expression fold difference) at 3, 6, or 12 months post-initial treatment in the experimental (LECT2 siRNAs) or control (PBS) groups.

FIGS. 6A-6B assess long term LECT-2 knockdown in cynomolgus monkeys. In **FIG. 6A**, relative levels of LECT2 mRNA (expression fold difference) in the livers of monkeys at six months post-initial treatment were quantified in the experimental (siRNA AD-81725) and control (PBS) groups. In **FIG. 6B**, relative, circulating levels of LECT2 plasma protein (percent protein remaining) were measured pre-treatment and each month for six months post-first dosing of the experimental (siRNA AD-81725) and control (PBS) groups.

DETAILED DESCRIPTION

iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). Described herein are iRNAs and methods of using them for modulating (*e.g.*, inhibiting) the expression of a LECT2 gene. Also provided are compositions and methods for treatment of disorders related to LECT2 expression, such as amyloidosis (*e.g.*, LECT2 amyloidosis).

The iRNAs of the compositions featured herein include an RNA strand (the antisense strand) having a region which is 30 nucleotides or less in length, *i.e.*, 15-30 nucleotides in length, generally 19-24 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of a LECT2 gene (also referred to herein as an “LECT2-specific iRNA”). The use of such an iRNA enables the targeted degradation of mRNAs of genes that are implicated in disorders related to LECT2 expression, as described herein. Very low dosages of LECT2-specific iRNAs can specifically and efficiently mediate RNAi, resulting in significant inhibition of expression of a LECT2 gene. iRNAs targeting LECT2 can specifically and efficiently mediate RNAi, resulting in significant inhibition of expression of a LECT2 gene, which can be assessed, *e.g.*, in cell-based assays.

The following description discloses how to make and use compositions containing iRNAs to modulate (*e.g.*, inhibit) the expression of a LECT2 gene, as well as compositions and methods for treating disorders related to expression of a LECT2 gene.

Embodiments of the pharmaceutical compositions featured herein include an iRNA having an antisense strand comprising a region which is 30 nucleotides or less in length,

generally 19-24 nucleotides in length, which region is substantially complementary to at least part of an RNA transcript of a LECT2 gene.

In some aspects, pharmaceutical compositions containing a LECT2 iRNA and a pharmaceutically acceptable carrier, methods of using the compositions to inhibit expression of a LECT2 gene, and methods of using the pharmaceutical compositions to treat disorders related to expression of a LECT2 gene (*e.g.*, LECT2 amyloidosis) are featured herein.

I. Definitions

For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in other parts of this specification and its definition provided in this section, the definition in this section shall prevail.

As used herein, “LECT2” refers to leukocyte chemotactic factor 2 (also known as leukocyte cell-derived chemotaxin 2, chondromodulin-II, chm-II or chm2). *See, e.g.*, Yamagoe S *et al. Genomics*, 1998 Mar 15; 48(3):324-9. LECT2 was first identified as a novel neutrophil chemotactic protein and is identical with chondromodulin II, a growth stimulator for chondrocytes and osteoblasts. The human LECT2 gene was mapped to chromosome 5q31.1-q32. *Ibid.*

The sequence of a human LECT2 mRNA transcript can be found at NM_002302.2 (SEQ ID NO: 1). The sequence of a mouse LECT2 mRNA can be found at NM_010702.1 and at NM_010702.2, and the sequence of a rat LECT2 mRNA can be found at NM_001108405.1.

The human LECT2 protein is a secreted, 16 kDa protein. The LECT2 protein is secreted by the liver. It has high sequence similarity to the chondromodulin repeat regions of the chicken myb-induced myeloid 1 protein (www.genecards.org/cgi-bin/carddisp.pl?gene=LECT2; accessed August 29, 2013). Polymorphism in the LECT2 gene has been associated with rheumatoid arthritis. *Ibid.*

LECT2 is expressed in various tissues, including the brain and stomach as well as the liver. Koshimizu, Y & Ohtomi, M. (2010) *Brain Res.* 1311:1-11. In a study using indirect immuno-peroxidase staining to investigate the expression of LECT2 in normal and diseased human organs and tissues other than liver, it was found that LECT2 was generally expressed in vascular, endothelial and smooth muscle cells, adipocytes, cerebral nerve cells, apical squamous

epithelia, parathyroid cells, sweat and sebaceous glandular epithelia, Hassall bodies and some mononuclear cells in immuno-hematopoietic tissue. This protein was generally negative, although occasionally positively stained in osteoblasts, chondrocytes, cardiac and skeletal muscle cells, smooth muscle cells of the gastrointestinal tract, and the epithelial cells of some tissues.

5 Nagai *et al.* (1998) *Pathol Int.* 48(11):882-6.

The human LECT2 gene codes for 151 amino acids including an 18 amino acid signal peptide. The secreted protein has 133 residues. A G/A polymorphism at nucleotide 172 in exon 3 of the gene (codon change GTC to ATC) has been identified and accounts for the presence of either valine or isoleucine at position 58 of the unprocessed protein (or position 40 of the mature
10 protein). The G allele has an overall frequency of 0.477 and a frequency range of 0.6-0.7 in individuals of European descent. See Benson, M.D. *et al.* (2008) *Kidney International*, 74: 218-222; Murphy, C. L. *et al.* (2010) *Am J Kidney Dis*, 56(6):1100-1107. Patients with LECT2 amyloidosis typically are homozygous for the G allele. Without wishing to be bound by theory, it has been suggested that replacement of the buried isoleucine (A allele) side chain with valine
15 (G allele) could destabilize the protein and possibly account for the amyloidogenic propensity of this LECT2 variant. Murphy, C. L. *et al.* (2010) *Am J Kidney Dis*, 56(6):1100-1107.

As used herein, a “LECT2 amyloidosis” or “ALECT2” includes an amyloidosis involving deposits of amyloid or amyloid fibrils that contain a LECT2 protein (*e.g.*, any polymorphic variant of a LECT2 protein) or a portion of a LECT2 protein. The LECT2 protein can be a
20 variant (*e.g.*, a mutant) LECT2 protein. The amyloidosis can be systemic or local. In some embodiments, the LECT2 amyloidosis involves amyloid deposits in the kidney and/or liver.

“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further
25 detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil may be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base may base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides
30 containing uracil, guanine, or adenine may be replaced in the nucleotide sequences of dsRNA featured in the disclosure by a nucleotide containing, for example, inosine. In another example,

adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the disclosure.

5 As used herein, the term “iRNA,” “RNAi”, “iRNA agent,” or “RNAi agent” refers to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript, *e.g.*, via an RNA-induced silencing complex (RISC) pathway. In one embodiment, an iRNA as described herein effects inhibition of ALECT2 expression. Inhibition of ALECT2 expression may be assessed based on a reduction in the level of ALECT2 mRNA or a
10 reduction in the level of the ALECT2 protein. As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an ALECT2 gene, including mRNA that is a product of RNA processing of a primary transcription product. The target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion. For example, the target
15 sequence will generally be from 9-36 nucleotides in length, *e.g.*, 15-30 nucleotides in length, including all sub-ranges therebetween. As non-limiting examples, the target sequence can be from 15-30 nucleotides, 15-26 nucleotides, 15-23 nucleotides, 15-22 nucleotides, 15-21 nucleotides, 15-20 nucleotides, 15-19 nucleotides, 15-18 nucleotides, 15-17 nucleotides, 18-30 nucleotides, 18-26 nucleotides, 18-23 nucleotides, 18-22 nucleotides, 18-21 nucleotides, 18-20
20 nucleotides, 19-30 nucleotides, 19-26 nucleotides, 19-23 nucleotides, 19-22 nucleotides, 19-21 nucleotides, 19-20 nucleotides, 20-30 nucleotides, 20-26 nucleotides, 20-25 nucleotides, 20-24 nucleotides, 20-23 nucleotides, 20-22 nucleotides, 20-21 nucleotides, 21-30 nucleotides, 21-26 nucleotides, 21-25 nucleotides, 21-24 nucleotides, 21-23 nucleotides, or 21-22 nucleotides.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide
25 comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to
30 hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled

person. Such conditions can, for example, be stringent conditions, where stringent conditions may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours followed by washing. Other conditions, such as physiologically relevant conditions as may be encountered inside an organism, can apply. The skilled person will be able to determine the set
5 of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

Complementary sequences within an iRNA, *e.g.*, within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over
10 the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they may form one or more, but generally not more than 5, 4, 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while
15 retaining the ability to hybridize under the conditions most relevant to their ultimate application, *e.g.*, inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another
20 oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, may yet be referred to as “fully complementary” for the purposes described herein.

“Complementary” sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified
25 nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs includes, but are not limited to, G:U Wobble or Hoogsteen base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense
30 strand of a dsRNA, or between the antisense strand of an iRNA agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (*e.g.*, an mRNA encoding an ALECT2 protein). For example, a polynucleotide is complementary to at least a part of a LECT2 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding LECT2. As another example, a polynucleotide is complementary to at least a part of a LECT2 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding LECT2.

The term “double-stranded RNA” or “dsRNA,” as used herein, refers to an iRNA that includes an RNA molecule or complex of molecules having a hybridized duplex region that comprises two anti-parallel and substantially complementary nucleic acid strands, which will be referred to as having “sense” and “antisense” orientations with respect to a target RNA. The duplex region can be of any length that permits specific degradation of a desired target RNA, *e.g.*, through a RISC pathway, but will typically range from 9 to 36 base pairs in length, *e.g.*, 15-30 base pairs in length. Considering a duplex between 9 and 36 base pairs, the duplex can be any length in this range, for example, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 and any sub-range therein between, including, but not limited to 15-30 base pairs, 15-26 base pairs, 15-23 base pairs, 15-22 base pairs, 15-21 base pairs, 15-20 base pairs, 15-19 base pairs, 15-18 base pairs, 15-17 base pairs, 18-30 base pairs, 18-26 base pairs, 18-23 base pairs, 18-22 base pairs, 18-21 base pairs, 18-20 base pairs, 19-30 base pairs, 19-26 base pairs, 19-23 base pairs, 19-22 base pairs, 19-21 base pairs, 19-20 base pairs, 20-30 base pairs, 20-26 base pairs, 20-25 base pairs, 20-24 base pairs, 20-23 base pairs, 20-22 base pairs, 20-21 base pairs, 21-30 base pairs, 21-26 base pairs, 21-25 base pairs, 21-24 base pairs, 21-23 base pairs, or 21-22 base pairs. dsRNAs generated in the cell by processing with Dicer and similar enzymes are generally in the range of 19-22 base pairs in length. One strand of the duplex region of a dsDNA comprises a sequence that is substantially complementary to a region of a target RNA. The two strands forming the duplex structure can be from a single RNA molecule having at least one self-complementary region, or can be formed from two or more separate RNA molecules. Where the duplex region is formed from two strands of a single molecule, the molecule can have a duplex region separated by a single stranded chain of nucleotides (herein referred to as a “hairpin loop”) between the 3’-end of one

strand and the 5'-end of the respective other strand forming the duplex structure. The hairpin loop can comprise at least one unpaired nucleotide; in some embodiments the hairpin loop can comprise at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides. Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. Where the two strands are connected covalently by means other than a hairpin loop, the connecting structure is referred to as a "linker." The term "siRNA" is also used herein to refer to a dsRNA as described above.

In another embodiment, the iRNA agent may be a "single-stranded siRNA" that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Patent No. 8,101,348 and in Lima *et al.*, (2012) *Cell* 150: 883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein (*e.g.*, sequences provided in Tables 2A-2B, 3A-3B, 6 or 7) may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima *et al.*, (2012) *Cell* 150:883-894.

The skilled artisan will recognize that the term "RNA molecule" or "ribonucleic acid molecule" encompasses not only RNA molecules as expressed or found in nature, but also analogs and derivatives of RNA comprising one or more ribonucleotide/ribonucleoside analogs or derivatives as described herein or as known in the art. Strictly speaking, a "ribonucleoside" includes a nucleoside base and a ribose sugar, and a "ribonucleotide" is a ribonucleoside with one, two or three phosphate moieties. However, the terms "ribonucleoside" and "ribonucleotide" can be considered to be equivalent as used herein. The RNA can be modified in the nucleobase structure, in the ribose structure, or in the ribose-phosphate backbone structure, *e.g.*, as described herein below. However, the molecules comprising ribonucleoside analogs or derivatives must retain the ability to form a duplex. As non-limiting examples, an RNA molecule can also include at least one modified ribonucleoside including but not limited to a 2'-O-methyl modified nucleoside, a nucleoside comprising a 5' phosphorothioate group, a terminal nucleoside linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a locked nucleoside, an abasic nucleoside, an acyclic nucleoside, a glycol nucleotide, a 2'-deoxy-2'-fluoro modified nucleoside,

a 2'-amino-modified nucleoside, 2'-alkyl-modified nucleoside, morpholino nucleoside, a phosphoramidate or a non-natural base comprising nucleoside, or any combination thereof. Alternatively, an RNA molecule can comprise at least two modified ribonucleosides, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20 or
5 more, up to the entire length of the dsRNA molecule. The modifications need not be the same for each of such a plurality of modified ribonucleosides in an RNA molecule. In one embodiment, modified RNAs contemplated for use in methods and compositions described herein are peptide nucleic acids (PNAs) that have the ability to form the required duplex
10 structure and that permit or mediate the specific degradation of a target RNA, *e.g.*, via a RISC pathway.

In one aspect, a modified ribonucleoside includes a deoxyribonucleoside. In such an instance, an iRNA agent can comprise one or more deoxynucleosides, including, for example, a deoxynucleoside overhang(s), or one or more deoxynucleosides within the double stranded portion of a dsRNA. In certain embodiments, the RNA molecule comprises a percentage of
15 deoxyribonucleosides of at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% or higher (but not 100%) deoxyribonucleosides, *e.g.*, in one or both strands. In other embodiments, the term "iRNA" does not encompass a double stranded DNA molecule (*e.g.*, a naturally-occurring double stranded DNA molecule or a 100% deoxynucleoside-containing DNA molecule).

In one aspect, an RNA interference agent includes a single stranded RNA that interacts with a target RNA sequence to direct the cleavage of the target RNA. Without wishing to be bound by theory, long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp *et al.*, *Genes Dev.* 2001, 15:485). Dicer, a
20 ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs (Bernstein, *et al.*, (2001) *Nature* 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, *et al.*, (2001) *Cell* 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleaves the target to induce silencing
25 (Elbashir, *et al.*, (2001) *Genes Dev.* 15:188). Thus, in one aspect the disclosure relates to a
30

single stranded RNA that promotes the formation of a RISC complex to effect silencing of the target gene.

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of an iRNA, *e.g.*, a dsRNA. For example, when a 3'-end of one strand of a dsRNA extends beyond the 5'-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) may be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5' end, 3' end or both ends of either an antisense or sense strand of a dsRNA.

In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide overhang at the 3' end and/or the 5' end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide overhang at the 3' end and/or the 5' end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

The terms “blunt” or “blunt ended” as used herein in reference to a dsRNA mean that there are no unpaired nucleotides or nucleotide analogs at a given terminal end of a dsRNA, *i.e.*, no nucleotide overhang. One or both ends of a dsRNA can be blunt. Where both ends of a dsRNA are blunt, the dsRNA is said to be blunt ended. To be clear, a “blunt ended” dsRNA is a dsRNA that is blunt at both ends, *i.e.*, no nucleotide overhang at either end of the molecule. Most often such a molecule will be double-stranded over its entire length.

The term “antisense strand” or “guide strand” refers to the strand of an iRNA, *e.g.*, a dsRNA, which includes a region that is substantially complementary to a target sequence. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches may be in the internal or terminal regions of the molecule. In some embodiments, the region of complementarity comprises 0, 1, or 2 mismatches.

The term “sense strand” or “passenger strand” as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle. A
5 SNALP represents a vesicle of lipids coating a reduced aqueous interior comprising a nucleic acid such as an iRNA or a plasmid from which an iRNA is transcribed. SNALPs are described, *e.g.*, in U.S. Patent Application Publication Nos. 2006/0240093, 2007/0135372, and in International Application No. WO 2009/082817. These applications are incorporated herein by reference in their entirety.

10 “Introducing into a cell,” when referring to an iRNA, means facilitating or effecting uptake or absorption into the cell, as is understood by those skilled in the art. Absorption or uptake of an iRNA can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. The meaning of this term is not limited to cells *in vitro*; an iRNA may also be “introduced into a cell,” wherein the cell is part of a living organism. In such an
15 instance, introduction into the cell will include the delivery to the organism. For example, for *in vivo* delivery, iRNA can be injected into a tissue site or administered systemically. *In vivo* delivery can also be by a β -glucan delivery system, such as those described in U.S. Patent Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781, which are hereby incorporated by reference in their entirety. *In vitro* introduction into a cell includes methods
20 known in the art such as electroporation and lipofection. Further approaches are described herein below or known in the art.

As used herein, the term “modulate the expression of,” refers to at an least partial “inhibition” or partial “activation” of a LECT2 gene expression in a cell treated with an iRNA composition as described herein compared to the expression of LECT2 in a control cell. A
25 control cell includes an untreated cell, or a cell treated with a non-targeting control iRNA.

The terms “activate,” “enhance,” “up-regulate the expression of,” “increase the expression of,” and the like, in so far as they refer to a LECT2 gene, herein refer to the at least partial activation of the expression of a LECT2 gene, as manifested by an increase in the amount of LECT2 mRNA, which may be isolated from or detected in a first cell or group of cells in
30 which a LECT2 gene is transcribed and which has or have been treated such that the expression of a LECT2 gene is increased, as compared to a second cell or group of cells substantially

identical to the first cell or group of cells but which has or have not been so treated (control cells).

In one embodiment, expression of a LECT2 gene is activated by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by administration of an iRNA as described herein. In some embodiments, a LECT2 gene is activated by at least about 60%, 70%, or 80% by administration of an iRNA featured in the disclosure. In some embodiments, expression of a LECT2 gene is activated by at least about 85%, 90%, or 95% or more by administration of an iRNA as described herein. In some embodiments, the LECT2 gene expression is increased by at least 1-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold or more in cells treated with an iRNA as described herein compared to the expression in an untreated cell. Activation of expression by small dsRNAs is described, for example, in Li *et al.*, 2006 *Proc. Natl. Acad. Sci. U.S.A.* 103:17337-42, and in US2007/0111963 and US2005/226848, each of which is incorporated herein by reference.

The terms “silence,” “inhibit expression of,” “down-regulate expression of,” “suppress expression of,” and the like, in so far as they refer to a LECT2 gene, herein refer to the at least partial suppression of the expression of a LECT2 gene, as assessed, *e.g.*, based on LECT2 mRNA expression, LECT2 protein expression, or another parameter functionally linked to LECT2 gene expression. For example, inhibition of LECT2 expression may be manifested by a reduction of the amount of LECT2 mRNA which may be isolated from or detected in a first cell or group of cells in which a LECT2 gene is transcribed and which has or have been treated such that the expression of a LECT2 gene is inhibited, as compared to a control. The control may be a second cell or group of cells substantially identical to the first cell or group of cells, except that the second cell or group of cells have not been so treated (control cells). The degree of inhibition is usually expressed as a percentage of a control level, *e.g.*,

$$\frac{(\text{mRNA in control cells}) - (\text{mRNA in treated cells})}{(\text{mRNA in control cells})} \bullet 100\%$$

Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to LECT2 gene expression, *e.g.*, the amount of protein encoded by a LECT2 gene. The reduction of a parameter functionally linked to LECT2 gene expression may similarly be expressed as a percentage of a control level. In principle, LECT2

gene silencing may be determined in any cell expressing LECT2, either constitutively or by genomic engineering, and by any appropriate assay.

For example, in certain instances, expression of a LECT2 gene is suppressed by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by administration of an iRNA disclosed herein. In some embodiments, a LECT2 gene is suppressed by at least about 60%, 65%, 70%, 75%, or 80% by administration of an iRNA disclosed herein. In some embodiments, a LECT2 gene is suppressed by at least about 85%, 90%, 95%, 98%, 99%, or more by administration of an iRNA as described herein.

In the context of the present disclosure, the terms “treat,” “treatment,” and the like mean to prevent, relieve or alleviate at least one symptom associated with a disorder related to LECT2 expression, or to slow or reverse the progression or anticipated progression of such a disorder. For example, the methods featured herein, when employed to treat a LECT2 amyloidosis, may serve to inhibit amyloid deposition, to reduce or prevent one or more symptoms of the amyloidosis, or to reduce the risk or severity of associated conditions (*e.g.*, nephrotic syndrome or hepatitis). Thus, unless the context clearly indicates otherwise, the terms “treat,” “treatment,” and the like are intended to encompass prophylaxis, *e.g.*, prevention of disorders and/or symptoms of disorders related to LECT2 expression.

By “lower” in the context of a disease marker or symptom is meant any decrease, *e.g.*, a statistically or clinically significant decrease in such level. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%. The decrease can be down to a level accepted as within the range of normal for an individual without such disorder.

As used herein, the phrases “therapeutically effective amount” and “prophylactically effective amount” and the like refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of any disorder or pathological process related to LECT2 expression. The specific amount that is therapeutically effective may vary depending on factors known in the art, such as, for example, the type of disorder or pathological process, the patient’s history and age, the stage of the disorder or pathological process, and the administration of other therapies.

As used herein, a “pharmaceutical composition” comprises a pharmacologically effective amount of an iRNA and a pharmaceutically acceptable carrier. As used herein,

“pharmacologically effective amount,” “therapeutically effective amount” or simply “effective amount” refers to that amount of an iRNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, in a method of treating a disorder related to LECT2 expression (*e.g.*, a LECT2 amyloidosis), an effective amount includes an amount effective to reduce one or more symptoms associated with the LECT2 amyloidosis, an amount effective to inhibit amyloid deposition (*e.g.*, LECT2 amyloid deposition), or an amount effective to reduce the risk of developing conditions associated with LECT2 amyloidosis. For example, if a given clinical treatment is considered effective when there is at least a 10% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to obtain at least a 10% reduction in that parameter. For example, a therapeutically effective amount of an iRNA targeting LECT2 can reduce a level of LECT2 mRNA or a level of LECT2 protein by any measurable amount, *e.g.*, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.

The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Agents included in drug formulations are described further herein below.

The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary from, for example, between 1% and 15% of the stated number or numerical range.

II. iRNA Agents

Described herein are iRNA agents that modulate (*e.g.*, inhibit) the expression of a LECT2 gene.

In some embodiments, the iRNA agent activates the expression of a LECT2 gene in a cell
5 or mammal.

In some embodiments, the iRNA agent includes double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of a LECT2 gene in a cell or in a subject (*e.g.*, in a mammal, *e.g.*, in a human), where the dsRNA includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the
10 expression of a LECT2 gene, and where the region of complementarity is 30 nucleotides or less in length, generally 19-24 nucleotides in length, and where the dsRNA, upon contact with a cell expressing the LECT2 gene, inhibits the expression of the LECT2 gene, *e.g.*, by at least 10%, 20%, 30%, 40%, or 50%.

The modulation (*e.g.*, inhibition) of expression of the LECT2 gene can be assayed by, for
15 example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by Western blot. Expression of a LECT2 gene in cell culture, such as in COS cells, HeLa cells, primary hepatocytes, HepG2 cells, primary cultured cells or in a biological sample from a subject can be assayed by measuring LECT2 mRNA levels, such as by bDNA or TaqMan assay, or by measuring protein levels, such as by immunofluorescence analysis, using, for example, Western
20 Blotting or flow cytometric techniques.

A dsRNA includes two RNA strands that are sufficiently complementary to hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence, derived from the
25 sequence of an mRNA formed during the expression of a LECT2 gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. Generally, the duplex structure is between 15 and 30 inclusive, more generally between 18 and 25 inclusive, yet more generally between 19 and 24 inclusive, and most generally between 19
30 and 21 base pairs in length, inclusive. Similarly, the region of complementarity to the target sequence is between 15 and 30 inclusive, more generally between 18 and 25 inclusive, yet more

generally between 19 and 24 inclusive, and most generally between 19 and 21 nucleotides in length, inclusive.

In some embodiments, the dsRNA is between 15 and 20 nucleotides in length, inclusive, and in other embodiments, the dsRNA is between 25 and 30 nucleotides in length, inclusive. As the ordinarily skilled person will recognize, the targeted region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to be a substrate for RNAi-directed cleavage (*i.e.*, cleavage through a RISC pathway). dsRNAs having duplexes as short as 9 base pairs can, under some circumstances, mediate RNAi-directed RNA cleavage. Most often a target will be at least 15 nucleotides in length, *e.g.*, 15-30 nucleotides in length.

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, *e.g.*, a duplex region of 9 to 36, *e.g.*, 15-30 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex of *e.g.*, 15-30 base pairs that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, then, an miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target LECT2 expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein may further include one or more single-stranded nucleotide overhangs. The dsRNA can be synthesized by standard methods known in the art as further discussed below, *e.g.*, by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc.

In one embodiment, a LECT2 gene is a human LECT2 gene. In another embodiment the LECT2 gene is a mouse or a rat LECT2 gene.

In specific embodiments, the dsRNA comprises a sense strand that comprises or consists of a sense sequence selected from the sense sequences provided in Tables 2A-2B, 3A-3B, 6, or 7, and an antisense strand that comprises or consists of an antisense sequence selected from the antisense sequences provided in Tables 2A-2B, 3A-3B, 6, or 7.

In one aspect, a dsRNA will include at least sense and antisense nucleotide sequences, whereby the sense strand is selected from the sequences provided in Tables 2A-2B, 3A-3B, 6, or

7, and the corresponding antisense strand is selected from the sequences provided in Tables 2A-2B, 3A-3B, 6, or 7.

In these aspects, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated by the expression of a LECT2 gene. As such, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand, and the second oligonucleotide is described as the corresponding antisense strand. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

The skilled person is well aware that dsRNAs having a duplex structure of between 20 and 23, but specifically 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir *et al.*, *EMBO* 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can be effective as well.

In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in Tables 2A-2B, 3A-3B, 6, or 7, dsRNAs described herein can include at least one strand of a length of minimally 19 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of Tables 2A-2B, 3A-3B, 6, or 7 minus only a few nucleotides on one or both ends will be similarly effective as compared to the dsRNAs described above.

In some embodiments, the dsRNA has a partial sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from one of the sequences of Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the dsRNA has an antisense sequence that comprises at least 15, 16, 17, 18, or 19 contiguous nucleotides of an antisense sequence provided in Tables 2A-2B, 3A-3B, 6, or 7 and a sense sequence that comprises at least 15, 16, 17, 18, or 19 contiguous nucleotides of a corresponding sense sequence provided in Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the dsRNA comprises an antisense sequence that comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of an antisense sequence provided in Tables 2A-2B or 3A-3B and a sense sequence that comprises at least 15, 16, 17, 18, 19, 20, or 21 contiguous nucleotides of a corresponding sense sequence provided in Tables 2A-2B, 3A-3B, 6, or 7.

In some embodiments, the dsRNA comprises an antisense sequence that comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of an antisense sequence provided in Table 2A or 2B and a sense sequence that comprises at least 15, 16, 17, 18, 19, 20, or 21 contiguous nucleotides of a corresponding sense sequence provided in Table 2A or 2B.

5 In some embodiments, the dsRNA comprises an antisense sequence that comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of an antisense sequence provided in Table 3A or 3B and a sense sequence that comprises at least 15, 16, 17, 18, 19, 20, or 21 contiguous nucleotides of a corresponding sense sequence provided in Table 3A or 3B.

10 In some embodiments, the dsRNA comprises an antisense sequence that comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of an antisense sequence provided in Table 6 or 7 and a sense sequence that comprises at least 15, 16, 17, 18, 19, 20, or 21 contiguous nucleotides of a corresponding sense sequence provided in Table 6 or 7.

In some such embodiments, the dsRNA, although it comprises only a portion of the
15 sequences provided in Tables 2A-2B, 3A-3B, 6 or 7 is equally effective in inhibiting a level of LECT2 expression as is a dsRNA that comprises the full-length sequences provided in Tables 2A-2B, 3A-3B, 6 or 7. In some embodiments, the dsRNA differs in its inhibition of a level of expression of a LECT2 gene by not more than 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 % inhibition compared with a dsRNA comprising the full sequence disclosed herein.

20 The iRNAs provided in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7 identify a site in a LECT2 transcript that is susceptible to RISC-mediated cleavage. As such, the present disclosure further features iRNAs that target within one of such sequences. As used herein, an iRNA is said to target within a particular site of an RNA transcript if the iRNA promotes cleavage of the transcript anywhere within that particular site. Such an iRNA will generally include at least 15
25 contiguous nucleotides from one of the sequences provided in Tables 2A-2B, 3A-3B, 4A-4B, or 5-7 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in a LECT2 gene.

While a target sequence is generally 15-30 nucleotides in length, there is wide variation in the suitability of particular sequences in this range for directing cleavage of any given target
30 RNA. Various software packages and the guidelines set out herein provide guidance for the identification of optimal target sequences for any given gene target, but an empirical approach

can also be taken in which a “window” or “mask” of a given size (as a non-limiting example, 21 nucleotides) is literally or figuratively (including, *e.g.*, in silico) placed on the target RNA sequence to identify sequences in the size range that may serve as target sequences. By moving the sequence “window” progressively one nucleotide upstream or downstream of an initial target sequence location, the next potential target sequence can be identified, until the complete set of possible sequences is identified for any given target size selected. This process, coupled with systematic synthesis and testing of the identified sequences (using assays described herein or known in the art) to identify those sequences that perform optimally can identify those RNA sequences that, when targeted with an iRNA agent, mediate the best inhibition of target gene expression. Thus, while the sequences identified, for example, in Tables 2A-2B, 3A-3B, 6 or 7, represent effective target sequences, it is contemplated that further optimization of inhibition efficiency can be achieved by progressively “walking the window” one nucleotide upstream or downstream of the given sequences to identify sequences with equal or better inhibition characteristics.

Further, it is contemplated that for any sequence identified, *e.g.*, in Tables 2A-2B, 3A-3B, 6 or 7, further optimization can be achieved by systematically either adding or removing nucleotides to generate longer or shorter sequences and testing those and sequences generated by walking a window of the longer or shorter size up or down the target RNA from that point. Again, coupling this approach to generating new candidate targets with testing for effectiveness of iRNAs based on those target sequences in an inhibition assay as known in the art or as described herein can lead to further improvements in the efficiency of inhibition. Further still, such optimized sequences can be adjusted by, *e.g.*, the introduction of modified nucleotides as described herein or as known in the art, addition or changes in overhang, or other modifications as known in the art and/or discussed herein to further optimize the molecule (*e.g.*, increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to a particular location or cell type, increasing interaction with silencing pathway enzymes, increasing release from endosomes, *etc.*) as an expression inhibitor.

An iRNA as described herein can contain one or more mismatches to the target sequence. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch not be located in the center of the region of complementarity. If the antisense

strand of the iRNA contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5' or 3' end of the region of complementarity. For example, for a 23 nucleotide iRNA agent RNA strand which is complementary to a region of a LECT2 gene, the RNA strand generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of a LECT2 gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of a LECT2 gene is important, especially if the particular region of complementarity in a LECT2 gene is known to have polymorphic sequence variation within the population.

In one embodiment, at least one end of a dsRNA has a single-stranded nucleotide overhang of 1 to 4, generally 1 or 2 nucleotides. dsRNAs having at least one nucleotide overhang have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. In yet another embodiment, the RNA of an iRNA (*e.g.*, a dsRNA) is chemically modified to enhance stability or other beneficial characteristics. The nucleic acids featured in the disclosure may be synthesized and/or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry," Beaucage, S.L. *et al.* (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is hereby incorporated herein by reference. Modifications include, for example, (a) end modifications, *e.g.*, 5' end modifications (phosphorylation, conjugation, inverted linkages, *etc.*) 3' end modifications (conjugation, DNA nucleotides, inverted linkages, *etc.*), (b) base modifications, *e.g.*, replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases, (c) sugar modifications (*e.g.*, at the 2' position or 4' position, or having an acyclic sugar) or replacement of the sugar, as well as (d) backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of RNA compounds useful in this disclosure include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also

be considered to be oligonucleosides. In particular embodiments, the modified RNA will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl
5 and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked
10 analogs of these, and those) having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717;
15 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and US Pat RE39464, each of which is herein
20 incorporated by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed
25 in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134;

5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, each of which is herein incorporated by reference.

5 In other RNA mimetics suitable or contemplated for use in iRNAs, both the sugar and the internucleoside linkage, *i.e.*, the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA
10 compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference.
15 Further teaching of PNA compounds can be found, for example, in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

Some embodiments featured in the disclosure include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular --CH₂--NH--CH₂--, --CH₂--N(CH₃)--O--CH₂--[known as a methylene (methylimino) or MMI backbone], --CH₂--O--
20 --N(CH₃)--CH₂--, --CH₂--N(CH₃)--N(CH₃)--CH₂-- and --N(CH₃)--CH₂--CH₂--[wherein the native phosphodiester backbone is represented as --O--P--O--CH₂--] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

25 Modified RNAs may also contain one or more substituted sugar moieties. The iRNAs, *e.g.*, dsRNAs, featured herein can include one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃,
30 O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2'


position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the

5 pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-O--CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, *Helv. Chim. Acta*, 1995, 78:486-504) *i.e.*, an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminoethoxyethoxy, *i.e.*, a
10 O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), *i.e.*, 2'-O--CH₂--O--CH₂--N(CH₂)₂.

In other embodiments, an iRNA agent comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides (or nucleosides). In certain embodiments, the sense strand
15 or the antisense strand, or both sense strand and antisense strand, include less than five acyclic nucleotides per strand (*e.g.*, four, three, two or one acyclic nucleotides per strand). The one or more acyclic nucleotides can be found, for example, in the double-stranded region, of the sense or antisense strand, or both strands; at the 5'-end, the 3'-end, both of the 5' and 3'-ends of the sense or antisense strand, or both strands, of the iRNA agent. In one embodiment, one or more
20 acyclic nucleotides are present at positions 1 to 8 of the sense or antisense strand, or both. In one embodiment, one or more acyclic nucleotides are found in the antisense strand at positions 4 to 10 (*e.g.*, positions 6-8) from the 5'-end of the antisense strand. In another embodiment, the one or more acyclic nucleotides are found at one or both 3'-terminal overhangs of the iRNA agent.

The term "acyclic nucleotide" or "acyclic nucleoside" as used herein refers to any
25 nucleotide or nucleoside having an acyclic sugar, *e.g.*, an acyclic ribose. An exemplary acyclic nucleotide or nucleoside can include a nucleobase, *e.g.*, a naturally-occurring or a modified nucleobase (*e.g.*, a nucleobase as described herein). In certain embodiments, a bond between any of the ribose carbons (C1, C2, C3, C4, or C5), is independently or in combination absent from the nucleotide. In one embodiment, the bond between C2-C3 carbons of the ribose ring is
30 absent, *e.g.*, an acyclic 2'-3'-seco-nucleotide monomer. In other embodiments, the bond between C1-C2, C3-C4, or C4-C5 is absent (*e.g.*, a 1'-2', 3'-4' or 4'-5'-seco nucleotide

monomer). Exemplary acyclic nucleotides are disclosed in US 8,314,227, incorporated herein by reference in its entirety. For example, an acyclic nucleotide can include any of monomers D-J in Figures 1-2 of US 8,314,227. In one embodiment, the acyclic nucleotide includes the following monomer:



wherein Base is a nucleobase, *e.g.*, a naturally-occurring or a modified nucleobase (*e.g.*, a nucleobase as described herein).

In certain embodiments, the acyclic nucleotide can be modified or derivatized, *e.g.*, by coupling the acyclic nucleotide to another moiety, *e.g.*, a ligand (*e.g.*, a GalNAc, a cholesterol ligand), an alkyl, a polyamine, a sugar, a polypeptide, among others.

In other embodiments, the iRNA agent includes one or more acyclic nucleotides and one or more LNAs (*e.g.*, an LNA as described herein). For example, one or more acyclic nucleotides and/or one or more LNAs can be present in the sense strand, the antisense strand, or both. The number of acyclic nucleotides in one strand can be the same or different from the number of LNAs in the opposing strand. In certain embodiments, the sense strand and/or the antisense strand comprises less than five LNAs (*e.g.*, four, three, two or one LNAs) located in the double stranded region or a 3'-overhang. In other embodiments, one or two LNAs are located in the double stranded region or the 3'-overhang of the sense strand. Alternatively, or in combination, the sense strand and/or antisense strand comprises less than five acyclic nucleotides (*e.g.*, four, three, two or one acyclic nucleotides) in the double-stranded region or a 3'-overhang. In one embodiment, the sense strand of the iRNA agent comprises one or two LNAs in the 3'-overhang of the sense strand, and one or two acyclic nucleotides in the double-stranded region of the antisense strand (*e.g.*, at positions 4 to 10 (*e.g.*, positions 6-8) from the 5'-end of the antisense strand) of the iRNA agent.

In other embodiments, inclusion of one or more acyclic nucleotides (alone or in addition to one or more LNAs) in the iRNA agent results in one or more (or all) of: (i) a reduction in an off-target effect; (ii) a reduction in passenger strand participation in RNAi; (iii) an increase in specificity of the guide strand for its target mRNA; (iv) a reduction in a microRNA off-target

effect; (v) an increase in stability; or (vi) an increase in resistance to degradation, of the iRNA molecule.

Other modifications include 2'-methoxy (2'-OCH₃), 2'-5 aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the RNA of an iRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. iRNAs may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

An iRNA may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine.

Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in *Modified Nucleosides in Biochemistry, Biotechnology and Medicine*, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in *The Concise Encyclopedia of Polymer Science and Engineering*, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, those disclosed by Englisch *et al.*, *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, *dsRNA Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B.,

Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., *dsRNA Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, also herein incorporated by reference.

The RNA of an iRNA can also be modified to include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acids (LNA) (also referred to herein as "locked nucleotides"). In one embodiment, a locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting, *e.g.*, the 2' and 4' carbons. This structure effectively "locks" the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, increase thermal stability, and to reduce off-target effects (Elmen, J. *et al.*, (2005) *Nucleic Acids Research* 33(1):439-447; Mook, OR. *et al.*, (2007) *Mol Canc Ther* 6(3):833-843; Grunweller, A. *et al.*, (2003) *Nucleic Acids Research* 31(12):3185-3193).

Representative U.S. Patents that teach the preparation of locked nucleic acids include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,670,461; 6,794,499; 6,998,484; 7,053,207; 7,084,125; 7,399,845, and 8,314,227, each of which is herein incorporated by reference in its entirety. Exemplary LNAs include but are not limited to, a 2', 4'-C methylene bicyclo nucleotide (see for example Wengel *et al.*, International PCT 5 Publication No. WO 00/66604 and WO 99/14226).

In other embodiments, the iRNA agents include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J.*

Am. Chem. Soc., 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in the iRNA molecules can result in enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3"- phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in PCT

Publication No. WO 2011/005861.

iRNA Motifs

In one embodiment, the sense strand sequence may be represented by formula (I):



wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

each N_a independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p and n_q independently represent an overhang nucleotide;

wherein N_b and Y do not have the same modification; and

XXX, YYY and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. Preferably YYY is all 2'-F modified nucleotides.

In one embodiment, the N_a and/or N_b comprise modifications of alternating pattern.

In one embodiment, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (*e.g.*: can occur at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12 or 11, 12, 13) of the sense strand, the count starting from the 1st nucleotide, from the 5'-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'-end.

In one embodiment, *i* is 1 and *j* is 0, or *i* is 0 and *j* is 1, or both *i* and *j* are 1. The sense strand can therefore be represented by the following formulas:

5' n_p -N_a-YYY-N_b-ZZZ-N_a-n_q 3' (Ib);

5' n_p -N_a-XXX-N_b-YYY-N_a-n_q 3' (Ic); or

5' n_p -N_a-XXX-N_b-YYY-N_b-ZZZ-N_a-n_q 3' (Id).

When the sense strand is represented by formula (Ib), N_b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_b independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Preferably, N_b is 0, 1, 2, 3, 4, 5 or 6. Each N_a can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X, Y and Z may be the same or different from 5 each other.

In other embodiments, *i* is 0 and *j* is 0, and the sense strand may be represented by the formula:

5' n_p -N_a-YYY- N_a-n_q 3' (Ia).

When the sense strand is represented by formula (Ia), each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):

5' n_q'-N_a'-(Z'Z'Z')_k-N_b'-Y'Y'Y'-N_b'-(X'X'X')_l-N'_a-n_p' 3' (II)

wherein:

k and l are each independently 0 or 1;

p' and q' are each independently 0-6;

each N_a' independently represents an oligonucleotide sequence comprising 0-25

5 modified

nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p' and n_q' independently represent an overhang nucleotide;

10 wherein N_b' and Y' do not have the same modification;

and

X'X'X', Y'Y'Y', and Z'Z'Z' each independently represent one of three identical modification on three consecutive nucleotides.

In one embodiment, the N_a' and/or N_b' comprise modification of alternating pattern.

15 The Y'Y'Y' motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the Y'Y'Y' motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14 ; or 13, 14, 15 of the antisense strand, with the count starting from the 1st nucleotide, from the 5'-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'- end.

20 Preferably, the Y'Y'Y' motif occurs at positions 11, 12, 13.

In one embodiment, Y'Y'Y' motif is all 2'-Ome modified nucleotides.

In one embodiment, k is 1 and l is 0, or k is 0 and l is 1, or both k and l are 1.

The antisense strand can therefore be represented by the following formulas:

5' n_q'-N_a'-Z'Z'Z'-N_b'-Y'Y'Y'-N_a'-n_p' 3' (IIb);

25 5' n_q'-N_a'-Y'Y'Y'-N_b'-X'X'X'-n_p' 3' (IIc); or


5' n_q'-N_a'-Z'Z'Z'-N_b'-Y'Y'Y'-N_b'-X'X'X'-N_a'-n_p' 3' (IId).

When the antisense strand is represented by formula (IIb), N_b' represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified

30 nucleotides.

When the antisense strand is represented as formula (IIId), each N_b independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Preferably, N_b is 0, 1, 2, 3, 4, 5 or 6.

In other embodiments, k is 0 and l is 0 and the antisense strand may be represented by the formula:



When the antisense strand is represented as formula (IIa), each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X' , Y' and Z' may be the same or different from each other.


Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, HNA, CeNA, GNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-hydroxyl, or 2'-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2'-O-methyl or 2'-fluoro. Each X , Y , Z , X' , Y' and Z' , in particular, may represent a 2'-O-methyl modification or a 2'-fluoro modification.

In one embodiment, the sense strand of the RNAi agent may contain YYY motif occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the count starting from the 1st nucleotide from the 5'-end, or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'-end; and Y represents 2'-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2'-OMe modification or 2'-F modification.

In one embodiment the antisense strand may $Y'Y'Y'$ motif occurring at positions 11, 12, 13 of the strand, the count starting from the 1st nucleotide from the 5'-end, or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'-end; and Y' represents 2'-O-methyl modification. The antisense strand may additionally contain $X'X'X'$ motif or $Z'Z'Z'$ motifs as wing modifications at the opposite end of the duplex region; and $X'X'X'$ and $Z'Z'Z'$ each independently represents a 2'-OMe modification or 2'-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with an antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, the RNAi agents for use in the methods of the disclosure may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex represented by formula (III):



wherein,

i, j, k, and l are each independently 0 or 1;

p, p', q, and q' are each independently 0-6;

each N_a and N_a' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b and N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;




wherein

each n_p , n_p , n_q , and n_q , each of which may or may not be present independently represents an overhang nucleotide; and


XXX, YYY, ZZZ, $X'X'X'$, $Y'Y'Y'$, and $Z'Z'Z'$ each independently represent one motif of three identical modification on three consecutive nucleotides.

In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and l is 0; or k is 1 and l is 0; k is 0 and l is 1; or both k and l are 0; or both k and l are 1.

Exemplary combinations of the sense strand and antisense strand forming a RNAi duplex include the formulas below:



(IIIc)



(IIIId)

5 When the RNAi agent is represented by formula (IIIa), each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented by formula (IIIb), each N_b independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified
10 nucleotides.

When the RNAi agent is represented as formula (IIIc), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

15 When the RNAi agent is represented as formula (IIId), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a , N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N_a , N_a' , N_b and N_b' independently comprises modifications of alternating pattern.

20 Each of X, Y and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.

When the RNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y' nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y'
25 nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y' nucleotides.

When the RNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z' nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z' nucleotides; or all three of the Z
30 nucleotides all form base pairs with the corresponding Z' nucleotides.

When the RNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X' nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X' nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X' nucleotides.

5 In one embodiment, the modification on the Y nucleotide is different than the modification on the Y' nucleotide, the modification on the Z nucleotide is different than the modification on the Z' nucleotide, and/or the modification on the X nucleotide is different than the modification on the X' nucleotide.

10 In one embodiment, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications. In another embodiment, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications and $n_{p'} > 0$ and at least one $n_{p'}$ is linked to a neighboring nucleotide via a phosphorothioate linkage. In yet another embodiment, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_{p'} > 0$ and at least one $n_{p'}$ is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. In another embodiment, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_{p'} > 0$ and at least one $n_{p'}$ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

25 In one embodiment, when the RNAi agent is represented by formula (IIIa), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_{p'} > 0$ and at least one $n_{p'}$ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

30 In one embodiment, the RNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, the RNAi agent is a multimer containing three, four, five, six or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, two RNAi agents represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5' end, and one or both of the 3' ends and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

iRNA Conjugates

The iRNA agents disclosed herein can be in the form of conjugates. The conjugate may be attached at any suitable location in the iRNA molecule, *e.g.*, at the 3' end or the 5' end of the sense or the antisense strand. The conjugates are optionally attached via a linker.

In some embodiments, an iRNA agent described herein is chemically linked to one or more ligands, moieties or conjugates, which may confer functionality, *e.g.*, by affecting (*e.g.*, enhancing) the activity, cellular distribution or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86: 6553-6556), cholic acid (Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1994, 4:1053-1060), a thioether, *e.g.*, beryl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306-309; Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1993, 3:2765-2770), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533-538), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J*, 1991, 10:1111-1118; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327-330; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49-54), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969-973), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923-937).

In one embodiment, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In some embodiments, a ligand provides an enhanced affinity for a selected target, *e.g.*, molecule, cell or cell type, compartment, *e.g.*, a cellular or organ compartment, tissue, organ or region of the body, as, *e.g.*, compared to a species absent
5 such a ligand. Typical ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (*e.g.*, human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (*e.g.*, a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, *e.g.*, a synthetic
10 polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or
15 polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an α helical peptide.

Ligands can also include targeting groups, *e.g.*, a cell or tissue targeting agent, *e.g.*, a
20 lectin, glycoprotein, lipid or protein, *e.g.*, an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate,
25 polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic.

In some embodiments, the ligand is a GalNAc ligand that comprises one or more N-acetylgalactosamine (GalNAc) derivatives. In some embodiments, the GalNAc ligand is used to target the iRNA to the liver (*e.g.*, to hepatocytes). Additional description of GalNAc ligands is
30 provided in the section titled Carbohydrate Conjugates.

Other examples of ligands include dyes, intercalating agents (*e.g.* acridines), cross-linkers (*e.g.* psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (*e.g.*, phenazine, dihydrophenazine), artificial endonucleases (*e.g.* EDTA), lipophilic molecules, *e.g.* cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (*e.g.*, antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (*e.g.*, PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (*e.g.* biotin), transport/absorption facilitators (*e.g.*, aspirin, vitamin E, folic acid), synthetic ribonucleases (*e.g.*, imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu³⁺ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, *e.g.*, glycoproteins, or peptides, *e.g.*, molecules having a specific affinity for a co-ligand, or antibodies *e.g.*, an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF- κ B.

The ligand can be a substance, *e.g.*, a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, *e.g.*, by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins *etc.* Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin *etc.* Oligonucleotides that comprise a number of phosphorothioate linkages are

also known to bind to serum protein, thus short oligonucleotides, *e.g.*, oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present disclosure as ligands (*e.g.* as PK modulating ligands). In addition, aptamers that bind serum components (*e.g.* serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated oligonucleotides of the disclosure may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present disclosure may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present disclosure, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present disclosure are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

Lipid Conjugates

In one embodiment, the ligand is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule can typically bind a serum protein, such as human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, neproxin or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, *e.g.*, HSA.

A lipid-based ligand can be used to modulate, *e.g.*, control (*e.g.*, inhibit) the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In one embodiment, the lipid-based ligand binds HSA. For example, the ligand can bind HSA with a sufficient affinity such that distribution of the conjugate to a non-kidney tissue is enhanced. However, the affinity is typically not so strong that the HSA-ligand binding cannot be reversed.

In another embodiment, the lipid-based ligand binds HSA weakly or not at all, such that distribution of the conjugate to the kidney is enhanced. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid-based ligand.

In another aspect, the ligand is a moiety, *e.g.*, a vitamin, which is taken up by a target cell, *e.g.*, a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, *e.g.*, of the malignant or non-malignant type, *e.g.*, cancer cells.

Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include B vitamin, *e.g.*, folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HSA and low-density lipoprotein (LDL).

Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, such as a helical cell-permeation agent. In one embodiment, the agent is amphipathic. An exemplary agent is a peptide such as

tat or antennopodia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is typically an α -helical agent, and can have a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to
5 herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, *e.g.*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

10 A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (*e.g.*, consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF
15 having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 903). An RFGF analogue (*e.g.*, amino acid sequence AALLPVLLAAP (SEQ ID NO: 904)) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein
20 (GRKKRRQRRRPPQ (SEQ ID NO: 905)) and the *Drosophila Antennapedia* protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 906)) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam *et al.*, *Nature*, 354:82-84, 1991). Typically, the peptide or
25 peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

30 An RGD peptide for use in the compositions and methods of the disclosure may be linear or cyclic, and may be modified, *e.g.*, glycosylated or methylated, to facilitate targeting to a

specific tissue(s). RGD-containing peptides and peptidomimetics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PECAM-1 or VEGF.

An RGD peptide moiety can be used to target a particular cell type, *e.g.*, a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann *et al.*, *Cancer Res.*, 62:5139-43, 2002). An RGD peptide can facilitate targeting of an dsRNA agent to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki *et al.*, *Cancer Gene Therapy* 8:783-787, 2001). Typically, the RGD peptide will facilitate targeting of an iRNA agent to the kidney. The RGD peptide can be linear or cyclic, and can be modified, *e.g.*, glycosylated or methylated to facilitate targeting to specific tissues. For example, a glycosylated RGD peptide can deliver a iRNA agent to a tumor cell expressing $\alpha_v\beta_3$ (Haubner *et al.*, *Jour. Nucl. Med.*, 42:326-336, 2001).

A “cell permeation peptide” is capable of permeating a cell, *e.g.*, a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α -helical linear peptide (*e.g.*, LL-37 or Ceropin P1), a disulfide bond-containing peptide (*e.g.*, α -defensin, β -defensin or bactenecin), or a peptide containing only one or two dominating amino acids (*e.g.*, PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni *et al.*, *Nucl. Acids Res.* 31:2717-2724, 2003).

Carbohydrate Conjugates


In some embodiments of the compositions and methods of the disclosure, an iRNA oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the *in vivo* delivery of nucleic acids, as well as compositions suitable for *in vivo* therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate *per se* made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can

be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (*e.g.*, C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (*e.g.*, C5, C6, C7, or C8).

In one embodiment, a carbohydrate conjugate comprises a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine (GalNAc). GalNAc conjugates, which comprise one or more N-acetylgalactosamine (GalNAc) derivatives, are described, for example, in U.S. Patent No. 8,106,022, the entire content of which is hereby incorporated herein by reference. In some embodiments, the GalNAc conjugate serves as a ligand that targets the iRNA to particular cells. In some embodiments, the GalNAc conjugate targets the iRNA to liver cells, *e.g.*, by serving as a ligand for the asialoglycoprotein receptor of liver cells (*e.g.*, hepatocytes).


In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives may be attached via a linker, *e.g.*, a bivalent or trivalent branched linker. In some embodiments the GalNAc conjugate is conjugated to the 3' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (*e.g.*, to the 3' end of the sense strand) via a linker, *e.g.*, a linker as described herein.

In some embodiments, the GalNAc conjugate is




Formula II.

In some embodiments, the RNAi agent is attached to the carbohydrate conjugate via a linker as shown in the following schematic, wherein X is O or S




In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below




5

In some embodiments, L96 is as follows:




In some embodiments, a carbohydrate conjugate for use in the compositions and methods of the disclosure is selected from the group consisting of:


10




Formula II,




Formula III,




Formula IV,




Formula V,




Formula VI,




Formula VII,




Formula VIII,




Formula IX,




Formula X,




Formula XI,




Formula XII,




Formula XIII,




Formula XIV,




Formula XV,




Formula XVI,




Formula XVII,




Formula XVIII,




Formula XIX,



Formula XX,




Formula XXI,



Formula XXII.

Another representative carbohydrate conjugate for use in the embodiments described


5 herein includes, but is not limited to,




(Formula XXIII), when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator and/or a cell permeation peptide.


In one embodiment, an iRNA of the disclosure is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the




(Formula XXIV),




(Formula XXV),




(Formula XXVI),




(Formula XXVII),



(Formula XXVIII),



5 (Formula XXIX), and



(Formula XXX), when one of X or Y is an oligonucleotide, the other is a hydrogen.

Linkers


10 In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term "linker" or "linking group" means an organic moiety that connects two parts of a compound, *e.g.*, covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR₈, C(O), C(O)NH, SO, SO₂,
 15 SO₂NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl,




arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclalkyl,
 heterocyclalkenyl, heterocyclalkynyl, aryl, heteroaryl, heterocycl, cycloalkyl, cycloalkenyl,
 alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl,
 alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl,
 5 alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl,
 alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl,
 alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclalkyl,
 alkylheterocyclalkenyl, alkylheterocyclalkynyl, alkenylheterocyclalkyl,
 alkenylheterocyclalkenyl, alkenylheterocyclalkynyl, alkynylheterocyclalkyl,
 10 alkynylheterocyclalkenyl, alkynylheterocyclalkynyl, alkylaryl, alkenylaryl, alkynylaryl,
 alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl, which one or more methylenes can be
 interrupted or terminated by O, S, S(O), SO₂, N(R₈), C(O), substituted or unsubstituted aryl,
 substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R₈ is
 15 hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is between
 about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or
 8-16 atoms.

In one embodiment, a dsRNA of the disclosure is conjugated to a bivalent or trivalent
 branched linker selected from the group of structures shown in any of formula (XXXI) –
 (XXXIV):

Formula XXXI



Formula XXXII



Formula XXXIII

Formula XXXIV

5


wherein:

q^{2A}, q^{2B}, q^{3A}, q^{3B}, q^{4A}, q^{4B}, q^{5A}, q^{5B} and q^{5C} represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

10 P^{2A}, P^{2B}, P^{3A}, P^{3B}, P^{4A}, P^{4B}, P^{5A}, P^{5B}, P^{5C}, T^{2A}, T^{2B}, T^{3A}, T^{3B}, T^{4A}, T^{4B}, T^{4A}, T^{5B}, T^{5C} are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O;


Q^{2A}, Q^{2B}, Q^{3A}, Q^{3B}, Q^{4A}, Q^{4B}, Q^{5A}, Q^{5B}, Q^{5C} are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(R^N), C(R')=C(R''), C≡C or C(O);

15 R^{2A}, R^{2B}, R^{3A}, R^{3B}, R^{4A}, R^{4B}, R^{5A}, R^{5B}, R^{5C} are each independently for each occurrence absent, NH, O, S, CH₂, C(O)O, C(O)NH, NHCH(R^a)C(O), -C(O)-CH(R^a)-NH-, CO, CH=N-O,



L^{2A} , L^{2B} , L^{3A} , L^{3B} , L^{4A} , L^{4B} , L^{5A} , L^{5B} and L^{5C} represent the ligand; *i.e.* each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R^a is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXV):

Formula XXXV



(VII)

wherein L^{5A} , L^{5B} and L^{5C} represent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, *e.g.*, be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, *e.g.*, be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, *e.g.*, pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, *e.g.*, oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, *e.g.*, those that result in a

pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, *e.g.*, blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood or serum (or under *in vitro* conditions selected to mimic extracellular conditions).

Redox cleavable linking groups

In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents known in the art, which mimic the rate of cleavage which would be observed in a cell, *e.g.*, a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood (or under *in vitro* conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

Phosphate-based cleavable linking groups

In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -O-P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, -O-P(S)(Rk)-S-. Preferred embodiments are -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-. A preferred embodiment is -O-P(O)(OH)-O-. These candidates can be evaluated using methods analogous to those described above.

Acid cleavable linking groups

In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (*e.g.*, about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula $-C=NN-$, $C(O)O-$, or $-OC(O)-$.

A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

Ester-based cleavable linking groups

In another embodiment, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula $-C(O)O-$, or $-OC(O)-$. These candidates can be evaluated using methods analogous to those described above.

Peptide-based cleavable linking groups

In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (*e.g.*, dipeptides, tripeptides *etc.*) and polypeptides. Peptide-based cleavable groups do not include the amide group ($-C(O)NH-$). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide-based cleavage group is generally limited to the peptide bond (*i.e.*, the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula – $NHCHRAC(O)NHCHRBC(O)-$, where RA and RB are the R groups of the two adjacent amino

acids. These candidates can be evaluated using methods analogous to those described above.

Representative U.S. patents that teach the preparation of RNA conjugates include, but are not

limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730;

5,552,538; 5,578,717; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077;

5 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;

4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963;

5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536;

5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475;

5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726;

10 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931;

6,900,297; 7,037,646; 8,106,022, the entire contents of each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single

15 compound or even at a single nucleoside within an iRNA. The present disclosure also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds, or “chimeras,” in the context of the present disclosure, are iRNA compounds, *e.g.*, dsRNAs, that contain two or more chemically distinct regions, each made up of at least one monomer unit, *i.e.*, a nucleotide in the case of a dsRNA compound.

20 These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the iRNA may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA
25 duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA
30 target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. *et al.*, *Biochem. Biophys. Res. Comm.*, 2007, 365(1):54-61; Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86:6553), cholic acid (Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1994, 4:1053), a thioether, *e.g.*, hexyl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306; Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1993, 3:2765), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J.*, 1991, 10:111; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

Delivery of iRNA

The delivery of an iRNA to a subject in need thereof can be achieved in a number of different ways. *In vivo* delivery can be performed directly by administering a composition comprising an iRNA, *e.g.* a dsRNA, to a subject. Alternatively, delivery can be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

Direct delivery

In general, any method of delivering a nucleic acid molecule can be adapted for use with an iRNA (see e.g., Akhtar S. and Julian RL. (1992) *Trends Cell. Biol.* 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). However, there are

5 three factors that are important to consider in order to successfully deliver an iRNA molecule *in vivo*: (a) biological stability of the delivered molecule, (2) preventing non-specific effects, and (3) accumulation of the delivered molecule in the target tissue. The non-specific effects of an iRNA can be minimized by local administration, for example by direct injection or implantation into a tissue (as a non-limiting example, a tumor) or topically administering the preparation.

10 Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that may otherwise be harmed by the agent or that may degrade the agent, and permits a lower total dose of the iRNA molecule to be administered.

Several studies have shown successful knockdown of gene products when an iRNA is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal

15 injection in cynomolgus monkeys (Tolentino, MJ., *et al* (2004) *Retina* 24:132-138) and subretinal injections in mice (Reich, SJ., *et al* (2003) *Mol. Vis.* 9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J., *et al* (2005) *Mol. Ther.* 11:267-274) and can prolong survival of tumor-bearing mice (Kim, WJ., *et al* (2006) *Mol. Ther.* 14:343-350; Li, S., *et al* (2007) *Mol. Ther.* 15:515-523). RNA interference has

20 also shown success with local delivery to the CNS by direct injection (Dorn, G., *et al.* (2004) *Nucleic Acids* 32:e49; Tan, PH., *et al* (2005) *Gene Ther.* 12:59-66; Makimura, H., *et al* (2002) *BMC Neurosci.* 3:18; Shishkina, GT., *et al* (2004) *Neuroscience* 129:521-528; Thakker, ER., *et al* (2004) *Proc. Natl. Acad. Sci. U.S.A.* 101:17270-17275; Akaneya, Y., *et al* (2005) *J.*

25 *Neurophysiol.* 93:594-602) and to the lungs by intranasal administration (Howard, KA., *et al* (2006) *Mol. Ther.* 14:476-484; Zhang, X., *et al* (2004) *J. Biol. Chem.* 279:10677-10684; Bitko, V., *et al* (2005) *Nat. Med.* 11:50-55). For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases *in*

30 *vivo*.

Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to other groups, *e.g.*, a lipid or carbohydrate group as described herein. Such conjugates can be used to target iRNA to particular cells, *e.g.*, liver cells, *e.g.*, hepatocytes. For example, GalNAc conjugates or lipid (*e.g.*, LNP) formulations can be used to target iRNA to particular cells, *e.g.*, liver cells, *e.g.*, hepatocytes.

Lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., *et al* (2004) *Nature* 432:173-178). Conjugation of an iRNA to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, JO., *et al* (2006) *Nat. Biotechnol.* 24:1005-1015). In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (*see e.g.*, Kim SH., *et al* (2008) *Journal of Controlled Release* 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (*see e.g.*, Sorensen, DR., *et al* (2003) *J. Mol. Biol* 327:761-766; Verma, UN., *et al* (2003) *Clin. Cancer Res.* 9:1291-1300; Arnold, AS *et al* (2007) *J. Hypertens.* 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., *et al* (2003), *supra*; Verma, UN., *et al* (2003), *supra*), Oligofectamine, "solid nucleic acid lipid particles" (Zimmermann, TS., *et al* (2006) *Nature* 441:111-114), cardiolipin (Chien, PY., *et al* (2005) *Cancer Gene Ther.* 12:321-328; Pal, A., *et al* (2005) *Int J. Oncol.* 26:1087-1091), polyethyleneimine (Bonnet ME., *et al* (2008) *Pharm. Res.* Aug 16 Epub ahead of print; Aigner, A. (2006) *J. Biomed. Biotechnol.* 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) *Mol. Pharm.* 3:472-487), and polyamidoamines (Tomalia, DA., *et al* (2007) *Biochem. Soc. Trans.*

35:61-67; Yoo, H., *et al* (1999) *Pharm. Res.* 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Patent No. 7,427,605, which is herein incorporated by reference in its entirety.

5

Vector encoded iRNAs

In another aspect, iRNA targeting the LECT2 gene can be expressed from transcription units inserted into DNA or RNA vectors (*see, e.g.,* Couture, A, *et al., TIG.* (1996), 12:5-10; Skillern, A., *et al.,* International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be
10 transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an
15 extrachromosomal plasmid (Gassmann, *et al., Proc. Natl. Acad. Sci. USA* (1995) 92:1292).

The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (*e.g.,* by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by
20 promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as an inverted repeat joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

An iRNA expression vector is typically a DNA plasmid or viral vector. An expression vector compatible with eukaryotic cells, *e.g.,* with vertebrate cells, can be used to produce
25 recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors contain convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the
30 patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

An iRNA expression plasmid can be transfected into a target cell as a complex with a cationic lipid carrier (*e.g.*, Oligofectamine) or a non-cationic lipid-based carrier (*e.g.*, Transit-TKOTM). Multiple lipid transfections for iRNA-mediated knockdowns targeting different regions of a target RNA over a period of a week or more are also contemplated by the disclosure. Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells *ex vivo* can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (*e.g.*, antibiotics and drugs), such as hygromycin B resistance.

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, *etc.*; (c) adeno- associated virus vectors; (d) herpes simplex virus vectors; (e) SV40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, *e.g.*, vaccinia virus vectors or avipox, *e.g.* canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct may be incorporated into vectors capable of episomal replication, *e.g.* EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, *e.g.*, promoters, enhancers, *etc.*, to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.

Vectors useful for the delivery of an iRNA will include regulatory elements (promoter, enhancer, *etc.*) sufficient for expression of the iRNA in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression.

Expression of the iRNA can be precisely regulated, for example, by using an inducible regulatory sequence that is sensitive to certain physiological regulators, *e.g.*, circulating glucose levels, or hormones (Docherty *et al.*, 1994, *FASEB J.* 8:20-24). Such inducible expression systems, suitable for the control of dsRNA expression in cells or in mammals include, for example, regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of

dimerization, and isopropyl- β -D1-thiogalactopyranoside (IPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the iRNA transgene.

In a specific embodiment, viral vectors that contain nucleic acid sequences encoding an
5 iRNA can be used. For example, a retroviral vector can be used (see Miller *et al.*, *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding an iRNA are cloned into one or more vectors, which facilitates delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example,
10 in Boesen *et al.*, *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes *et al.*, *J. Clin. Invest.* 93:644-651 (1994); Kiem *et al.*, *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson,
15 *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Patent Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.

Adenoviruses are also contemplated for use in delivery of iRNAs. Adenoviruses are especially attractive vehicles, *e.g.*, for delivering genes to respiratory epithelia. Adenoviruses
20 naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout *et al.*, *Human Gene Therapy* 5:3-10 (1994)
25 demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld *et al.*, *Science* 252:431-434 (1991); Rosenfeld *et al.*, *Cell* 68:143-155 (1992); Mastrangeli *et al.*, *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, *et al.*, *Gene Therapy* 2:775-783 (1995). A suitable AV vector for expressing an iRNA featured in the
30 disclosure, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H *et al.* (2002), *Nat. Biotech.* 20: 1006-1010.

Use of Adeno-associated virus (AAV) vectors is also contemplated (Walsh *et al.*, *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Pat. No. 5,436,146). In one embodiment, the iRNA can be expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector having, for example, either the U6 or H1 RNA promoters, or the
5 cytomagalovirus (CMV) promoter. Suitable AAV vectors for expressing the dsRNA featured in the disclosure, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R *et al.* (1987), *J. Virol.* 61: 3096-3101; Fisher K J *et al.* (1996), *J. Virol.*, 70: 520-532; Samulski R *et al.* (1989), *J. Virol.* 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO
10 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.

Another typical viral vector is a pox virus such as a vaccinia virus, for example an attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.

15 The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein
20 serotypes; *see, e.g.*, Rabinowitz J E *et al.* (2002), *J Virol* 76:791-801, the entire disclosure of which is herein incorporated by reference.

The pharmaceutical preparation of a vector can include the vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant
25 cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

III. Pharmaceutical compositions containing iRNA

In one embodiment, the disclosure provides pharmaceutical compositions containing an
30 iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical composition containing the iRNA is useful for treating a disease or disorder related to the

expression or activity of a LECT2 gene (*e.g.*, a LECT2 amyloidosis). Such pharmaceutical compositions are formulated based on the mode of delivery. For example, compositions can be formulated for systemic administration via parenteral delivery, *e.g.*, by intravenous (IV) delivery. In some embodiments, a composition provided herein (*e.g.*, an LNP formulation) is formulated for intravenous delivery. In some embodiments, a composition provided herein (*e.g.*, a composition comprising a GalNAc conjugate) is formulated for subcutaneous delivery.

The pharmaceutical compositions featured herein are administered in a dosage sufficient to inhibit expression of a LECT2 gene. In general, a suitable dose of iRNA will be in the range of 0.01 to 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of 1 to 50 mg per kilogram body weight per day. For example, the dsRNA can be administered at 0.05 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, or 50 mg/kg per single dose. The pharmaceutical composition may be administered once daily, or the iRNA may be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the iRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, *e.g.*, using a conventional sustained release formulation which provides sustained release of the iRNA over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a particular site, such as can be used with the agents of the present disclosure. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.

The effect of a single dose on LECT2 levels can be long lasting, such that subsequent doses are administered at not more than 3, 4, or 5-day intervals, or at not more than 1, 2, 3, or 4 week intervals.

The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and *in vivo* half-lives for the individual iRNAs encompassed by the disclosure can be

made using conventional methodologies or on the basis of *in vivo* testing using a suitable animal model.

A suitable animal model, *e.g.*, a mouse containing a transgene expressing human LECT2, can be used to determine the therapeutically effective dose and/or an effective dosage regimen
5 administration of LECT2 siRNA.

The present disclosure also includes pharmaceutical compositions and formulations that include the iRNA compounds featured herein. The pharmaceutical compositions of the present disclosure may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (*e.g.*, by a
10 transdermal patch), pulmonary, *e.g.*, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, *e.g.*, via an implanted device; or intracranial, *e.g.*, by intraparenchymal, intrathecal or intraventricular, administration.

15 The iRNA can be delivered in a manner to target a particular tissue, such as a tissue that produces erythrocytes. For example, the iRNA can be delivered to bone marrow, liver (*e.g.*, hepatocytes of liver), lymph glands, spleen, lungs (*e.g.*, pleura of lungs) or spine. In one embodiment, the iRNA is delivered to bone marrow.

Pharmaceutical compositions and formulations for topical administration may include
20 transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Suitable topical formulations include those in which the iRNAs featured in the disclosure are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters,
25 steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (*e.g.*, dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (*e.g.*, dimyristoylphosphatidyl glycerol DMPG) and cationic (*e.g.*, dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). iRNAs featured in the disclosure may be encapsulated within liposomes or may form
30 complexes thereto, in particular to cationic liposomes. Alternatively, iRNAs may be complexed to lipids, in particular to cationic lipids. Suitable fatty acids and esters include but are not limited

to arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₂₀ alkyl ester (*e.g.*, isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. Patent No. 6,747,014, which is incorporated herein by reference.

Liposomal formulations

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present disclosure, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to traverse intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou *et al.*, *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while

anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

5 Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (*e.g.*, as a solution or as an emulsion) were ineffective (Weiner *et al.*, *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal
10 formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis *et al.*, *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and
15 cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu *et al.*
20 S.T.P. *Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming
25 lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically
30 stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, 1987, 223, 42; Wu *et al.*, *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (*e.g.*, PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klivanov *et al.* (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, *e.g.*, DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Pat. No. 5,540,935 (Miyazaki *et al.*) and U.S. Pat. No. 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include a dsRNA. U.S. Pat. No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising dsRNAs targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, *e.g.*, they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this

class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Nucleic acid lipid particles

In one embodiment, a LECT2 dsRNA featured in the disclosure is fully encapsulated in the lipid formulation, *e.g.*, to form a SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle. As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle, including SPLP. As used herein, the term “SPLP” refers to a nucleic acid-lipid particle comprising plasmid DNA encapsulated within a lipid vesicle. SNALPs and SPLPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (*e.g.*, a PEG-lipid conjugate). SNALPs and SPLPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (*e.g.*, sites physically separated from the administration site). SPLPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The particles of the present disclosure typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about

70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid- lipid particles of the present disclosure are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, *e.g.*, U.S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; and PCT Publication No. WO 96/40964.

In one embodiment, the lipid to drug ratio (mass/mass ratio) (*e.g.*, lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1.

The cationic lipid may be, for example, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleoyloxypropylamine (DODMA), 1,2-DiLinoleoyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleoyloxy-3-(dimethylamino)acetoxyp propane (DLin-DAC), 1,2-Dilinoleoyloxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleoyloxy-3-dimethylaminopropane (DLin-2-DMA), 1,2-Dilinoleoyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleoyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleoyloxy-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyldidodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid may

comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle.

In another embodiment, the compound 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane can be used to prepare lipid-siRNA nanoparticles. Synthesis of 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane is described in United States provisional patent application number 61/107,998 filed on October 23, 2008, which is herein incorporated by reference.

In one embodiment, the lipid-siRNA particle includes 40% 2, 2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG (mole percent) with a particle size of 63.0 ± 20 nm and a 0.027 siRNA/Lipid Ratio.

The non-cationic lipid may be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyl-oleoylphosphatidylcholine (POPC), palmitoyl-oleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1 -trans PE, 1 -stearoyl-2-oleoyl- phosphatidylethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid may be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.


The conjugated lipid that inhibits aggregation of particles may be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkylloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate may be, for example, a PEG-dilauryloxypropyl (C_{12}), a PEG-dimyristyloxypropyl (C_{14}), a PEG-dipalmitoyloxypropyl (C_{16}), or a PEG-distearoyloxypropyl (C_{18}). The conjugated lipid that prevents aggregation of particles may be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.

In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, *e.g.*, about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.

In some embodiments, the iRNA is formulated in a lipid nanoparticle (LNP).

LNP01

In one embodiment, the lipidoid ND98·4HCl (MW 1487) (see U.S. Patent Application No. 12/056,230, filed 3/26/2008, which is herein incorporated by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (*e.g.*, LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml; Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, *e.g.*, 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (*e.g.*, in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (*e.g.*, 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, *e.g.*, about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.



Formula 1

LNP01 formulations are described, *e.g.*, in International Application Publication No. WO 2008/042973, which is hereby incorporated by reference.

Additional exemplary lipid-dsRNA formulations are provided in the following table.

Table 8: Exemplary lipid formulations

	Cationic Lipid	cationic lipid/non-cationic lipid/cholesterol/PEG-lipid conjugate Lipid:siRNA ratio
SNALP	1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)	DLinDMA/DPPC/Cholesterol/PEG-cDMA (57.1/7.1/34.4/1.4) lipid:siRNA ~ 7:1
S-XTC	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DPPC/Cholesterol/PEG-cDMA 57.1/7.1/34.4/1.4 lipid:siRNA ~ 7:1
LNP05	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid:siRNA ~ 6:1
LNP06	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid:siRNA ~ 11:1
LNP07	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid:siRNA ~ 6:1
LNP08	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid:siRNA ~ 11:1
LNP09	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP10	(3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100)	ALN100/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP11	(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3)	MC-3/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1

LNP12	1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediy)l)didodecan-2-ol (C12-200)	C12-200/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP13	XTC	XTC/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 33:1
LNP14	MC3	MC3/DSPC/Chol/PEG-DMG 40/15/40/5 Lipid:siRNA: 11:1
LNP15	MC3	MC3/DSPC/Chol/PEG-DSG/GalNAc-PEG-DSG 50/10/35/4.5/0.5 Lipid:siRNA: 11:1
LNP16	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP17	MC3	MC3/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP18	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 12:1
LNP19	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/35/5 Lipid:siRNA: 8:1
LNP20	MC3	MC3/DSPC/Chol/PEG-DPG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP21	C12-200	C12-200/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP22	XTC	XTC/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1

DSPC: distearoylphosphatidylcholine

DPPC: dipalmitoylphosphatidylcholine

PEG-DMG: PEG-didimyrystoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000)

5 PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000)

PEG-cDMA: PEG-carbamoyl-1,2-dimyristyloxypylamine (PEG with avg mol wt of 2000)

SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO2009/127060, filed April 15, 10 2009, which is hereby incorporated by reference.

XTC comprising formulations are described, *e.g.*, in U.S. Provisional Serial No. 61/148,366, filed January 29, 2009; U.S. Provisional Serial No. 61/156,851, filed March 2, 2009; U.S. Provisional Serial No. 61/185,712, filed June 10, 2009; U.S. Provisional Serial No. 61/228,373, filed July 24, 2009; U.S. Provisional Serial No. 61/239,686, filed September 3, 15 2009, and International Application No. PCT/US2010/022614, filed January 29, 2010, which are hereby incorporated by reference.

MC3 comprising formulations are described, *e.g.*, in U.S. Provisional Serial No. 61/244,834, filed September 22, 2009, U.S. Provisional Serial No. 61/185,800, filed June 10, 2009, and International Application No. PCT/US10/28224, filed June 10, 2010, which are hereby 20 incorporated by reference.

ALNY-100 comprising formulations are described, *e.g.*, International patent application number PCT/US09/63933, filed on November 10, 2009, which is hereby incorporated by reference.

C12-200 comprising formulations are described in U.S. Provisional Serial No. 61/175,770, filed May 5, 2009 and International Application No. PCT/US10/33777, filed May 5, 25 2010, which are hereby incorporated by reference.

Synthesis of cationic lipids

Any of the compounds, *e.g.*, cationic lipids and the like, used in the nucleic acid-lipid 30 particles featured in the disclosure may be prepared by known organic synthesis techniques. All substituents are as defined below unless indicated otherwise.

“Alkyl” means a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like.

5 Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.

“Alkenyl” means an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both *cis* and *trans* isomers. Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-
10 pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.

“Alkynyl” means any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched
15 alkynyls include acetylenyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, and the like.

“Acyl” means any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. For example, -C(=O)alkyl, -C(=O)alkenyl, and -C(=O)alkynyl are acyl groups.

20 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused
25 to a benzene ring. The heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined below. Heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
30 tetrahydrothiopyranyl, and the like.

The terms “optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted acyl”, and “optionally substituted heterocycle” means that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (=O) two hydrogen atoms are replaced. In this regard, substituents

include oxo, halogen, heterocycle, -CN, -

OR^x, -NR^xR^y, -NR^xC(=O)R^y, -NR^xSO₂R^y, -C(=O)R^x, -C(=O)OR^x, -C(=O)NR^xR^y, -SO_nR^x

and -SO_nNR^xR^y, wherein n is 0, 1 or 2, R^x and R^y are the same or different and independently hydrogen, alkyl or heterocycle, and each of said alkyl and heterocycle substituents may be further substituted with one or more of oxo, halogen, -OH, -CN, alkyl, -OR^x,

heterocycle, -NR^xR^y, -NR^xC(=O)R^y, -NR^xSO₂R^y, -C(=O)R^x, -C(=O)OR^x, -C(=O)NR^xR^y, -SO_nR^x and -SO_nNR^xR^y.

“Halogen” means fluoro, chloro, bromo and iodo.

In some embodiments, the methods featured in the disclosure may require the use of protecting groups. Protecting group methodology is well known to those skilled in the art (*see, for example*, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, Green, T.W. *et al.*, Wiley-


Interscience, New York City, 1999). Briefly, protecting groups within the context of this

disclosure are any group that reduces or eliminates unwanted reactivity of a functional group. A protecting group can be added to a functional group to mask its reactivity during certain reactions and then removed to reveal the original functional group. In some embodiments an

“alcohol protecting group” is used. An “alcohol protecting group” is any group which decreases or eliminates unwanted reactivity of an alcohol functional group. Protecting groups can be added and removed using techniques well known in the art.


Synthesis of Formula A

In one embodiment, nucleic acid-lipid particles featured in the disclosure are formulated using a cationic lipid of formula A:




where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In some embodiments, the cationic lipid is XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane). In general, the lipid of formula A above may be made by the following Reaction Schemes 1 or 2, wherein all substituents are as defined above unless indicated otherwise.

Scheme 1



Lipid A, where R₁ and R₂ are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R₃ and R₄ are independently lower alkyl or R₃ and R₄ can be taken together to form an optionally substituted heterocyclic ring, can be prepared according to Scheme 1. Ketone 1 and bromide 2 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 1 and 2 yields ketal 3. Treatment of ketal 3 with amine 4 yields lipids of formula A. The lipids of formula A can be converted to the corresponding ammonium salt with an organic salt of formula 5, where X is anion counter ion selected from halogen, hydroxide, phosphate, sulfate, or the like.

Scheme 2



Alternatively, the ketone 1 starting material can be prepared according to Scheme 2.


Grignard reagent 6 and cyanide 7 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 6 and 7 yields ketone 1. Conversion of ketone 1 to the corresponding lipids of formula A is as described in Scheme 1.

Synthesis of MC3

Preparation of DLin-M-C3-DMA (*i.e.*, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) was as follows. A solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol (0.53 g), 4-N,N-dimethylaminobutyric acid hydrochloride (0.51 g), 4-N,N-dimethylaminopyridine (0.61 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.53 g) in dichloromethane (5 mL) was stirred at room temperature overnight. The solution was washed with dilute hydrochloric acid followed by dilute aqueous sodium bicarbonate. The organic fractions were dried over anhydrous magnesium sulphate, filtered and the solvent removed on a rotovap. The residue was passed down a silica gel column (20 g) using a 1-5% methanol/dichloromethane elution gradient. Fractions containing the purified product were combined and the solvent removed, yielding a colorless oil (0.54 g).

Synthesis of ALNY-100

Synthesis of ketal 519 [ALNY-100] was performed using the following scheme 3:



Synthesis of 515:

To a stirred suspension of LiAlH₄ (3.74 g, 0.09852 mol) in 200 ml anhydrous THF in a two neck RBF (1L), was added a solution of 514 (10g, 0.04926mol) in 70 mL of THF slowly at 0°C under nitrogen atmosphere. After complete addition, reaction mixture was warmed to room temperature and then heated to reflux for 4 h. Progress of the reaction was monitored by TLC. After completion of reaction (by TLC) the mixture was cooled to 0°C and quenched with careful addition of saturated Na₂SO₄ solution. Reaction mixture was stirred for 4 h at room temperature and filtered off. Residue was washed well with THF. The filtrate and washings were mixed and diluted with 400 mL dioxane and 26 mL conc. HCl and stirred for 20 minutes at room temperature. The volatilities were stripped off under vacuum to furnish the hydrochloride salt of 515 as a white solid. Yield: 7.12 g 1H-NMR (DMSO, 400MHz): δ = 9.34 (broad, 2H), 5.68 (s, 2H), 3.74 (m, 1H), 2.66-2.60 (m, 2H), 2.50-2.45 (m, 5H).

Synthesis of 516:

To a stirred solution of compound 515 in 100 mL dry DCM in a 250 mL two neck RBF, was added NEt₃ (37.2 mL, 0.2669 mol) and cooled to 0°C under nitrogen atmosphere. After a slow addition of N-(benzyloxy-carbonyloxy)-succinimide (20 g, 0.08007 mol) in 50 mL dry DCM, reaction mixture was allowed to warm to room temperature. After completion of the reaction (2-3 h by TLC) mixture was washed successively with 1N HCl solution (1 x 100 mL) and saturated NaHCO₃ solution (1 x 50 mL). The organic layer was then dried over anhyd. Na₂SO₄ and the solvent was evaporated to give crude material which was purified by silica gel column chromatography to get 516 as sticky mass. Yield: 11g (89%). 1H-NMR (CDCl₃,

400MHz): δ = 7.36-7.27(m, 5H), 5.69 (s, 2H), 5.12 (s, 2H), 4.96 (br., 1H) 2.74 (s, 3H), 2.60(m, 2H), 2.30-2.25(m, 2H). LC-MS [M+H] -232.3 (96.94%).

Synthesis of 517A and 517B:

5 The cyclopentene 516 (5 g, 0.02164 mol) was dissolved in a solution of 220 mL acetone and water (10:1) in a single neck 500 mL RBF and to it was added N-methyl morpholine-N-oxide (7.6 g, 0.06492 mol) followed by 4.2 mL of 7.6% solution of OsO₄ (0.275 g, 0.00108 mol) in tert-butanol at room temperature. After completion of the reaction (~ 3 h), the mixture was quenched with addition of solid Na₂SO₃ and resulting mixture was stirred for 1.5 h at room
10 temperature. Reaction mixture was diluted with DCM (300 mL) and washed with water (2 x 100 mL) followed by saturated NaHCO₃ (1 x 50 mL) solution, water (1 x 30 mL) and finally with brine (1x 50 mL). Organic phase was dried over an.Na₂SO₄ and solvent was removed in vacuum. Silica gel column chromatographic purification of the crude material was afforded a mixture of diastereomers, which were separated by prep HPLC. Yield: - 6 g crude

15 517A - Peak-1 (white solid), 5.13 g (96%). ¹H-NMR (DMSO, 400MHz): δ = 7.39-7.31(m, 5H), 5.04(s, 2H), 4.78-4.73 (m, 1H), 4.48-4.47(d, 2H), 3.94-3.93(m, 2H), 2.71(s, 3H), 1.72- 1.67(m, 4H). LC-MS - [M+H]-266.3, [M+NH₄ +]-283.5 present, HPLC-97.86%. Stereochemistry confirmed by X-ray.

20 Synthesis of 518:

 Using a procedure analogous to that described for the synthesis of compound 505, compound 518 (1.2 g, 41%) was obtained as a colorless oil. ¹H-NMR (CDCl₃, 400MHz): δ = 7.35-7.33(m, 4H), 7.30-7.27(m, 1H), 5.37-5.27(m, 8H), 5.12(s, 2H), 4.75(m,1H), 4.58-4.57(m,2H), 2.78-2.74(m,7H), 2.06-2.00(m,8H), 1.96-1.91(m, 2H), 1.62(m, 4H), 1.48(m, 2H),
25 1.37-1.25(br m, 36H), 0.87(m, 6H). HPLC-98.65%.

General Procedure for the Synthesis of Compound 519:

 A solution of compound 518 (1 eq) in hexane (15 mL) was added in a drop-wise fashion to an ice-cold solution of LAH in THF (1 M, 2 eq). After complete addition, the mixture was
30 heated at 40°C over 0.5 h then cooled again on an ice bath. The mixture was carefully hydrolyzed with saturated aqueous Na₂SO₄ then filtered through celite and reduced to an oil.

Column chromatography provided the pure 519 (1.3 g, 68%) which was obtained as a colorless oil. ^{13}C NMR = 130.2, 130.1 (x2), 127.9 (x3), 112.3, 79.3, 64.4, 44.7, 38.3, 35.4, 31.5, 29.9 (x2), 29.7, 29.6 (x2), 29.5 (x3), 29.3 (x2), 27.2 (x3), 25.6, 24.5, 23.3, 22.6, 14.1; Electrospray MS (+ve): Molecular weight for $\text{C}_{44}\text{H}_{80}\text{NO}_2$ (M + H)⁺ Calc. 654.6, Found 654.6.

5 Formulations prepared by either the standard or extrusion-free method can be characterized in similar manners. For example, formulations are typically characterized by visual inspection. They should be whitish translucent solutions free from aggregates or sediment. Particle size and particle size distribution of lipid-nanoparticles can be measured by light scattering using, for example, a Malvern Zetasizer Nano ZS (Malvern, USA). Particles
10 should be about 20-300 nm, such as 40-100 nm in size. The particle size distribution should be unimodal. The total dsRNA concentration in the formulation, as well as the entrapped fraction, is estimated using a dye exclusion assay. A sample of the formulated dsRNA can be incubated with an RNA-binding dye, such as Ribogreen (Molecular Probes) in the presence or absence of a formulation disrupting surfactant, *e.g.*, 0.5% Triton-X100. The total dsRNA in the formulation
15 can be determined by the signal from the sample containing the surfactant, relative to a standard curve. The entrapped fraction is determined by subtracting the “free” dsRNA content (as measured by the signal in the absence of surfactant) from the total dsRNA content. Percent entrapped dsRNA is typically >85%. For SNALP formulation, the particle size is at least 30 nm, at least 40 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at
20 least 100 nm, at least 110 nm, and at least 120 nm. The suitable range is typically about at least 50 nm to about at least 110 nm, about at least 60 nm to about at least 100 nm, or about at least 80 nm to about at least 90 nm.

 Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media,
25 capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the disclosure are administered in conjunction with one or more penetration enhancers surfactants and chelators. Suitable surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof.
30 Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid,

glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, 5 monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (*e.g.*, sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include 10 polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the disclosure may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; 15 polyalkylcyanoacrylates; DEAE-derivatized polyimines, pullulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (*e.g.*, p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), 20 poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. Patent 6,887,906, US Publn. No. 20030027780, and U.S. Patent No. 6,747,014, 25 each of which is incorporated herein by reference.

Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or 30 excipients.

Pharmaceutical compositions of the present disclosure include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

5 The pharmaceutical formulations featured in the present disclosure, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association
10 the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions featured in the present disclosure may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions may also be formulated as suspensions
15 in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Additional Formulations

Emulsions

20 The compositions of the present disclosure may be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1µm in diameter (*see e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y.,
25 volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York,
30 N.Y., volume 2, p. 335; Higuchi *et al.*, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two

immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation.

Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and

Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199).

5 Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (see e.g., Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

15 Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

25 A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

30 Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose

and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

5 Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also
10 commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes
15 and methods for their manufacture have been reviewed in the literature (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been
20 very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical*
25 *Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present disclosure, the compositions of iRNAs and nucleic
30 acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid

solution (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems
5 that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotopically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled*
10 *Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar
15 heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's *Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*,
20 Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the
25 advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310),
30 hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol

decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (*see e.g.*, U.S. Patent Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides *et al.*, *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (*see e.g.*, U.S. Patent Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides *et al.*, *Pharmaceutical Research*, 1994, 11, 1385; Ho *et al.*, *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or iRNAs. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present disclosure will facilitate the increased systemic absorption of iRNAs and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of iRNAs and nucleic acids.

Microemulsions of the present disclosure may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the iRNAs and nucleic acids of the present disclosure. Penetration enhancers used in the microemulsions of the present disclosure may be classified as belonging to one of five broad categories--surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Penetration Enhancers

In one embodiment, the present disclosure employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present disclosure, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of iRNAs through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi *et al.*, *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-

5 dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₂₀ alkyl esters thereof (*e.g.*, methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (*i.e.*, oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, *etc.*) (*see e.g.*, Touitou, E., *et al. Enhancement in Drug Delivery*, CRC Press, Danvers, MA, 2006; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*,
10 1990, 7, 1-33; El Hariri *et al.*, *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman *et al.* Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Suitable bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (*see e.g.*, Malmsten, M. Surfactants and polymers in drug
20 delivery, *Informa Health Care*, New York, NY, 2002; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto *et al.*, *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita *et al.*, *J. Pharm. Sci.*, 1990, 79, 579-583).

30 *Chelating Agents:* Chelating agents, as used in connection with the present disclosure, can be defined as compounds that remove metallic ions from solution by forming complexes

therewith, with the result that absorption of iRNAs through the mucosa is enhanced. With regards to their use as penetration enhancers in the present disclosure, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Suitable chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (*e.g.*, sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of β -diketones (enamines)(*see e.g.*, Katdare, A. *et al.*, *Excipient development for pharmaceutical, biotechnology, and drug delivery*, CRC Press, Danvers, MA, 2006; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur *et al.*, *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of iRNAs through the alimentary mucosa (*see e.g.*, Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita *et al.*, *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of iRNAs at the cellular level may also be added to the pharmaceutical and other compositions of the present disclosure. For example, cationic lipids, such as lipofectin (Junichi *et al.*, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo *et al.*, PCT Application WO 97/30731), are also known to enhance the cellular uptake of dsRNAs. Examples of commercially available transfection reagents include, for example Lipofectamine™ (Invitrogen; Carlsbad, CA), Lipofectamine 2000™ (Invitrogen; Carlsbad, CA), 293fectin™ (Invitrogen; Carlsbad, CA), Cellfectin™ (Invitrogen; Carlsbad, CA), DMRIE-C™ (Invitrogen; Carlsbad, CA), FreeStyle™ MAX (Invitrogen; Carlsbad, CA), Lipofectamine™ 2000 CD (Invitrogen; Carlsbad, CA), Lipofectamine™ (Invitrogen; Carlsbad, CA), RNAiMAX (Invitrogen; Carlsbad, CA),

Oligofectamine™ (Invitrogen; Carlsbad, CA), Optifect™ (Invitrogen; Carlsbad, CA), XtremeGENE Q2 Transfection Reagent (Roche; Grenzacherstrasse, Switzerland), DOTAP Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), DOSPER Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), or Fugene (Grenzacherstrasse, Switzerland), Transfectam® Reagent (Promega; Madison, WI), TransFast™ Transfection Reagent (Promega; Madison, WI), Tfx™-20 Reagent (Promega; Madison, WI), Tfx™-50 Reagent (Promega; Madison, WI), DreamFect™ (OZ Biosciences; Marseille, France), EcoTransfect (OZ Biosciences; Marseille, France), TransPass^a D1 Transfection Reagent (New England Biolabs; Ipswich, MA, USA), LyoVec™/LipoGen™ (Invivogen; San Diego, CA, USA), PerFectin Transfection Reagent (Genlantis; San Diego, CA, USA), NeuroPORTER Transfection Reagent (Genlantis; San Diego, CA, USA), GenePORTER Transfection reagent (Genlantis; San Diego, CA, USA), GenePORTER 2 Transfection reagent (Genlantis; San Diego, CA, USA), Cytofectin Transfection Reagent (Genlantis; San Diego, CA, USA), BaculoPORTER Transfection Reagent (Genlantis; San Diego, CA, USA), TroganPORTER™ transfection Reagent (Genlantis; San Diego, CA, USA), RiboFect (Bioline; Taunton, MA, USA), PlasFect (Bioline; Taunton, MA, USA), UniFECTOR (B-Bridge International; Mountain View, CA, USA), SureFECTOR (B-Bridge International; Mountain View, CA, USA), or HiFect™ (B-Bridge International, Mountain View, CA, USA), among others.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present disclosure also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs,

presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate dsRNA in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *DsRNA Res. Dev.*, 1995, 5, 115-121; Takakura *et al.*, *DsRNA & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, *etc.*, when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, *etc.*); fillers (*e.g.*, lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, *etc.*); lubricants (*e.g.*, magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, *etc.*); disintegrants (*e.g.*, starch, sodium starch glycolate, *etc.*); and wetting agents (*e.g.*, sodium lauryl sulphate, *etc.*).

Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present disclosure. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients

suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc,
5 silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present disclosure may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage
10 levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present disclosure, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.

15 However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present disclosure. The formulations can be sterilized and, if desired, mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic
20 acid(s) of the formulation.

Aqueous suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the disclosure include
25 (a) one or more iRNA compounds and (b) one or more biologic agents which function by a non-RNAi mechanism. Examples of such biologic agents include agents that interfere with an interaction of LECT2 and at least one LECT2 binding partner.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the
30 LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic

index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are typical.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured in the disclosure lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (*e.g.*, achieving a decreased concentration of the polypeptide) that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the iRNAs featured in the disclosure can be administered in combination with other known agents effective in treatment of diseases or disorders related to LECT2 expression. In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

Methods of treating disorders related to expression of a LECT2 gene

The present disclosure relates to the use of an iRNA targeting LECT2 to inhibit LECT2 expression and/or to treat a disease, disorder, or pathological process that is related to LECT2 expression.

In one aspect, a method of treatment of a disorder related to expression of LECT2 is provided, the method comprising administering an iRNA (*e.g.*, a dsRNA) disclosed herein to a subject in need thereof. In some embodiments, the iRNA inhibits (decreases) LECT2 expression. In some embodiments, the iRNA increases LECT2 expression.

As used herein, “a disorder related to LECT2 expression,” a “disease related to LECT2 expression, a “pathological process related to LECT2 expression,” or the like includes any

condition, disorder, or disease in which LECT2 expression is altered (*e.g.*, decreased or increased relative to a normal level). In some embodiments, LECT2 expression is decreased. In some embodiments, LECT2 expression is increased. In some embodiments, the decrease or increase in LECT2 expression is detectable in the blood (*e.g.*, in the plasma) of the subject. In some
5 embodiments, the decrease or increase in LECT2 expression is detectable in a tissue sample from the subject (*e.g.*, in a kidney sample or a liver sample). The decrease or increase may be assessed relative the level observed in the same individual prior to the development of the disorder or relative to other individual(s) who do not have the disorder. The decrease or increase may be limited to a particular organ, tissue, or region of the body (*e.g.*, the kidney or the liver).

10 As used herein, a “subject” to be treated according to the methods described herein, includes a human or non-human animal, *e.g.*, a mammal. The mammal may be, for example, a rodent (*e.g.*, a rat or mouse) or a primate (*e.g.*, a monkey). In some embodiments, the subject is a human.

15 A “subject in need thereof” includes a subject having, suspected of having, or at risk of developing a disorder related to LECT2 expression. In some embodiments, the subject has, or is suspected of having, a disorder related to LECT2 expression. In some embodiments, the subject is at risk of developing a disorder related to LECT2 expression.

In some embodiments, the subject is an animal that serves as a model for a disorder related to LECT2 expression, *e.g.*, a LECT2 amyloidosis.

20 LECT2 Amyloidosis

In some embodiments, the disorder related to LECT2 expression is an amyloidosis, *e.g.*, a LECT2 amyloidosis. LECT2 amyloidosis has been described in several clinical studies. *See, e.g.*, Benson, M.D. *et al* (2008) *Kidney International*, 74: 218-222; Murphy, C. L. *et al.* (2010) *Am J Kidney Dis*, 56(6):1100-1107; Larsen, C.P. *et al.* (2010) *Kidney Int.*, 77(9):816-819;
25 Holanda, D.G. *et al.* (20011) *Nephrol. Dial. Transplant.*, 26 (1): 373-376; and Sethi, S. *et al.* (2012) *Kidney International* 82, 226–234 (hereinafter Sethi *et al.*).

Clinical and pathological features of LECT2 amyloidosis mimic those of amyloid light chain (AL) amyloidosis. These symptoms include, *e.g.*, symptoms of kidney disease and renal failure, *e.g.*, fluid retention, swelling, and shortness of breath. Amyloidosis may affect the heart,
30 peripheral nervous system, gastrointestinal tract, blood, lungs and skin. Heart complications include, *e.g.*, heart failure and irregular heartbeat. Other symptoms include, *e.g.*, stroke,

gastrointestinal disorders, enlarged liver, diminished spleen function, diminished function of the adrenal and other endocrine glands, skin color change or growths, lung problems, bleeding and bruising problems, fatigue and weight loss. In some embodiments, the methods described herein are associated with improvement in one or more symptoms described herein.

5 Methods for diagnosis of amyloidosis, *e.g.*, LECT2 amyloidosis, are described, *e.g.*, in Leung, N. *et al.* (2010) *Blood*, published online September 4, 2012; DOI 10.1182/blood-2012-03-413682; Shiller, S.M. *et al.* (2011). Laboratory Methods for the Diagnosis of Hereditary Amyloidoses, Amyloidosis - Mechanisms and Prospects for Therapy, Dr. Svetlana Sarantseva (Ed.), ISBN: 978-953-307-253-1; Sethi *et al.* (*see above*) and in U.S. Patent Application
10 Publication No. 20100323381.

 Based on the results provided by Sethi *et al.*, LECT2 amyloidosis accounts for a significant percentage of cases of renal amyloidosis. *See* Table 1 of Sethi *et al.*, which shows that 26 out of 127 cases of renal amyloidosis studied by laser microdissection and mass spectrometry of renal biopsy and/or nephrectomy specimens were determined to be of the
15 LECT2 amyloid type. Sethi *et al.* further report that apolipoprotein E protein and serum amyloid P component (SAP) were also present in all cases of LECT2 amyloidosis.

 In some embodiments, the amyloidosis, *e.g.*, the LECT2 amyloidosis, involves systemic amyloid deposition. In some embodiments, the amyloidosis, *e.g.*, the LECT2 amyloidosis, is localized entirely or predominately to a particular tissue or organ (*e.g.*, to the kidney or liver).

20 In some embodiments, the amyloidosis, *e.g.*, the LECT2 amyloidosis, is hereditary.

 In some embodiments, a LECT2 amyloidosis is diagnosed using analysis of a sample from the subject (*e.g.*, a biopsy sample). In some embodiments, the biopsy sample is a renal biopsy. In some embodiments, the sample is a nephrectomy sample. In some embodiments, the sample is from a liver biopsy or from other resected liver tissue. In some embodiments, the
25 sample is analyzed using methods selected from one or more of immunohistochemistry, LECT2 immunoassay, electron microscopy, laser microdissection, and mass spectrometry. In some embodiments, the LECT2 amyloidosis is diagnosed using laser microdissection and mass spectrometry.

 In some embodiments, the amyloidosis, *e.g.*, the LECT2 amyloidosis, affects the kidney,
30 *e.g.*, involves amyloid deposition in the kidney. In some embodiments, kidney function is compromised as a result of the amyloidosis. In some embodiments, the subject suffers from one

or more of fluid retention, swelling, and shortness of breath. In some embodiments, the subject has nephrotic syndrome. In some embodiments, the subject suffers from proteinuria. In some embodiments, the subject has renal failure.

In some embodiments, the amyloidosis, *e.g.*, the LECT2 amyloidosis, affects the liver, *e.g.*, involves amyloid deposition in the liver. In some embodiments, liver function is compromised as a result of the amyloidosis. In some embodiments, the subject has hepatitis, *e.g.*, chronic hepatitis. In some embodiments, the hepatitis is a viral hepatitis.

LECT2 amyloidosis has been found to be particularly prevalent in Mexican Americans and has also been associated with homozygosity for the G allele of the LECT2 gene that encodes valine at position 40 in the mature protein (amino acid 58 in the unprocessed protein). *See, e.g.*, Benson, M.D. *et al.* (2008) *Kidney International*, 74: 218-222; Murphy, C. L. *et al.* (2010) *Am J Kidney Dis*, 56(6):1100-1107.

In some embodiments, the subject is of Mexican descent. In some embodiments, the subject is a Mexican American.

In some embodiments, the subject carries the G allele of the LECT2 gene that encodes valine at position 40 in the mature protein (amino acid 58 in the unprocessed protein). In some embodiments, the subject is homozygous for the G allele (G/G genotype). In some embodiments, a LECT2 protein expressed in the subject has valine at position 40 in the mature protein (or at amino acid 58 in the unprocessed protein).

In some embodiments, the method decreases LECT2 expression. In some embodiments, the decrease in LECT2 expression is assessed relative to the level in the same individual prior to the treatment. In some embodiments, the method is shown to decrease LECT2 expression by comparing the levels of LECT2 expression in a treated subject (or group of subjects) with the levels in a control subject (or group of subjects), *e.g.*, an untreated subject (or group of subjects) or a subject (or group of subjects) treated with a control treatment (*e.g.*, an iRNA (*e.g.*, a dsRNA) that does not target LECT2).

In some embodiments, the method reduces amyloid deposition, *e.g.*, deposition of amyloid comprising a LECT2 protein or a portion thereof. In some embodiments, the protein is a wild type protein. In some embodiments, the protein is a human LECT2 protein, or a portion thereof, that includes valine at position 40 (position 40 of the mature, secreted protein, or at

amino acid 58 in the unprocessed protein, as described herein). In some embodiments, the method decreases the size, number, and/or extent of amyloid deposits.

In some embodiments, the method decreases one or more symptoms associated with amyloid deposition.

5 In some embodiments, the dsRNA is administered in a form that targets the dsRNA to a particular organ or tissue to inhibit amyloid deposition in the organ or tissue.

In some embodiments, the dsRNA is targeted to the liver. In some embodiments, the dsRNA is conjugated to a ligand, *e.g.*, a GalNAc ligand (*e.g.*, a GalNAc ligand as described herein) that targets the dsRNA to the liver (*e.g.*, to hepatocytes).

10 Also provided herein is a method of reducing amyloid deposition, the method comprising administering a dsRNA as disclosed herein to a subject in need thereof (*e.g.*, a subject having, suspected of having, or at risk for developing a LECT2 amyloidosis). In some embodiments, the method decreases (*e.g.*, prevents or diminishes) the size, number, and/or extent of amyloid deposits. The size, number, and/or extent of amyloid deposits may be assessed using any method
15 known in the art (*e.g.*, immunoassay, immunohistochemistry, mass spectrometry). The reduction of amyloid deposition may involve a decrease in amyloid deposition (*e.g.*, size, number, and/or extent of amyloid deposits) of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more.

In the methods provided herein, the iRNA (*e.g.*, dsRNA) and compositions thereof are
20 administered in a therapeutically effective amount. Therapeutic effects of administration of a LECT2 siRNA can be established, for example, by comparison with an appropriate control. For example, inhibition of amyloid deposition may be established, for example, in a group of patients with amyloidosis (*e.g.*, LECT2 amyloidosis) by comparison of any appropriate parameter (*e.g.*, a parameter assessing the size, number, or extent of amyloid deposition) with the same parameter
25 in an appropriate control group. A control group (*e.g.*, a group of similar individuals or the same group of individuals in a crossover design) may include, for example, an untreated population, a population that has been treated with a conventional treatment; a population that has been treated with placebo or a non-targeting iRNA; and the like.

Rheumatoid Arthritis

Rheumatoid arthritis is also a disorder related to LECT2 expression. In particular, in a Japanese population, it was found that possession of one A allele of the LECT2 gene that encodes isoleucine at position 40 in the mature protein (or amino acid 58 in the unprocessed protein) was found to increase the overall risk of developing rheumatoid arthritis. Possessing two A alleles was strongly associated with disease severity. See Kameoka, Y. *et al.* (2000) *Arth Rheum*, 43(6):1419-20.

In one embodiment of the methods provided herein, the disorder related to LECT2 expression is rheumatoid arthritis. In one embodiment, the dsRNA inhibits LECT2 expression in a subject having rheumatoid arthritis. In some such embodiments, the dsRNA inhibits LECT2 expression in synovial tissue and/or in synovial fluid-derived cells (*e.g.*, mononuclear cells and fibroblasts). In some embodiments, the dsRNA targets an mRNA that encodes isoleucine at position 40 in the mature protein (amino acid 58 in the unprocessed protein).

Liver Injury

LECT2 expression can increase during acute liver injury.

In one embodiment of the methods provided herein, the disorder related to LECT2 expression is acute liver injury. In some embodiments, the iRNA (*e.g.*, dsRNA) modulates (*e.g.*, increases or decreases) LECT2 expression. In some embodiments, the iRNA modulates LECT2 expression in the liver. In some embodiments, the iRNA decreases LECT2 expression in the liver. In some embodiments, the iRNA increases LECT2 expression in the liver.

Combination Therapies

In some embodiments, an iRNA (*e.g.*, a dsRNA) disclosed herein is administered in combination with a second therapy (*e.g.*, one or more additional therapies) known to be effective in treating a disorder related to LECT2 expression (*e.g.*, a LECT2 amyloidosis) or a symptom of such a disorder. The iRNA may be administered before, after, or concurrent with the second therapy. In some embodiments, the iRNA is administered before the second therapy. In some embodiments, the iRNA is administered after the second therapy. In some embodiments, the iRNA is administered concurrent with the second therapy.

The second therapy may be an additional therapeutic agent. The iRNA and the additional therapeutic agent can be administered in combination in the same composition or the additional therapeutic agent can be administered as part of a separate composition.

In some embodiments, the second therapy is a non-iRNA therapeutic agent that is effective to treat the disorder or symptoms of the disorder.

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis that affects kidney function, *e.g.*, through amyloid deposition in the kidney. In some such embodiments, the iRNA is administered in conjunction with a therapy that supports kidney function (*e.g.*, dialysis, a diuretic, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), or dialysis).

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis involving amyloid deposits in the liver. In some such embodiments, the iRNA is administered in conjunction with a therapy that supports liver function.

In some embodiments, the disorder to be treated by the compositions or methods disclosed herein is a LECT2 amyloidosis, and the iRNA is administered in conjunction with removal of all or part of the organ(s) affected by the amyloidosis (*e.g.*, resection of all or part of kidney or liver tissue affected by the amyloidosis). The removal is optionally conducted in conjunction with a replacement of all or part of the organ removed (*e.g.*, in conjunction with a kidney or liver organ transplant).

Administration dosages, routes, and timing

A subject (*e.g.*, a human subject, *e.g.*, a patient) can be administered a therapeutic amount of iRNA. The therapeutic amount can be, *e.g.*, 0.05-50 mg/kg. For example, the therapeutic amount can be 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, or 2.5, 3.0, 3.5, 4.0, 4.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg/kg dsRNA.

In some embodiments, the iRNA is formulated for delivery to a target organ, *e.g.*, to the liver.

In some embodiments, the iRNA is formulated as a lipid formulation, *e.g.*, an LNP formulation as described herein. In some such embodiments, the therapeutic amount is 0.05-5 mg/kg, *e.g.*, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or

5.0 mg/kg dsRNA. In some embodiments, the lipid formulation, *e.g.*, LNP formulation, is administered intravenously. In some embodiments, the iRNA (*e.g.*, dsRNA) is formulated as an LNP formulation and is administered (*e.g.*, intravenously administered) at a dose of 0.1 to 0.5 mg/kg.

5 In some embodiments, the iRNA is administered by intravenous infusion over a period of time, such as over a 5 minute, 10 minute, 15 minute, 20 minute, or 25 minute period.

In some embodiments, the iRNA is in the form of a GalNAc conjugate as described herein. In some such embodiments, the therapeutic amount is 0.5-50 mg, *e.g.*, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg/kg dsRNA.

10 In some embodiments, the GalNAc conjugate is administered subcutaneously. In some embodiments, the iRNA (*e.g.*, dsRNA) is in the form of a GalNAc conjugate and is administered (*e.g.*, subcutaneously administered) at a dose of 1 to 10 mg/kg.

In some embodiments, the administration is repeated, for example, on a regular basis, such as, daily, biweekly (*i.e.*, every two weeks) for one month, two months, three months, four
15 months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration biweekly for three months, administration can be repeated once per month, for six months or a year or longer.

In some embodiments, the iRNA agent is administered in two or more doses. In some
20 embodiments, the number or amount of subsequent doses is dependent on the achievement of a desired effect, *e.g.*, inhibition of amyloid deposition, or the achievement of a therapeutic or prophylactic effect, *e.g.*, reduction or prevention of one or more symptoms associated with the disorder.

In some embodiments, the iRNA agent is administered according to a schedule. For example, the iRNA agent may be administered once per week, twice per week, three times per
25 week, four times per week, or five times per week. In some embodiments, the schedule involves regularly spaced administrations, *e.g.*, hourly, every four hours, every six hours, every eight hours, every twelve hours, daily, every 2 days, every 3 days, every 4 days, every 5 days, weekly, biweekly, or monthly. In some embodiments, the iRNA agent is administered at the frequency required to achieve a desired effect.

30 In some embodiments, the schedule involves closely spaced administrations followed by a longer period of time during which the agent is not administered. For example, the schedule

may involve an initial set of doses that are administered in a relatively short period of time (*e.g.*, about every 6 hours, about every 12 hours, about every 24 hours, about every 48 hours, or about every 72 hours) followed by a longer time period (*e.g.*, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or about 8 weeks) during which the iRNA agent is not administered. In one embodiment, the iRNA agent is initially administered hourly and is later administered at a longer interval (*e.g.*, daily, weekly, biweekly, or monthly). In another embodiment, the iRNA agent is initially administered daily and is later administered at a longer interval (*e.g.*, weekly, biweekly, or monthly). In certain embodiments, the longer interval increases over time or is determined based on the achievement of a desired effect.

Before administration of a full dose of the iRNA, patients can be administered a smaller dose, such as a 5% infusion dose, and monitored for adverse effects, such as an allergic reaction, or for elevated lipid levels or blood pressure. In another example, the patient can be monitored for unwanted effects.

Methods for modulating expression of a LECT2 gene

In yet another aspect, the disclosure provides a method for modulating (*e.g.*, inhibiting or activating) the expression of LECT2 gene, *e.g.*, in a cell or in a subject. In some embodiments, the cell is *ex vivo*, *in vitro*, or *in vivo*. In some embodiments, the cell is in the liver (*e.g.*, a hepatocyte). In some embodiments, the cell is in a subject (*e.g.*, a mammal, such as, for example, a human). In some embodiments, the subject (*e.g.*, the human) is at risk, or is diagnosed with a disorder related to expression of LECT2 expression, as described herein.

In one embodiment, the method includes contacting the cell with an iRNA as described herein, in an amount effective to decrease the expression of a LECT2 gene in the cell.

“Contacting,” as used herein, includes directly contacting a cell, as well as indirectly contacting a cell. For example, a cell within a subject may be contacted when a composition comprising an iRNA is administered (*e.g.*, intravenously or subcutaneously) to the subject.

The expression of a LECT2 gene may be assessed based on the level of expression of a LECT2 mRNA, a LECT2 protein, or the level of another parameter functionally linked to the level of expression of a LECT2 gene. In some embodiments, the expression of LECT2 is inhibited by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at

least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the iRNA has an IC₅₀ in the range of 0.001-0.01 nM, 0.001-0.10 nM, 0.001-1.0 nM, 0.001-10 nM, 0.01-0.05 nM, 0.01-0.50 nM, 0.02-0.60 nM, 0.01-1.0 nM, 0.01-1.5 nM, 0.01-10 nM. The IC₅₀ value may be normalized relative to an appropriate control value, *e.g.*, the IC₅₀ of a non-targeting iRNA.

In some embodiments, the method includes introducing into the cell an iRNA as described herein and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of a LECT2 gene, thereby inhibiting the expression of the LECT2 gene in the cell.

In one embodiment, the method includes administering a composition described herein, *e.g.*, a composition comprising an iRNA that targets LECT2, to the mammal such that expression of the target LECT2 gene is decreased, such as for an extended duration, *e.g.*, at least two, three, four days or more, *e.g.*, one week, two weeks, three weeks, or four weeks or longer. In some embodiments, the decrease in expression of LECT2 is detectable within 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, or 24 hours of the first administration.

In another embodiment, the method includes administering a composition as described herein to a mammal such that expression of the target LECT2 gene is increased by *e.g.*, at least 10% compared to an untreated animal. In some embodiments, the activation of LECT2 occurs over an extended duration, *e.g.*, at least two, three, four days or more, *e.g.*, one week, two weeks, three weeks, four weeks, or more. Without wishing to be bound by theory, an iRNA can activate LECT2 expression by stabilizing the LECT2 mRNA transcript, interacting with a promoter in the genome, and/or inhibiting an inhibitor of LECT2 expression.

The iRNAs useful for the methods and compositions featured in the disclosure specifically target RNAs (primary or processed) of a LECT2 gene. Compositions and methods for inhibiting the expression of a LECT2 gene using iRNAs can be prepared and performed as described elsewhere herein.

In one embodiment, the method includes administering a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the LECT2 gene of the subject, *e.g.*, the mammal, *e.g.*, the human, to be treated. The composition may be administered by any appropriate means known in the art

including, but not limited to oral, intraperitoneal, or parenteral routes, including intracranial (*e.g.*, intraventricular, intraparenchymal and intrathecal), intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration.

5 In certain embodiments, the composition is administered by intravenous infusion or injection. In some such embodiments, the composition comprises a lipid formulated siRNA (*e.g.*, an LNP formulation, such as an LNP11 formulation) for intravenous infusion.

 In other embodiments, the composition is administered subcutaneously. In some such
10 embodiments, the composition comprises an iRNA conjugated to a GalNAc ligand. In some such embodiments, the ligand targets the iRNA to the liver (*e.g.*, to hepatocytes).

 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be
15 used in the practice or testing of the iRNAs and methods featured in the disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

20

Specific Embodiments

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, which antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from one of the antisense sequences listed in Tables 2A-2B, 3A-3B, 6, or 7, or a pharmaceutically acceptable salt thereof.

2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand that is 15-30 nucleotides in length and an antisense strand that is 15-30 nucleotides in length and the antisense strand is complementary to at least 15 contiguous nucleotides of a target sequence listed in Table 2A, 2B, 3A, 3B, 6, or 7, or a pharmaceutically acceptable salt thereof.

3. The dsRNA of embodiment 1 or 2, wherein said dsRNA comprises at least one modified nucleotide.

4. The dsRNA agent of embodiment 3, wherein no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand are unmodified nucleotides.

5

5. The dsRNA agent of embodiment 3, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

6. The dsRNA of any of the preceding embodiments, wherein the dsRNA comprises a duplex region that is 15-30 base pairs in length.

7. The dsRNA of embodiment 6, wherein the duplex region is 17-25 base pairs in length.

8. The dsRNA of embodiment 6 or 7, wherein the duplex region is 19-22 base pairs in length.

9. The dsRNA of any of embodiments 6-8, wherein the duplex region is 21 base pairs in length.

10. The dsRNA of any of the preceding embodiments, wherein the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 6, or 7.

5

11. The dsRNA agent of any of the preceding embodiments, wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 4A, 4B, 5A, 5B, 6A, and 6B that corresponds to the antisense sequence.

12. The dsRNA of any of the preceding embodiments, wherein the antisense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 6, or 7.

10

13. The dsRNA agent of any of the preceding embodiments, wherein the sense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 4A, 4B, 5A, 5B, 6A, and 6B that corresponds to the antisense sequence.

15

14. The dsRNA of any of the preceding embodiments, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 6, or 7.

20

15. The dsRNA agent of any of the preceding embodiments, wherein the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 4A, 4B, 5A, 5B, 6A, and 6B that corresponds to the antisense sequence.

5

16. The dsRNA of any of the preceding embodiments, wherein the antisense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 6, or 7.

10

17. The dsRNA agent of any of the preceding embodiments, wherein the sense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 4A, 4B, 5A, 5B, 6A, and 6B that corresponds to the antisense sequence.

18. The dsRNA of any of embodiments 1-17, wherein the region of complementarity is at least 17 nucleotides in length.

19. The dsRNA of any of embodiments 1-18, wherein the region of complementarity is between 21 and 25 nucleotides in length.

20. The dsRNA of any of embodiments 1-19, wherein the region of complementarity is 23 nucleotides in length.

15 21. The dsRNA of any of the preceding embodiments, wherein each strand is no more than 30 nucleotides in length.

22. The dsRNA of any of the preceding embodiments, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide or 2 nucleotides.

23. The dsRNA of any of the preceding embodiments, wherein dsRNA comprises a blunt end.

24. The dsRNA of any of embodiments 3-23, wherein at least one of said modified nucleotides is chosen from the group consisting of: a 2'-O-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

25. The dsRNA of any of embodiments 3-24, wherein at least one of said modified nucleotides is chosen from the group consisting of: a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleic acid (LNA), an acyclic nucleotide, an abasic nucleotide, a glycol nucleotide (GNA), 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

26. The dsRNA of any of embodiments 3-25, wherein the modifications on the nucleotides are selected from the group consisting of a locked nucleic acid (LNA), an acyclic nucleotide, a hexitol or hexose nucleic acid (HNA), a cyclohexene nucleic acid (CeNA), a glycol nucleic acid (GNA), 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-deoxy, 2'-hydroxyl, and combinations thereof.

27. The dsRNA of any of embodiments 3-26, wherein the modifications on the nucleotides are 2'-O-methyl, 2'-fluoro, or both, and optionally GNA.

28. The dsRNA of any of embodiments 3-27, wherein no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand include modifications other than 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA).

29. The dsRNA agent of any of the preceding embodiments, wherein the agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

30. The dsRNA agent of embodiment 29, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand.

5 31. The dsRNA agent of embodiment 30, wherein the strand is the antisense strand.

32. The dsRNA agent of embodiment 30, wherein the strand is the sense strand.

10 33. The dsRNA agent of embodiment 30, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand.

34. The dsRNA agent of embodiment 33, wherein the strand is the antisense strand.

15 35. The dsRNA agent of embodiment 33, wherein the strand is the sense strand.

36. The dsRNA agent of embodiment 29, wherein each of the 5'- and 3'-terminus of one strand comprises a phosphorothioate or methylphosphonate internucleotide linkage.

20 37. The dsRNA agent of embodiment 36, wherein the strand is the antisense strand.

38. The dsRNA agent of any of the preceding embodiment, wherein the base pair at the 1 position of the 5'-end of the antisense strand of the duplex is an AU base pair.

25 39. The dsRNA agent of embodiment 36, wherein the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.


40. The dsRNA of any of the preceding embodiments wherein the sense strand is conjugated to at least one ligand.

41. The dsRNA of embodiment 40, wherein the ligand is attached to the 3' end of the sense strand.

42. The dsRNA of embodiment 40 or 41, wherein the ligand comprises a carbohydrate.

43. The dsRNA of any of embodiments 40-42, wherein the ligand is a GalNAc ligand.


44. The dsRNA of any of embodiments 40-43, wherein the ligand is



45. The dsRNA of any of embodiments 40-44, wherein the ligand is attached via a linker.

46. The dsRNA of embodiment 45, wherein the linker is a bivalent or trivalent branched linker.

47. The dsRNA of embodiment 45, wherein the ligand and linker are as shown in Formula XXIV:



48. The dsRNA of any of embodiments 40-47, wherein the ligand targets the dsRNA to hepatocytes.

49. The dsRNA of any of the preceding embodiments, wherein the region of complementarity consists of an antisense sequence selected from the antisense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7.

50. The dsRNA of any of the preceding embodiments, wherein the dsRNA comprises a sense strand consisting of a sense sequence selected from the sense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7, and an antisense strand consisting of an antisense sequence selected from the antisense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7.

51. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the sense strand comprises the sequence and all of the modifications of ggsucagAfuCfUfUfcaaaaauaaauL96 (SEQ ID NO: 143) and the antisense strand comprises the sequence and all of the modifications of asUfsuuaUfuUfUfgaagAfuCfugaccsgsg (SEQ ID NO: 144).

52. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the region of complementarity is substantially complementary to nucleotides 669-691 of SEQ ID NO: 1.

53. A cell containing the dsRNA of any of the preceding embodiments.

54. A human cell comprising a reduced level of LECT2 mRNA or a level of LECT2 protein as compared to an otherwise similar untreated cell, wherein optionally the level is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
5 85%, 90%, or 95%.

55. The human cell of embodiment 30a, which was produced by a process comprising contacting the human cell with the dsRNA agent of any one of embodiments 1-52.

56. A pharmaceutical composition for inhibiting expression of a LECT2 gene, the composition comprising the dsRNA of any of embodiments 1-52.

57. The pharmaceutical composition of embodiment 56, wherein dsRNA is administered in an unbuffered solution.

58. The pharmaceutical composition of embodiment 57, wherein said unbuffered solution is saline or water.

59. The pharmaceutical composition of embodiment 56, wherein said dsRNA is administered with a buffer solution.

60. The pharmaceutical composition of embodiment 59, wherein said buffer solution comprises acetate, citrate, prolamine, carbonate, phosphate or any combination thereof.

61. The pharmaceutical composition of embodiment 59 or 60, wherein said buffer solution is phosphate buffered saline (PBS).

62. The pharmaceutical composition of any of embodiments 56-61, wherein said composition comprises a lipid formulation.

63. The pharmaceutical composition of embodiment 62, wherein the lipid formulation is an LNP formulation.

64. The pharmaceutical composition of embodiment 62 or 63, wherein the lipid formulation is an LNP11 formulation.

65. The pharmaceutical composition of any of embodiments 56-64, wherein the dsRNA is targeted to a liver cell or a hepatocyte.

66. The pharmaceutical composition of any of embodiments 56-65, wherein said composition is administered intravenously.
67. The pharmaceutical composition of any of embodiments 56-65, wherein said composition is administered subcutaneously.
68. The pharmaceutical composition of embodiment 66, wherein said composition comprises a lipid formulation and is administered intravenously.
69. The pharmaceutical composition of any of embodiments 56-68, wherein said composition comprises a dsRNA that is conjugated to a ligand chosen from a carbohydrate ligand or a GalNAc ligand.
70. A method of inhibiting LECT2 expression in a cell, the method comprising:
- (a) contacting, e.g., introducing into the cell the dsRNA of any of embodiments 1-52, and
 - (b) maintaining the cell of step (a) for a time sufficient to obtain degradation of the mRNA transcript of a LECT2 gene, thereby inhibiting expression of the LECT2 gene in the cell.
71. A method of inhibiting LECT2 expression in a cell, the method comprising:
- (a) contacting, e.g., introducing into the cell the dsRNA of any of embodiments 1-52, and
 - (b) maintaining the cell of step (a) for a time sufficient to reduce levels of the LECT2 mRNA, LECT2 protein, or both of LECT2 mRNA or LECT2 protein, thereby inhibiting expression of the LECT2 gene in the cell.
72. The method of embodiment 70 or 71, wherein the cell is treated *ex vivo*, *in vitro*, or *in vivo*.

73. The method of any of embodiments 70-72, wherein the cell is present in a subject in need of treatment, prevention and/or management of a disorder related to LECT2 expression.
74. The method of embodiment 73, wherein the subject is a human.
75. The method of embodiment 73, wherein said disorder is amyloidosis.
76. The method of embodiment 75, wherein the amyloidosis is a LECT2 amyloidosis.
77. The method of any of embodiments 70-76, wherein the cell is a liver cell or a hepatocyte.
78. The method of any of embodiments 70-77, wherein the expression of LECT2 is inhibited by at least 20%.
79. The method of any of embodiments 70-78, wherein the expression of LECT2 mRNA and/or LECT protein is inhibited by at least 50%.
80. The method of any of embodiments 70-79, wherein the expression of LECT2 is inhibited by at least 90%.
81. The method of embodiments 70-80, wherein inhibiting expression of LECT2 gene decreases a LECT2 protein level in a biological sample (e.g., a serum sample) from the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.
82. A method of treating a disorder related to LECT2 expression, comprising administering to a subject in need of such treatment a therapeutically effective amount of
- (i) the dsRNA of any of embodiments 1-52 or
 - (ii) the pharmaceutical composition of any of embodiments 56-59.
83. A method of treating LECT2 amyloidosis, comprising administering to a subject in need of such treatment a therapeutically effective amount of

- (i) the dsRNA of any of embodiments 1-52 or
- (ii) the pharmaceutical composition of any of embodiments 56-59.

84. The method of embodiment 82 or 83, wherein the subject has amyloidosis or is at risk for developing amyloidosis.

85. The method of any of embodiments 82-84, wherein the amyloidosis is a LECT2 amyloidosis.

86. The method of any one of embodiments 82-85, wherein treating comprises amelioration of at least one sign or symptom of the disorder (e.g., wherein the disorder is amyloidosis (e.g., LECT2 amyloidosis)).

5 87. The method of embodiment 86, wherein at least one sign or symptom of an amyloidosis, e.g., LECT2 amyloidosis comprises a measure of amyloid deposits or presence or level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein)).

10 88. The method of any of embodiments 82-87, where treating comprises prevention of progression of the disorder.

89. The method of any of embodiments 82-88 the treating comprises inhibiting or reducing the expression or activity of LECT2 in a cell, e.g. a hepatocyte.

90. The method of embodiment 89, wherein the treating results in at least a 30% mean reduction from baseline of LECT2 mRNA in the cell.

15 91. The method of embodiment 89, wherein the treating results in at least a 60% mean reduction from baseline of LECT2 mRNA in the cell.

20 92. The method of embodiment 89, wherein the treating results in at least a 90% mean reduction from baseline of LECT2 mRNA in the cell.

93. The method of any of embodiments 82-92, wherein the subject is a human.

94. The method of any of embodiments 73-93, wherein the dsRNA is administered to the subject subcutaneously or intravenously.

95. The method of any of embodiments 70-94, wherein the dsRNA or composition comprising the dsRNA is administered according to a dosing regimen.

96. The method of embodiment 95, wherein the dosing regimen is weekly, biweekly, or monthly.

97. The method of any of embodiments 70-96, wherein the method reduces LECT2 amyloid deposition.

5 98. The method of any one of embodiments 73-97, further comprising measuring level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject.

99. The method of embodiment 98, where measuring the level of LECT2 in the subject comprises measuring the level of LECT2 gene, LECT2 protein or LECT2 mRNA in a biological
10 sample from the subject (e.g., a tissue, blood, or serum sample).

100. The method of any one of embodiments 73-99, further comprising performing a blood test, an imaging test, or a liver or kidney biopsy.

15 101. The method of any one of embodiments 98-100, wherein measuring level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject is performed prior to treatment with the dsRNA agent or the pharmaceutical composition.

102. The method of embodiment 101, wherein, upon determination that a subject has a level of
20 LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) that is greater than a reference level, the dsRNA agent or the pharmaceutical composition is administered to the subject.

103. The method of any one of embodiments 98-102, wherein measuring the level of LECT2 (e.g., LECT2 gene, LECT2 mRNA, or LECT2 protein) in the subject is performed after treatment with the dsRNA agent or the pharmaceutical composition.

104. A method of reducing LECT2 amyloid deposition in a subject having a LECT2 amyloidosis, the method comprising administering to the subject

(i) the dsRNA of any of embodiments 1-52 or

(ii) the pharmaceutical composition of any of embodiments 56-49.

105. The method of any of embodiments 82-104, wherein the dsRNA is administered at a dose of 0.05-50 mg/kg.

106. The method of any of embodiments 82-105, wherein the dsRNA is administered at a concentration of 0.01 mg/kg to 5 mg/kg bodyweight of the subject.

5

107. The method of any of embodiments 82-106, wherein the dsRNA is formulated as an LNP formulation and is administered at a dose of 0.1 mg/kg to 0.5 mg/kg.

108. The method of any of embodiments 82-107, wherein the dsRNA is conjugated to a GalNAc ligand.

109. The method of any of embodiments 82-108, wherein the dsRNA is conjugated to a GalNAc ligand and is administered at a dose of 1 mg/kg to 10 mg/kg, optionally at a dose of 1 mg/kg or 3 mg/kg.

110. A vector encoding at least one strand of the dsRNA of any of embodiments 1-52.

111. A cell comprising the vector of embodiment 110.

EXAMPLES

Example 1. LECT2 siRNA

Nucleic acid sequences provided herein are represented using standard nomenclature. *See* the abbreviations of Table 1.

5

Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation


It will be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.

Abbreviation	Nucleotide(s)
A	Adenosine-3'-phosphate
Ab	beta-L-adenosine-3'-phosphate
Abs	beta-L-adenosine-3'-phosphorothioate
Af	2'-fluoroadenosine-3'-phosphate
Afs	2'-fluoroadenosine-3'-phosphorothioate
As	adenosine-3'-phosphorothioate
C	cytidine-3'-phosphate
Cb	beta-L-cytidine-3'-phosphate
Cbs	beta-L-cytidine-3'-phosphorothioate
Cf	2'-fluorocytidine-3'-phosphate
Cfs	2'-fluorocytidine-3'-phosphorothioate
(Chd)	2'-O-hexadecyl-cytidine-3'-phosphate
(Chds)	2'-O-hexadecyl-cytidine-3'-phosphorothioate
Cs	cytidine-3'-phosphorothioate
G	guanosine-3'-phosphate
Gb	beta-L-guanosine-3'-phosphate
Gbs	beta-L-guanosine-3'-phosphorothioate
Gf	2'-fluoroguanosine-3'-phosphate
Gfs	2'-fluoroguanosine-3'-phosphorothioate
Gs	guanosine-3'-phosphorothioate

T	5'-methyluridine-3'-phosphate
Tb	beta-L-thymidine-3'-phosphate
Tbs	beta-L-thymidine-3'-phosphorothioate
Tf	2'-fluoro-5-methyluridine-3'-phosphate
Tfs	2'-fluoro-5-methyluridine-3'-phosphorothioate
Tgn	thymidine-glycol nucleic acid (GNA) S-Isomer
Agn	adenosine- glycol nucleic acid (GNA) S-Isomer
Cgn	cytidine-glycol nucleic acid (GNA) S-Isomer
Ggn	guanosine-glycol nucleic acid (GNA) S-Isomer
Ts	5-methyluridine-3'-phosphorothioate
U	Uridine-3'-phosphate
Ub	beta-L-uridine-3'-phosphate
Ubs	beta-L-uridine-3'-phosphorothioate
Uf	2'-fluorouridine-3'-phosphate
Ufs	2'-fluorouridine -3'-phosphorothioate
(Uhd)	2'-O-hexadecyl-uridine-3'-phosphate
(Uhds)	2'-O-hexadecyl-uridine-3'-phosphorothioate
Us	uridine -3'-phosphorothioate
N	any nucleotide (G, A, C, T or U)
a	2'-O-methyladenosine-3'-phosphate
as	2'-O-methyladenosine-3'- phosphorothioate
c	2'-O-methylcytidine-3'-phosphate
cs	2'-O-methylcytidine-3'- phosphorothioate
g	2'-O-methylguanosine-3'-phosphate
gs	2'-O-methylguanosine-3'- phosphorothioate
t	2'-O-methyl-5-methyluridine-3'-phosphate
ts	2'-O-methyl-5-methyluridine-3'-phosphorothioate
u	2'-O-methyluridine-3'-phosphate
us	2'-O-methyluridine-3'-phosphorothioate
dA	2'-deoxyadenosine-3'-phosphate

dAs	2'-deoxyadenosine-3'-phosphorothioate
dC	2'-deoxycytidine-3'-phosphate
dCs	2'-deoxycytidine-3'-phosphorothioate
dG	2'-deoxyguanosine-3'-phosphate
dGs	2'-deoxyguanosine-3'-phosphorothioate
dT	2'-deoxythymidine
dTs	2'-deoxythymidine-3'-phosphorothioate
dU	2'-deoxyuridine
s	phosphorothioate linkage
L96 ¹	N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol Hyp-(GalNAc-alkyl) ₃
Y34	2-hydroxymethyl-tetrahydrofuran-4-methoxy-3-phosphate (abasic 2'-OMe furanose)
(Aeo)	2'-O-methoxyethyladenosine-3'-phosphate
(Aeos)	2'-O-methoxyethyladenosine-3'-phosphorothioate
(Geo)	2'-O-methoxyethylguanosine-3'-phosphate
(Geos)	2'-O-methoxyethylguanosine-3'-phosphorothioate
(Teo)	2'-O-methoxyethyl-5-methyluridine-3'-phosphate
(Teos)	2'-O-methoxyethyl-5-methyluridine-3'-phosphorothioate
(m5Ceo)	2'-O-methoxyethyl-5-methylcytidine-3'-phosphate
(m5Ceos)	2'-O-methoxyethyl-5-methylcytidine-3'-phosphorothioate
(A3m)	3'-O-methyladenosine-2'-phosphate
(A3mx)	3'-O-methyl-xylofuranosyladenosine-2'-phosphate
(G3m)	3'-O-methylguanosine-2'-phosphate
(G3mx)	3'-O-methyl-xylofuranosylguanosine-2'-phosphate
(C3m)	3'-O-methylcytidine-2'-phosphate
(C3mx)	3'-O-methyl-xylofuranosylcytidine-2'-phosphate
(U3m)	3'-O-methyluridine-2'-phosphate
(U3mx)	3'-O-methyl-xylofuranosyluridine-2'-phosphate

¹The chemical structure of L96 is as follows:



5 Experimental Methods

Bioinformatics

Transcripts

A set of siRNAs targeting the human LECT2, “leukocyte cell derived chemotaxin 2” (human: NCBI refseqID NM_002302.2; NCBI GeneID: 3950), as well as toxicology-species LECT2 orthologs (cynomolgus monkey: XM_005557840; mouse: NM_010702; rat: NM_001108405) were designed using custom R and Python scripts. The human NM_002302REFSEQ mRNA, version 2, has a length of 1077 bases. The rationale and method for the set of siRNA designs is as follows: the predicted efficacy for every potential 19mer siRNA from position 10 through position 1077 was determined with a linear model derived the direct measure of mRNA knockdown from more than 20,000 distinct siRNA designs targeting a large number of vertebrate genes. Subsets of the LECT2 siRNAs were designed with perfect or near-perfect matches between human and cynomolgus monkey. A further subset was designed with perfect or near-perfect matches to human, cynomolgus monkey and mouse LECT2 orthologs. A further subset was designed with perfect or near-perfect matches to human, cynomolgus monkey, mouse and rat LECT2 orthologs. For each strand of the siRNA, a custom Python script was used in a brute force search to measure the number and positions of mismatches between the siRNA and all potential alignments in the target species transcriptome. Extra weight was given to mismatches in the seed region, defined in this example as positions 2-9 of the antisense oligonucleotide, as well the cleavage site of the siRNA, defined here as positions 10-11 of the antisense oligonucleotide. The relative weight of the mismatches was 2.8; 1.2: 1 for seed mismatches, cleavage site, and other positions up through antisense position 19. Mismatches in the first position were ignored. A specificity score was calculated for each strand

by summing the value of each weighted mismatch. Preference was given to siRNAs whose antisense score in human was ≥ 2.2 and predicted efficacy was $\geq 50\%$ knockdown of the LECT2 transcript. Pairs of exemplary oligos are evidenced in Table 2A and Table 2B (one set), as well as Table 3A and Table 3B (another set). Modified sequences for each set are presented

5 in Table 2A and Table 3A, respectively. Unmodified sequences for each set are presented in Tables 2B and Table 3B, respectively.

Table 2A. Human LECT2 siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Seq ID NO: (sense)	Sense sequence	Seq ID NO: (anti sense)	Antisense sequence	Seq ID NO: (target sequence of NM_00230 2.2)	Target Sequence
AD-133457.6	2	csasugugCfaCfAfUfugaaaaacugul96	3	asCfsaguu(Tgn)ucaaugUfgCfacaugscsg	4	CGCATGTGCACATTGAAAACTGT
AD-454742.1	5	csasugugCfaCfAfUfugaaaaacugul96	6	asCfsaguu(Tgn)ucaaugUfgCfacaugscsg	7	CCCATGTGCACATTGAAAACTGT
AD-454743.1	8	csasugugCfaCfAfUfugaaaaacugul96	9	asCfsaguu(Tgn)ucaaugUfgCfacaugscsg	10	ACCATGTGCACATTGAAAACTGT
AD-454744.1	11	usgsugCfaCfAfUfugaaaaacugul96	12	asCfsaguu(Tgn)ucaaugUfgCfacaugscsg	13	CATGTGCACATTGAAAACTGT
AD-397297.2	14	csasugugCfaCfAfUfugaaaaacugul96	15	asCfsaguu(Tgn)ucaaugUfgCfacaugscsg	16	CGCATGTGCACATTGAAAACTGT
AD-454745.1	17	csasugugCfaCfAfUfugaaaaacugul96	18	asCfsaGfuU(Tgn)ucaaugUfgCfacaugscsg	19	CGCATGTGCACATTGAAAACTGT
AD-397294.2	20	csasugugCfaCfAfUfugaaaaacugul96	21	asCfsaguu(Tgn)UfCfaaugUfgCfacaugscsg	22	CGCATGTGCACATTGAAAACTGT
AD-454746.1	23	csasugugCfaCfAfUfugaaaaacugul96	24	asCfsaGfuU(Tgn)UfCfaaUfgUfgCfacaugscsg	25	CGCATGTGCACATTGAAAACTGT
AD-454747.1	26	csasugugCfaCfAfUfugaaaaacugul96	27	asCfsaGfuU(Tgn)UfcaaaUfgUfgCfacaugscsg	28	CGCATGTGCACATTGAAAACTGT
AD-133461.7	29	asusggucAfgAfUfCfucaaaaaaual96	30	usUfsauuu(Tgn)gaagauCfuGfaccsausg	31	CAATGGTCAGATCTTCAAAAATAA
AD-454748.1	32	asusggucAfgAfUfCfucaaaaaaual96	33	usUfsauuu(Tgn)gaagauCfuGfaccsausg	34	CCATGGTCAGATCTTCAAAAATAA
AD-454749.1	35	asusggucAfgAfUfCfucaaaaaaual96	36	usUfsauuu(Tgn)gaagauCfuGfaccsausg	37	ACATGGTCAGATCTTCAAAAATAA
AD-454750.1	38	gsgsucAfgAfUfCfucaaaaaaual96	39	usUfsauuu(Tgn)gaagauCfuGfaccsausg	40	ATGGTCAGATCTTCAAAAATAA
AD-397303.2	41	asusggucAfgAfUfCfucaaaaaaual96	42	usUfsauuu(Tgn)gaagAfuCfuGfaccsausg	43	CAATGGTCAGATCTTCAAAAATAA

AD-454751.1	44	asusggucAfgAfUfCfucaaaaaaual96	45	usUfsaUfuU(Tgn)gaagAfuCfuGfaccsausg	46	CAATGGTCAGATCTTCAAAATAA
AD-397300.2	47	asusggucAfgAfUfCfucaaaaaaual96	48	usUfsauuu(Tgn)GfAfagauCfuGfaccsausg	49	CAATGGTCAGATCTTCAAAATAA
AD-454752.1	50	asusggucAfgAfUfCfucaaaaaaual96	51	usUfsaUfuU(Tgn)GfAfagAfuCfuGfaccsausg	52	CAATGGTCAGATCTTCAAAATAA
AD-454753.1	53	asusggucAfgAfUfCfucaaaaaaual96	54	usUfsaUfuU(Tgn)GfaagAfuCfuGfaccsausg	55	CAATGGTCAGATCTTCAAAATAA
AD-397298.1	56	asusggucAfgAfUfCfucaaaaaaual96	57	asUfsauuu(Tgn)gaagauCfuGfaccsausg	58	CAATGGTCAGATCTTCAAAATAT
AD-454754.1	59	asusggucAfgAfUfCfucaaaaaaual96	60	asUfsauuu(Tgn)gaagauCfuGfaccsausg	61	CCATGGTCAGATCTTCAAAATAT
AD-454755.1	62	asusggucAfgAfUfCfucaaaaaaual96	63	asUfsauuu(Tgn)gaagauCfuGfaccsausg	64	ACATGGTCAGATCTTCAAAATAT
AD-454756.1	65	gsusucAfgAfUfCfucaaaaaaual96	66	asUfsauuu(Tgn)gaagauCfuGfaccsas	67	ATGGTCAGATCTTCAAAATAT
AD-454757.1	68	asusggucAfgAfUfCfucaaaaaaual96	69	asUfsauuu(Tgn)gaagAfuCfuGfaccsausg	70	CAATGGTCAGATCTTCAAAATAT
AD-454758.1	71	asusggucAfgAfUfCfucaaaaaaual96	72	asUfsaUfuU(Tgn)gaagAfuCfuGfaccsausg	73	CAATGGTCAGATCTTCAAAATAT
AD-454759.1	74	asusggucAfgAfUfCfucaaaaaaual96	75	asUfsauuu(Tgn)GfAfagauCfuGfaccsausg	76	CAATGGTCAGATCTTCAAAATAT
AD-454760.1	77	asusggucAfgAfUfCfucaaaaaaual96	78	asUfsaUfuU(Tgn)GfAfagAfuCfuGfaccsausg	79	CAATGGTCAGATCTTCAAAATAT
AD-454761.1	80	asusggucAfgAfUfCfucaaaaaaual96	81	asUfsaUfuU(Tgn)GfaagAfuCfuGfaccsausg	82	CAATGGTCAGATCTTCAAAATAT
AD-81725.10	83	gsusucagAfuCfuUfcaaaaaaual96	84	usUfsuuaUfuUfUfgaagAfuCfugaccsas	85	ATGGTCAGATCTTCAAAATAAAA
AD-454762.1	86	gsusucagAfuCfuUfcaaaaaaual96	87	usUfsuuaUfuUfUfgaagAfuCfugaccsgs	88	ACGGTCAGATCTTCAAAATAAAA
AD-454763.1	89	gsusucagAfuCfuUfcaaaaaaual96	90	usUfsuuaUfuUfUfgaagAfuCfugaccscs	91	AGGGTCAGATCTTCAAAATAAAA
AD-454764.1	92	gsusucagAfuCfuUfcaaaaaaual96	93	usUfsuuaUfuUfUfgaagAfuCfugaccsgs	94	CCGGTCAGATCTTCAAAATAAAA
AD-454765.1	95	uscsagAfuCfuUfcaaaaaaual96	96	usUfsuuaUfuUfUfgaagAfuCfugaccsc	97	GGTCAGATCTTCAAAATAAAA

AD-454766.1	98	gsgsucagAfuCfUfUfcaaaaauaaaL96	99	usUfsuuaUfuUfUfgaAfgAfuCfugaccsas	100	ATGGTCAGATCTTCAAAATAAAA
AD-454767.1	101	gsgsucagAfuCfUfUfcaaaaauaaaL96	102	usUfsuuaUfuUfUfgaAfgAfuCfugaccsas	103	ATGGTCAGATCTTCAAAATAAAA
AD-454768.1	104	gsgsucagAfuCfUfUfcaaaaauaaaL96	105	usUfsuuaUfuUfgaAfgAfuCfugaccsas	106	ATGGTCAGATCTTCAAAATAAAA
AD-454769.1	107	gsgsucagAfuCfUfUfcaaaaauaaaL96	108	usUfsuuaUfuUfgaAfgAfuCfugaccsas	109	ATGGTCAGATCTTCAAAATAAAA
AD-454770.1	110	gsgsucagAfuCfUfUfcaaaaauaaaL96	111	usUfsuuaUfuUfUfgaAfgAfuCfugaccsas	112	ATGGTCAGATCTTCAAAATAAAA
AD-454771.1	113	gsgsucagAfuCfUfUfcaaaaauaaaL96	114	usUfsuuaUfuUfgaAfgAfuCfugaccsas	115	ATGGTCAGATCTTCAAAATAAAA
AD-454772.1	116	gsgsucagAfuCfUfUfcaaaaauaaaL96	117	usUfsuuaUfuUfUfgaAfgAfuCfugaccsas	118	ATGGTCAGATCTTCAAAATAAAA
AD-454773.1	119	gsgsucagAfuCfUfUfcaaaaauaaaL96	120	usUfsuuaUfuUfgaAfgAfuCfugaccsas	121	ATGGTCAGATCTTCAAAATAAAA
AD-454774.1	122	gsgsucagAfuCfUfUfcaaaaauaaaL96	123	usUfsuuaUfuUfgaAfgAfuCfugaccsgs	124	ACGGTCAGATCTTCAAAATAAAA
AD-454775.1	125	gsgsucagAfuCfUfUfcaaaaauaaaL96	126	usUfsuuaUfuUfgaAfgAfuCfugaccscs	127	AGGGTCAGATCTTCAAAATAAAA
AD-454776.1	128	gsgsucagAfuCfUfUfcaaaaauaaaL96	129	usUfsuuaUfuUfgaAfgAfuCfugaccsgsg	130	CCGGTCAGATCTTCAAAATAAAA
AD-454777.1	131	uscsagAfuCfUfUfcaaaaauaaaL96	132	usUfsuuaUfuUfgaAfgAfuCfugascsc	133	GGTCAGATCTTCAAAATAAAA
AD-454778.1	134	gsgsucagAfuCfUfUfcaaaaauaaaL96	135	asUfsuuaUfuUfUfgaAfgAfuCfugaccsas	136	ATGGTCAGATCTTCAAAATAAAAT
AD-454779.1	137	gsgsucagAfuCfUfUfcaaaaauaaaL96	138	asUfsuuaUfuUfUfgaAfgAfuCfugaccsgs	139	ACGGTCAGATCTTCAAAATAAAAT
AD-454780.1	140	gsgsucagAfuCfUfUfcaaaaauaaaL96	141	asUfsuuaUfuUfUfgaAfgAfuCfugaccscs	142	AGGGTCAGATCTTCAAAATAAAAT
AD-454781.1	143	gsgsucagAfuCfUfUfcaaaaauaaaL96	144	asUfsuuaUfuUfUfgaAfgAfuCfugaccsgsg	145	CCGGTCAGATCTTCAAAATAAAAT
AD-454782.1	146	uscsagAfuCfUfUfcaaaaauaaaL96	147	asUfsuuaUfuUfUfgaAfgAfuCfugascsc	148	GGTCAGATCTTCAAAATAAAAT
AD-454783.1	149	gsgsucagAfuCfUfUfcaaaaauaaaL96	150	asUfsuuaUfuUfUfgaAfgAfuCfugaccsas	151	ATGGTCAGATCTTCAAAATAAAAT

AD-454784.1	152	gsgsucagauCfUfUfcaaaaaaualL96	153	asUfsuuaUfuUfugaAfgAfuCfugaccsasus	154	ATGGTCAGATCTTCAAAATAAAAT
AD-454785.1	155	gsgsucagAfuCfUfUfcaaaaauaualL96	156	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	157	ATGGTCAGATCTTCAAAATAAAAT
AD-454786.1	158	gsgsucagAfuCfUfUfcaaaaauaualL96	159	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	160	ATGGTCAGATCTTCAAAATAAAAT
AD-454787.1	161	gsgsucagauCfUfUfcaaaaauaualL96	162	asUfsuuaUfuUfugaAfgAfuCfugaccsasus	163	ATGGTCAGATCTTCAAAATAAAAT
AD-454788.1	164	gsgsucagauCfUfUfcaaaaauaualL96	165	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	166	ATGGTCAGATCTTCAAAATAAAAT
AD-454789.1	167	gsgsucagauCfUfUfcaaaaauaualL96	168	asUfsuuaUfuUfugaAfgAfuCfugaccsasus	169	ATGGTCAGATCTTCAAAATAAAAT
AD-454790.1	170	gsgsucagauCfUfUfcaaaaauaualL96	171	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	172	ATGGTCAGATCTTCAAAATAAAAT
AD-454791.1	173	gsgsucagAfuCfUfUfcaaaaauaualL96	174	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	175	ACGGTCAGATCTTCAAAATAAAAT
AD-454792.1	176	gsgsucagAfuCfUfUfcaaaaauaualL96	177	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	178	AGGGTCAGATCTTCAAAATAAAAT
AD-454793.1	179	gsgsucagAfuCfUfUfcaaaaauaualL96	180	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	181	CCGGTCAGATCTTCAAAATAAAAT
AD-454794.1	182	uscsagAfuCfUfUfcaaaaauaualL96	183	asUfsuuaUfuuuugaAfgAfuCfugaccsasus	184	GGTCAGATCTTCAAAATAAAAT
AD-81723.6	185	asasugguCfaGfAfuCfUfcaaaaauaualL96	186	usAfsuuuUfgAfgaucUfgAfcuuusgsg	187	CCAATGGTCAGATCTTCAAAATA
AD-454795.1	188	asasugguCfaGfAfuCfUfcaaaaauaualL96	189	usAfsuuuUfgAfgaucUfgAfcuuusgsg	190	ACAATGGTCAGATCTTCAAAATA
AD-454796.1	191	asasugguCfaGfAfuCfUfcaaaaauaualL96	192	usAfsuuuUfgAfgaucUfgAfcuuusgsg	193	AGAATGGTCAGATCTTCAAAATA
AD-454797.1	194	usgsguCfaGfAfuCfUfcaaaaauaualL96	195	usAfsuuuUfgAfgaucUfgAfcuuusgsg	196	AATGGTCAGATCTTCAAAATA
AD-454798.1	197	asasugguCfaGfAfuCfUfcaaaaauaualL96	198	usAfsuuuUfgAfgaucUfgAfcuuusgsg	199	CCAATGGTCAGATCTTCAAAATA
AD-454799.1	200	asasugguCfaGfAfuCfUfcaaaaauaualL96	201	usAfsuuuUfgAfgaucUfgAfcuuusgsg	202	CCAATGGTCAGATCTTCAAAATA
AD-454800.1	203	asasugguCfaGfAfuCfUfcaaaaauaualL96	204	usAfsuuuUfgaagauCfUfgAfcuuusgsg	205	CCAATGGTCAGATCTTCAAAATA

AD-454801.1	206	asasugguCfaGfAfUfcuucacaaauaL96	207	usAfsuuuUfgaagaUfcUfgAfccauusgsg	208	CCAATGGTCAGATCTTCAAAATA
AD-454802.1	209	asasuggucaGfAfUfcuucacaaauaL96	210	usAfsuuuUfgAfAfgaUfcUfgAfccauusgsg	211	CCAATGGTCAGATCTTCAAAATA
AD-454803.1	212	asasuggucaGfAfUfcuucacaaauaL96	213	usAfsuuuUfgaagaUfcUfgAfccauusgsg	214	CCAATGGTCAGATCTTCAAAATA
AD-454804.1	215	asasuggucagAfUfcuucacaaauaL96	216	usAfsuuuUfgAfAfgaUfcUfgAfccauusgsg	218	CCAATGGTCAGATCTTCAAAATA
AD-454805.1	219	asasuggucagAfUfcuucacaaauaL96	220	usAfsuuuUfgaagaUfcUfgAfccauusgsg	221	CCAATGGTCAGATCTTCAAAATA
AD-454806.1	222	asasugguCfaGfAfUfcuucacaaauaL96	223	usAfsuuuUfgaagaUfcUfgAfccauusgsu	224	ACAATGGTCAGATCTTCAAAATA
AD-454807.1	225	asasugguCfaGfAfUfcuucacaaauaL96	226	usAfsuuuUfgaagaUfcUfgAfccauuscsu	227	AGAATGGTCAGATCTTCAAAATA
AD-454808.1	228	usgsuGfAfUfcuucacaaauaL96	229	usAfsuuuUfgaagaUfcUfgAfccasusu	230	AATGGTCAGATCTTCAAAATA
AD-454809.1	231	asasugguCfaGfAfUfcuucacaaauuL96	232	asAfsuuuUfgAfAfgaucUfgAfccauusgsg	233	CCAATGGTCAGATCTTCAAAATT
AD-454810.1	234	asasugguCfaGfAfUfcuucacaaauuL96	235	asAfsuuuUfgAfAfgaucUfgAfccauusgsu	236	ACAATGGTCAGATCTTCAAAATT
AD-454811.1	237	asasugguCfaGfAfUfcuucacaaauuL96	238	asAfsuuuUfgAfAfgaucUfgAfccauuscsu	239	AGAATGGTCAGATCTTCAAAATT
AD-454812.1	240	usgsuGfAfUfcuucacaaauuL96	241	asAfsuuuUfgAfAfgaucUfgAfccasusu	242	AATGGTCAGATCTTCAAAATT
AD-454813.1	243	asasugguCfaGfAfUfcuucacaaauuL96	244	asAfsuuuUfgAfAfgaUfcUfgAfccauusgsg	245	CCAATGGTCAGATCTTCAAAATT
AD-454814.1	246	asasuggucaGfAfUfcuucacaaauuL96	247	asAfsuuuUfgAfAfgaucUfgAfccauusgsg	248	CCAATGGTCAGATCTTCAAAATT
AD-454815.1	249	asasugguCfaGfAfUfcuucacaaauuL96	250	asAfsuuuUfgaagaUfcUfgAfccauusgsg	251	CCAATGGTCAGATCTTCAAAATT
AD-454816.1	252	asasugguCfaGfAfUfcuucacaaauuL96	253	asAfsuuuUfgaagaUfcUfgAfccauusgsg	254	CCAATGGTCAGATCTTCAAAATT
AD-454817.1	255	asasuggucaGfAfUfcuucacaaauuL96	256	asAfsuuuUfgAfAfgaUfcUfgAfccauusgsg	257	CCAATGGTCAGATCTTCAAAATT
AD-454818.1	258	asasuggucaGfAfUfcuucacaaauuL96	259	asAfsuuuUfgaagaUfcUfgAfccauusgsg	260	CCAATGGTCAGATCTTCAAAATT

AD-454819.1	261	asasuggucagAfUfcuucacaaauuL96	262	asAfsuuuUfgAfAfgaUfcUfgAfccauusgsg	263	CCAATGGTCAGATCTTCAAAAATT
AD-454820.1	264	asasuggucagAfUfcuucacaaauuL96	265	asAfsuuuUfgaagaUfcUfgAfccauusgsg	266	CCAATGGTCAGATCTTCAAAAATT
AD-454821.1	267	asasugguCfaGfAfUfcuucacaaauuL96	268	asAfsuuuUfgaagaUfcUfgAfccauusgsu	269	ACAATGGTCAGATCTTCAAAAATT
AD-454822.1	270	asasugguCfaGfAfUfcuucacaaauuL96	271	asAfsuuuUfgaagaUfcUfgAfccauuscsu	272	AGAATGGTCAGATCTTCAAAAATT
AD-454823.1	273	usgsuGfAfaUfcuucacaaauuL96	274	asAfsuuuUfgaagaUfcUfgAfccasusu	275	AATGGTCAGATCTTCAAAAATT

Table 2B. Human LECT2 siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Seq ID No: (sense)	Sense Sequence	mRNA Target Range	Seq ID No: (anti sense)	Antisense sequence	mRNA Target Range
AD-133457.6	276	CAUGUGCACAUGGAAAAACUGU	607-627	277	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454742.1	278	CAUGUGCACAUGGAAAAACUGU	607-627	279	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454743.1	280	CAUGUGCACAUGGAAAAACUGU	607-627	281	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454744.1	282	UGUGCACAUGGAAAAACUGU	609-627	283	ACAGUUTUCAAUGUGCACAUCCG	607-627
AD-397297.2	284	CAUGUGCACAUGGAAAAACUGU	607-627	285	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454745.1	286	CAUGUGCACAUGGAAAAACUGU	607-627	287	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-397294.2	288	CAUGUGCACAUGGAAAAACUGU	607-627	289	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454746.1	290	CAUGUGCACAUGGAAAAACUGU	607-627	291	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-454747.1	292	CAUGUGCACAUGGAAAAACUGU	607-627	293	ACAGUUTUCAAUGUGCACAUCCG	605-627
AD-133461.7	294	AUGGUCAGAUUCUAAAAUAA	669-689	295	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454748.1	296	AUGGUCAGAUUCUAAAAUAA	669-689	297	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454749.1	298	AUGGUCAGAUUCUAAAAUAA	669-689	299	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454750.1	300	GGUCAGAUUCUAAAAUAA	671-689	301	UUAUUUTGAAGAUUCUGACCAUUG	669-689
AD-397303.2	302	AUGGUCAGAUUCUAAAAUAA	669-689	303	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454751.1	304	AUGGUCAGAUUCUAAAAUAA	669-689	305	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-397300.2	306	AUGGUCAGAUUCUAAAAUAA	669-689	307	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454752.1	308	AUGGUCAGAUUCUAAAAUAA	669-689	309	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454753.1	310	AUGGUCAGAUUCUAAAAUAA	669-689	311	UUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-397298.1	312	AUGGUCAGAUUCUAAAAUAA	669-689	313	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454754.1	314	AUGGUCAGAUUCUAAAAUAA	669-689	315	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454755.1	316	AUGGUCAGAUUCUAAAAUAA	669-689	317	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454756.1	318	GGUCAGAUUCUAAAAUAA	671-689	319	AUAUUUTGAAGAUUCUGACCAUUG	669-689
AD-454757.1	320	AUGGUCAGAUUCUAAAAUAA	669-689	321	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454758.1	322	AUGGUCAGAUUCUAAAAUAA	669-689	323	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454759.1	324	AUGGUCAGAUUCUAAAAUAA	669-689	325	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454760.1	326	AUGGUCAGAUUCUAAAAUAA	669-689	327	AUAUUUTGAAGAUUCUGACCAUUG	667-689
AD-454761.1	328	AUGGUCAGAUUCUAAAAUAA	669-689	329	AUAUUUTGAAGAUUCUGACCAUUG	667-689

AD-81725.10	330	GGUCAGAUUCUCAAUUAAAA	671-691	331	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454762.1	332	GGUCAGAUUCUCAAUUAAAA	671-691	333	UUUUUUUUUGAAGAUUCUGACCGU	669-691
AD-454763.1	334	GGUCAGAUUCUCAAUUAAAA	671-691	335	UUUUUUUUUGAAGAUUCUGACCCU	669-691
AD-454764.1	336	GGUCAGAUUCUCAAUUAAAA	671-691	337	UUUUUUUUUGAAGAUUCUGACCGG	669-691
AD-454765.1	338	UCAGAUUCUCAAUUAAAA	673-691	339	UUUUUUUUUGAAGAUUCUGACC	671-691
AD-454766.1	340	GGUCAGAUUCUCAAUUAAAA	671-691	341	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454767.1	342	GGUCAGAUUCUCAAUUAAAA	671-691	343	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454768.1	344	GGUCAGAUUCUCAAUUAAAA	671-691	345	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454769.1	346	GGUCAGAUUCUCAAUUAAAA	671-691	347	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454770.1	348	GGUCAGAUUCUCAAUUAAAA	671-691	349	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454771.1	350	GGUCAGAUUCUCAAUUAAAA	671-691	351	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454772.1	352	GGUCAGAUUCUCAAUUAAAA	671-691	353	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454773.1	354	GGUCAGAUUCUCAAUUAAAA	671-691	355	UUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454774.1	356	GGUCAGAUUCUCAAUUAAAA	671-691	357	UUUUUUUUUGAAGAUUCUGACCGU	669-691
AD-454775.1	358	GGUCAGAUUCUCAAUUAAAA	671-691	359	UUUUUUUUUGAAGAUUCUGACCCU	669-691
AD-454776.1	360	GGUCAGAUUCUCAAUUAAAA	671-691	361	UUUUUUUUUGAAGAUUCUGACCGG	669-691
AD-454777.1	362	UCAGAUUCUCAAUUAAAA	673-691	363	UUUUUUUUUGAAGAUUCUGACC	671-691
AD-454778.1	364	GGUCAGAUUCUCAAUUAAAA	671-691	365	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454779.1	366	GGUCAGAUUCUCAAUUAAAA	671-691	367	AUUUUUUUUGAAGAUUCUGACCGU	669-691
AD-454780.1	368	GGUCAGAUUCUCAAUUAAAA	671-691	369	AUUUUUUUUGAAGAUUCUGACCCU	669-691
AD-454781.1	370	GGUCAGAUUCUCAAUUAAAA	671-691	371	AUUUUUUUUGAAGAUUCUGACCGG	669-691
AD-454782.1	372	UCAGAUUCUCAAUUAAAA	673-691	373	AUUUUUUUUGAAGAUUCUGACC	671-691
AD-454783.1	374	GGUCAGAUUCUCAAUUAAAA	671-691	375	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454784.1	376	GGUCAGAUUCUCAAUUAAAA	671-691	377	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454785.1	378	GGUCAGAUUCUCAAUUAAAA	671-691	379	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454786.1	380	GGUCAGAUUCUCAAUUAAAA	671-691	381	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454787.1	382	GGUCAGAUUCUCAAUUAAAA	671-691	383	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454788.1	384	GGUCAGAUUCUCAAUUAAAA	671-691	385	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454789.1	386	GGUCAGAUUCUCAAUUAAAA	671-691	387	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454790.1	388	GGUCAGAUUCUCAAUUAAAA	671-691	389	AUUUUUUUUGAAGAUUCUGACCAU	669-691
AD-454791.1	390	GGUCAGAUUCUCAAUUAAAA	671-691	391	AUUUUUUUUGAAGAUUCUGACCGU	669-691

AD-454792.1	392	GGUCAGAUUCUCAAUAAAUA	671-691	393	AUUUAUUUUGAAGAUUCUGACCCU	669-691
AD-454793.1	394	GGUCAGAUUCUCAAUAAAUA	671-691	395	AUUUAUUUUGAAGAUUCUGACCCG	669-691
AD-454794.1	396	UCAGAUUCUCAAUAAAUA	673-691	397	AUUUAUUUUGAAGAUUCUGACCC	671-691
AD-81723.6	398	AAUGGUCAGAUUCUCAAUAAAUA	668-688	399	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454795.1	400	AAUGGUCAGAUUCUCAAUAAAUA	668-688	401	UAUUUUGAAGAUUCUGACCAUUGU	666-688
AD-454796.1	402	AAUGGUCAGAUUCUCAAUAAAUA	668-688	403	UAUUUUGAAGAUUCUGACCAUUCU	666-688
AD-454797.1	404	UGGUCAGAUUCUCAAUAAAUA	670-688	405	UAUUUUGAAGAUUCUGACCAU	668-688
AD-454798.1	406	AAUGGUCAGAUUCUCAAUAAAUA	668-688	407	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454799.1	408	AAUGGUCAGAUUCUCAAUAAAUA	668-688	409	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454800.1	410	AAUGGUCAGAUUCUCAAUAAAUA	668-688	411	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454801.1	412	AAUGGUCAGAUUCUCAAUAAAUA	668-688	413	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454802.1	414	AAUGGUCAGAUUCUCAAUAAAUA	668-688	415	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454803.1	416	AAUGGUCAGAUUCUCAAUAAAUA	668-688	417	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454804.1	418	AAUGGUCAGAUUCUCAAUAAAUA	668-688	419	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454805.1	420	AAUGGUCAGAUUCUCAAUAAAUA	668-688	421	UAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454806.1	422	AAUGGUCAGAUUCUCAAUAAAUA	668-688	423	UAUUUUGAAGAUUCUGACCAUUGU	666-688
AD-454807.1	424	AAUGGUCAGAUUCUCAAUAAAUA	668-688	425	UAUUUUGAAGAUUCUGACCAUUCU	666-688
AD-454808.1	426	UGGUCAGAUUCUCAAUAAAUA	670-688	427	UAUUUUGAAGAUUCUGACCAU	668-688
AD-454809.1	428	AAUGGUCAGAUUCUCAAUAAAUA	668-688	429	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454810.1	430	AAUGGUCAGAUUCUCAAUAAAUA	668-688	431	AAUUUUGAAGAUUCUGACCAUUGU	666-688
AD-454811.1	432	AAUGGUCAGAUUCUCAAUAAAUA	668-688	433	AAUUUUGAAGAUUCUGACCAUUCU	666-688
AD-454812.1	434	UGGUCAGAUUCUCAAUAAAUA	670-688	435	AAUUUUGAAGAUUCUGACCAU	668-688
AD-454813.1	436	AAUGGUCAGAUUCUCAAUAAAUA	668-688	437	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454814.1	438	AAUGGUCAGAUUCUCAAUAAAUA	668-688	439	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454815.1	440	AAUGGUCAGAUUCUCAAUAAAUA	668-688	441	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454816.1	442	AAUGGUCAGAUUCUCAAUAAAUA	668-688	443	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454817.1	444	AAUGGUCAGAUUCUCAAUAAAUA	668-688	445	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454818.1	446	AAUGGUCAGAUUCUCAAUAAAUA	668-688	447	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454819.1	448	AAUGGUCAGAUUCUCAAUAAAUA	668-688	449	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454820.1	450	AAUGGUCAGAUUCUCAAUAAAUA	668-688	451	AAUUUUGAAGAUUCUGACCAUUGG	666-688
AD-454821.1	452	AAUGGUCAGAUUCUCAAUAAAUA	668-688	453	AAUUUUGAAGAUUCUGACCAUUGU	666-688

AD-454822.1	454	AAUGGUCAGAUUCUCAAUUU	668-688	455	AAUUUUGAAGAUCUGACCAUUCU	666-688
AD-454823.1	456	UGGUCAGAUUCUCAAUUU	670-688	457	AAUUUUGAAGAUCUGACCAUU	668-688

Table 3A. Human LECT2 siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Seq ID No: (sense)	Sense sequence	Seq ID No: (anti sense)	Antisense sequence	Seq ID NO: (target sequence of NM_002302.2)	Target Sequence
AD-81680.1	458	asusggucAfgAfUfCfuU(Chd)aaaaaual96	459	usUfsauuUfuGfAfagauCfuGfaccsausg	460	CAATGGTCAGATCTTCAAAAATAA
AD-81708.1	461	ususGfuGfuCfaAfAfAfuGfuUfcUfaCfaul96	462	asUfsgUfaGfaAfAfuUfuUfgAfcaAfasasa	463	TTTTGTGTCAAAAATGTTCTACAT
AD-81679.1	464	asusggU(Chd)AfgAfUfCfucaaaaaual96	465	usUfsauuUfuGfAfagauCfuGfaccsausg	466	CAATGGTCAGATCTTCAAAAATAA
AD-81715.1	467	ususG(Uhd)GfuCfaAfAfUfuguucuaCfaUfl96	468	asUfsguAfGfaAfcauUfuUfgAfcaacaasasa	469	TTTTGTGTCAAAAATGTTCTACAT
AD-78150.5	470	asusggucAfgAfUfCfucaaaaaual96	471	usUfsauuUfuGfAfagauCfuGfaccsausg	472	CAATGGTCAGATCTTCAAAAATAA
AD-81696.1	473	csasugGfuCfaAfUfugaaaaacug(U3m)l96	474	asCfsaguUfuUfcfaaugUfgCfacaugscsg	475	CGCATGTGCACATTGAAAACTGT
AD-81728.1	476	asasccagAfuGfuUfuuccaccacaaal96	477	usUfsuggUfgGfAfaaacAfucfugguusus	478	AAAACCAGATGTTTTCCACCACAA
AD-81690.2	479	asusGfgUfcAfgAfUfCfuUfcAfAfafUfaal96	480	usUfsauuUfuGfAfagauCfuGfaccsausg	481	CAATGGTCAGATCTTCAAAAATAA
AD-81723.1	482	asasugguCfaGfAfUfcuucacaaual96	483	usAfsuuUfgAfAfgaucUfgAfccauusgsg	484	CCAATGGTCAGATCTTCAAAAATA
AD-81690.1	485	asusGfgUfcAfgAfUfCfuUfcAfAfafUfaal96	486	usUfsauuUfuGfAfagauCfuGfaccsausg	487	CAATGGTCAGATCTTCAAAAATAA
AD-81707.2	488	ususguguCfaAfAfuguuuacaul96	489	asUfsguaGfaAfCfaUfuUfgAfcaacaasasa	490	TTTTGTGTCAAAAATGTTCTACAT
AD-81707.1	491	ususguguCfaAfAfuguuuacaul96	492	asUfsguaGfaAfCfaUfuUfgAfcaacaasasa	493	TTTTGTGTCAAAAATGTTCTACAT
AD-81736.1	494	gscsuaggAfaGfUfAfuucuucaaaal96	495	usUfsugaAfuGfAfaucUfuCfcuagcsusa	496	TAGCTAGGAAGATATTCTTCAAAA
AD-81714.1	497	ususguGfuCfaAfAfUfg(Uhd)ucuaCfaUfl96	498	asUfsguAfGfaAfcauUfuUfgAfcaacaasasa	499	TTTTGTGTCAAAAATGTTCTACAT
AD-78140.4	500	csasugGfuCfaAfUfugaaaaacugul96	501	asCfsaguUfuUfcfaaugUfgCfacaugscsg	502	CGCATGTGCACATTGAAAACTGT

AD- 81721.1	503	ususguGfuCfaAfaUfguucuaCfaUfl96	504	asUfsuGfaAfcAuUfuUfgAfcacaAfsasa	505	TTTTGTGCAAAATGTTCTACAT
AD- 81724.1	506	usgsucaGfaUfCfUfucaaaaaaL96	507	usUfsuuUfuUfGfaagaUfcUfgaccasusu	508	AATGGTCAGATCTTCAAAATAAA
AD- 81710.1	509	ususguguCfaAfaUfgUfUhd)ucuaL96	510	asUfsuGfaAfcAuUfuUfgAfcacaasasa	511	TTTTGTGCAAAATGTTCTACAT
AD- 81711.1	512	ususguguCfaAfaUfgUfUhd)ucuaL96	513	asUfsuGfaAfcAuUfuUfgAfcacaasasa	514	TTTTGTGCAAAATGTTCTACAT
AD- 81722.1	515	csasaggUfcAfcAfcAuUfuUhd)ucuaL96	516	asUfsuuUfuUfGfaagaUfcUfgaccasusu	517	GCCAATGGTCAGATCTTCAAAAT
AD- 81708.2	518	ususGfuGfuCfaAfaUfgUfUhd)ucuaL96	519	asUfsuGfaAfcAuUfuUfgAfcacaasasa	520	TTTTGTGCAAAATGTTCTACAT
AD- 81681.1	521	asusggucAfcAfcAuUfuUhd)ucuaL96	522	usUfsuuUfuUfGfaagaUfcUfgaccasusu	523	CAATGGTCAGATCTTCAAAATAA
AD- 81678.2	524	asusGfuGfuCfaAfaUfgUfUhd)ucuaL96	525	usUfsuGfaAfcAuUfuUfgAfcacaasasa	526	CAATGGTCAGATCTTCAAAATAA
AD- 81725.1	527	gsgsucagAfuCfUfUhd)ucuaL96	528	usUfsuuUfuUfGfaagaUfcUfgaccasusu	529	ATGGTCAGATCTTCAAAATAAA
AD- 81720.1	530	ususGfuGfuCfaAfaUfgUfUhd)ucuaL96	531	asUfsuGfaAfcAuUfuUfgAfcacaasasa	532	TTTTGTGCAAAATGTTCTACAT
AD- 81678.1	533	asusGfuGfuCfaAfaUfgUfUhd)ucuaL96	534	usUfsuGfaAfcAuUfuUfgAfcacaasasa	535	CAATGGTCAGATCTTCAAAATAA
AD- 81691.1	536	asusggucAfcAfcAuUfuUhd)ucuaL96	537	usUfsuuUfuUfGfaagaUfcUfgaccasusu	538	CAATGGTCAGATCTTCAAAATAA
AD- 81709.1	539	ususgug(Uhd)CfaAfaUfgUfUhd)ucuaL96	540	asUfsuGfaAfcAuUfuUfgAfcacaasasa	541	TTTTGTGCAAAATGTTCTACAT
AD- 81713.1	542	ususguGfuCfaAfaUfgUfUhd)ucuaL96	543	asUfsuGfaAfcAuUfuUfgAfcacaasasa	544	TTTTGTGCAAAATGTTCTACAT
AD- 81712.1	545	ususguGfuCfaAfaUfgUfUhd)ucuaL96	546	asUfsuGfaAfcAuUfuUfgAfcacaasasa	547	TTTTGTGCAAAATGTTCTACAT
AD- 81682.1	548	asusggucAfcAfcAuUfuUhd)ucuaL96	549	usUfsuuUfuUfGfaagaUfcUfgaccasusu	550	CAATGGTCAGATCTTCAAAATAA
AD- 81693.1	551	csasUfgUfgCfaAfaUfgUfUhd)ucuaL96	552	asCfsaGfuUfuUfGfaagaUfcUfgaccasusu	553	CGCATGTGCACATTGAAAACTGT
AD- 81720.2	554	ususGfuGfuCfaAfaUfgUfUhd)ucuaL96	555	asUfsuGfaAfcAuUfuUfgAfcacaasasa	556	TTTTGTGCAAAATGTTCTACAT

AD- 81745.1	557	uscsaaacUfuGfAfAfuaauuuccaalL96	558	usUfsgaaGfAfUfauucAfaGfuuuugasasu	559	ATCAAACTTGAATATTCTTCAA
AD- 81719.1	560	ususguguCfaAfaAfuguuuacaulL96	561	asUfsguaga(Agn)cauUfuUfgAfcacaasasa	562	TTTTGTGTCAAAATGTTCTACAT
AD- 81692.1	563	csasugugCfaCfaUfugaaaacugulL96	564	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	565	CGCATGTGCACATTGAAAACTGT
AD- 81692.2	566	csasugugCfaCfaUfugaaaacugulL96	567	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	568	CGCATGTGCACATTGAAAACTGT
AD- 81742.1	569	ususcauuCfaAfAfCfuugaauuualL96	570	usAfsauaUfuCfAfaguuUfgAfaugaasusa	571	TATTCAATCAAACTTGAATATTA
AD- 81693.2	572	csasUfgUfgCfaCfaUfuGfAfAfUfgulL96	573	asCfsaGfuUfuUfcAfaugUfgCfaCfaUfgscsg	574	CGCATGTGCACATTGAAAACTGT
AD- 81718.1	575	ususgugucaAfaAfuguuuacaulL96	576	asUfsguag(Agn)jacauUfuUfgAfcacaasasa	577	TTTTGTGTCAAAATGTTCTACAT
AD- 78153.4	578	ususguguCfaAfAfAfuguuuacaulL96	579	asUfsguaGfAfAfcauuUfgAfcacaasasa	580	TTTTGTGTCAAAATGTTCTACAT
AD- 81705.2	581	csasUfgUfgCfaCfaUfuGfAfAfUfgulL96	582	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	583	CGCATGTGCACATTGAAAACTGT
AD- 81727.1	584	usgsugucAfaAfAfUfguuuacauulL96	585	asAfsuguAfgAfAfcauuUfuGfacacasasa	586	TTTTGTGTCAAAATGTTCTACATT
AD- 81705.1	587	csasUfgUfgCfaCfaUfuGfAfAfUfgulL96	588	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	589	CGCATGTGCACATTGAAAACTGT
AD- 81694.1	590	csasug(Uhd)gCfaCfaUfugaaaacugulL96	591	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	592	CGCATGTGCACATTGAAAACTGT
AD- 81683.1	593	asusggucAfaAfAfUfucaaaaUfaY34L96	594	usUfsauUfuUfuGfaagAfuCfuGfaccuusug	595	CAATGGTCAGATCTTCAAAAATAA
AD- 81677.2	596	asusggucAfaAfAfUfucaaaaauaalL96	597	usUfsauuUfuGfAfAfagAfuCfuGfaccuusug	598	CAATGGTCAGATCTTCAAAAATAA
AD- 81716.1	599	ususguguCfaAfaAfuguuuacaulL96	600	asUfsgua(Ggn)aacauUfuUfgAfcacaasasa	601	TTTTGTGTCAAAATGTTCTACAT
AD- 81717.1	602	ususguguCfaAfaAfuguuuacaulL96	603	asUfsguag(Agn)jacauUfuUfgAfcacaasasa	604	TTTTGTGTCAAAATGTTCTACAT
AD- 81735.1	605	asgscuagGfaAfGfUfauuauuuccaalL96	606	usUfsgaaUfgAfaAfuacuUfcCfuagcusasu	607	ATAGCTAGGAAGTATTTCATTCAA
AD- 81695.1	608	csasugugCfaCfaUf(Uhd)gaaaacugulL96	609	asCfsaguUfuUfcfaaUfgUfgCfacaugscsg	610	CGCATGTGCACATTGAAAACTGT

AD-81706.1	611	csasuguGfCfCfaCfaUfuUfgaaaacUfgUflL96	612	asCfsagUfuUfuUfcaaUfgUfgCfacaUgfscsg	613	CGCATGTGCACATTGAAAACTGT
AD-81737.1	614	csusaggaAfgUfAfUfucauucaaaaL96	615	usUfsuugAfaUfGfaauaCfuUfccuagscsu	616	AGCTAGGAAGTATTCTTCAAAA
AD-81744.1	617	ususcaaCfuUfGfAfauauucuualL96	618	usGfsaagAfaUfAfuucaAfgUfuugaasusg	619	CATTCAAACTTGAATATTCTTCA
AD-81677.1	620	asusggucAfgAfuCfuucaaaaauaalL96	621	usUfsauUfuGfAfagAfuCfuGfaccuusug	622	CAATGGTCAGATCTTCAAAAATAA
AD-81697.1	623	csasuguGfCfCfaCfaUfuUfgaaaacUfgUflL96	624	asCfsagUfuUfuUfcaaUfgUfgCfacaugscsg	625	CGCATGTGCACATTGAAAAACTGT
AD-81686.1	626	asusggucAfgAfuCfuucaaaaauaalL96	627	usUfsauu(Tgn)ugaagAfuCfuGfaccuusug	628	CAATGGTCAGATCTTCAAAAATAA
AD-81684.1	629	asusgguCfAfagAfuCfuUf(Uhd)caaaaUfaAflL96	630	usUfsauUfuUfuGfaagAfuCfuGfaccuusug	631	CAATGGTCAGATCTTCAAAAATAA
AD-81732.1	632	asasuagCufaGfGfAfaguuucauulL96	633	asAfsugaAfuAfCfuuccUfaGfcuauuusua	634	TAAATAGCTAGGAAGTATTTCATT
AD-81740.1	635	asgsuauuCfaUfuUfCfaaacuugaauL96	636	asUfsucaAfgUfuUfugaaUfgAfauacususc	637	GAAGTATTCTTCAAAACTTGAAT
AD-81738.1	638	asgsaagUfaUfuUfCfauucaaaacuulL96	639	asAfsguuUfgAfAfugaaUfaCfuuccusag	640	CTAGGAAGTATTCTTCAAAACTT
AD-81698.1	641	csasuguGfCfCfaCfaUfuUfgaaaacUfgY34L96	642	asCfsagUfuUfuUfcaaUfgUfgCfacaugscsg	643	CGCATGTGCACATTGAAAAACTGT
AD-81703.1	644	csasugugcaCfaUfugaaaaacuguL96	645	asCfsaguu(Tgn)ucaaUfgUfgCfacaugscsg	646	CGCATGTGCACATTGAAAAACTGT
AD-81731.1	647	gsgscuaaAfuAfGfCfuaggagauuL96	648	asUfsacuUfcCfUfagcuAfuUfuagccusu	649	AAGGCTAAATAGCTAGGAAGTAT
AD-81739.1	650	asasguauUfcAfUfuUfcaaacuugaalL96	651	usUfscaaGfuUfuUfgaaUgfaAfuacuuscsc	652	GGAAGTATTCTTCAAAACTTGAA
AD-81730.1	653	asasuucuAfaGfGfCfuaaaauagcuaL96	654	usAfsghuAfuUfuUfagccUfuAfgaauuscsu	655	AGAAATTCTAAGGCTAAATAGCTA
AD-81748.1	656	ususgaauAfuUfCfuUfucaaaagagaalL96	657	usUfscucUfuUfGfaagaAfuAfuucaasgsu	658	ACTTGAATATTCTTCAAAAGAGAA
AD-81734.1	659	usasgcuaGfgAfaGfuuuucauualL96	660	usGfsaauGfaAfUfacuuCfcUfagcuasusu	661	AATAGCTAGGAAGTATTTCATTCA
AD-81746.1	662	asascuugAfaUfaUfufucuucaaaagaL96	663	usCfsuuuGfaAfGfaauaUfuCfaaguusug	664	CAAACCTGAATAATTCTTCAAGA

AD- 81729.1	665	gsasauucUfaAfGfGfcuaaaauagcuL96	666	asGfscuaUfuUfaAfgccuUfaGfaauucsusg	667	CAGAAATTCTAAGGCTAAATAGCT
AD- 81688.1	678	asusggucagAfuCfuucaaaaaaual96	679	usUfsauuu(Tgn)gaagAfuCfuGfaccaususg	680	CAATGGTCAGATCTTCAAAAATAA
AD- 81733.1	681	asusagcuAfgGfAfAfguaauucauual96	682	usAfsaugAfaUfaAfcuucCfuAfgcuauusuu	683	AAATAGCTAGGAAGTATTCTTA
AD- 81701.1	684	csasugugCfaCfaUfugaaaacugul96	685	asCfsagu(Tgn)uucuuUfgUfgCfacaugscsg	686	CGCATGTGCACATTGAAAAACTGT
AD- 81704.1	687	csasugugCfaCfaUfugaaaacugul96	688	asCfsaguuu(Tgn)cauUfgUfgCfacaugscsg	689	CGCATGTGCACATTGAAAAACTGT
AD- 81702.1	690	csasugugCfaCfaUfugaaaacugul96	691	asCfsaguuu(Tgn)ucauUfgUfgCfacaugscsg	692	CGCATGTGCACATTGAAAAACTGT
AD- 81741.1	693	asusucauUfcAfAfAfcuugaauuuL96	694	asAfsuauUfcAfAfAfguuuGfaAfugaauasasc	695	GTATTCAATTCAAAACTTGAATATT
AD- 81747.1	696	ascsuugaAfuAfUfUfcuucuaaagaaL96	697	usUfscuuUfgAfAfAfgaaUfuUfcaagususu	698	AAACTTGAATATTCTTCAAAAGAA
AD- 81687.1	699	asusggucAfgAfuCfuucaaaaaaual96	700	usUfsauuu(Tgn)gaagAfuCfuGfaccaususg	701	CAATGGTCAGATCTTCAAAAATAA
AD- 81726.1	702	asusgugcAfcAfuUfgaaaacuguaL96	703	usAfsagUfuUfuUfcaauGfuGfcacausgsc	704	GCATGTGCACATTGAAAAACTGTA
AD- 81689.1	705	asusggucAfgAfuCfuucaaaaaaual96	706	usUfsauuuu(Ggn)aaagAfuCfuGfaccaususg	707	CAATGGTCAGATCTTCAAAAATAA
AD- 81685.1	708	asusgg(Uhd)CfAfgAfuCfuucaaaaaUfaAfL96	709	usUfsauUfuUfuGfaagAfuCfuGfaccaususg	710	CAATGGTCAGATCTTCAAAAATAA
AD- 81699.1	711	csasuguGfCfaCfaUf(Uhd)gaaaacUfgUfL96	712	asCfsagUfuUfuUfcauUfgUfgCfacaugscsg	713	CGCATGTGCACATTGAAAAACTGT
AD- 81743.1	714	asusucaaaAfcUfuGfaauuuuual96	715	usAfsagaAfuAfuUfucauGfuUfugaauusga	716	TCATTCAAAACCTTGAATATTCTTA
AD- 81700.1	717	csasug(Uhd)GfCfaCfaUfUfgaaaacUfgUfL96	718	asCfsagUfuUfuUfcauUfgUfgCfacaugscsg	719	CGCATGTGCACATTGAAAAACTGT

AD-81713.1	776	UUUGUGUCAAAAUGUUUCUACA	495-516	777	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81712.1	778	UUUGUGUCAAAAUGUUUCUACA	495-516	779	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81682.1	780	AUGGUCAGAUUCUCAAUAUA	669-690	781	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81693.1	782	CAUGUGCACAUAUGAAAAACUGU	607-628	783	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81720.2	784	UUUGUGUCAAAAUGUUUCUACA	495-516	785	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81745.1	786	UCAAACUUGAAUAUUCUUCAA	126-146	787	UUGAAGAAUAUUAAGUUUUGAAU	124-146
AD-81719.1	788	UUUGUGUCAAAAUGUUUCUACA	495-516	789	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81692.1	790	CAUGUGCACAUAUGAAAAACUGU	607-628	791	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81692.2	792	CAUGUGCACAUAUGAAAAACUGU	607-628	793	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81742.1	794	UUCAUUCAAACUUGAAUAUAUA	121-141	795	UAAUAUUCAAAGUUUUGAAUAUA	119-141
AD-81693.2	796	CAUGUGCACAUAUGAAAAACUGU	607-628	797	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81718.1	798	UUUGUGUCAAAAUGUUUCUACA	495-516	799	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-78153.4	800	UUUGUGUCAAAAUGUUUCUACA	495-516	801	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81705.2	802	CAUGUGCACAUAUGAAAAACUGU	607-628	803	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81727.1	804	UGUGUCAAAAUGUUCUACAUA	496-516	805	AAUGUAGAACAUIUUUGACACAAAA	494-516
AD-81705.1	806	CAUGUGCACAUAUGAAAAACUGU	607-628	807	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81694.1	808	CAUGUGCACAUAUGAAAAACUGU	607-628	809	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81683.1	810	AUGGUCAGAUUCUCAAUAUA	669-690	811	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81677.2	812	AUGGUCAGAUUCUCAAUAUA	669-690	813	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81716.1	814	UUUGUGUCAAAAUGUUUCUACA	495-516	815	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81717.1	816	UUUGUGUCAAAAUGUUUCUACA	495-516	817	AUGUAGAACAUIUUUGACACAAAA	493-515
AD-81735.1	818	AGCUAGGAAGUAUUCUUCAA	109-129	819	UUGAAGAAUAUACUCCUAGCUAU	107-129
AD-81695.1	820	CAUGUGCACAUAUGAAAAACUGU	607-628	821	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81706.1	822	CAUGUGCACAUAUGAAAAACUGU	607-628	823	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81737.1	824	CUAGGAAGUAUUCUUCAAAA	111-131	825	UUUUUGAAUAGAAUAUCCUAGCU	109-131
AD-81744.1	826	UUCAAAACUUGAAUAUUCUUA	125-145	827	UGAAGAAUAUUCUAAUUGAAUUG	123-145
AD-81677.1	828	AUGGUCAGAUUCUCAAUAUA	669-690	829	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81697.1	830	CAUGUGCACAUAUGAAAAACUGU	607-628	831	ACAGUUUUCAAUUGUGCACAUGCG	605-627
AD-81686.1	832	AUGGUCAGAUUCUCAAUAUA	669-690	833	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81684.1	834	AUGGUCAGAUUCUCAAUAUA	669-690	835	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81732.1	836	AAUAGCUAGGAAGUAUUCUUA	106-126	837	AAUGAAUAUACUCCUAGCUAUUA	104-126

AD-81740.1	838	AGUAUUCAUUCAAAACUUGAAU	117-137	839	AUUCAGUUUUGAAUGAAUACUUC	115-137
AD-81738.1	840	AGGAAGUAUUCAUUCAAAACUU	113-133	841	AAGUUUGAAUGAAUACUUCUAG	111-133
AD-81698.1	842	CAUGUGCACAUUGAAAACUG	607-628	843	ACAGUUUUCAAUGUGCACAUGCG	605-627
AD-81703.1	844	CAUGUGCACAUUGAAAACUGU	607-628	845	ACAGUUTUCAAUUGUGCACAUGCG	605-627
AD-81731.1	846	GGCUAAAUAGCUAGGAAGUAU	101-121	847	AUACUUCUAGCUAUUUUAGCCUU	99-121
AD-81739.1	848	AAGUAUUCAUUCAAACUUGAA	116-136	849	UUCAAGUUUGAAUGAAUACUUC	114-136
AD-81730.1	850	AAUUCUAAAGGCUAAAUAGCUA	93-113	851	UAGCUAUUUUAGCCUUAGAAUUCU	91-113
AD-81748.1	852	UUGAAUAUUCUUCAAAAGAGAA	132-152	853	UUCUCUUUGAAGAAUAUUAAGU	130-152
AD-81734.1	854	UAGCUAGGAAGUAUUCAUUCA	108-128	855	UGAAUGAAUACUUCUAGCUAUU	106-128
AD-81746.1	856	AACUUGAAUAUUCUUCAAAGA	129-149	857	UCUUUGAAGAAUAUUAAGUUUG	127-149
AD-81729.1	858	GAAUUCUAAAGGCUAAAUAGCU	92-112	859	AGCUAUUUAGCCUUAGAAUUCUG	90-112
AD-81688.1	860	AUGGUCAGAUUCUUCAAAUA	669-690	861	UUUUUTGAAGAUUCUGACCAUUG	667-689
AD-81733.1	862	AUAGCUAGGAAGUAUUCAUUA	107-127	863	UAAUGAAUACUUCUAGCUAUUU	105-127
AD-81701.1	864	CAUGUGCACAUUGAAAACUGU	607-628	865	ACAGUTUCAAUGUGCACAUGCG	605-627
AD-81704.1	866	CAUGUGCACAUUGAAAACUGU	607-628	867	ACAGUUUTCAAUGUGCACAUGCG	605-627
AD-81702.1	868	CAUGUGCACAUUGAAAACUGU	607-628	869	ACAGUUTCAAUGUGCACAUGCG	605-627
AD-81741.1	870	AUUCAUUCAAACUUGAAUAUU	120-140	871	AAUAUUCAAAGUUUGAAUGAAUAC	118-140
AD-81747.1	872	ACUUGAAUAUUCUUCAAAAGAA	130-150	873	UUCUUUGAAGAAUAUUAAGUUU	128-150
AD-81687.1	874	AUGGUCAGAUUCUUCAAAUA	669-690	875	UUUUUUUTGAAGAUUCUGACCAUUG	667-689
AD-81726.1	876	AUGUGCACAUUGAAAACUGUA	608-628	877	UACAGUUUUCAAUGUGCACAUGC	606-628
AD-81689.1	878	AUGGUCAGAUUCUUCAAAUA	669-690	879	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81685.1	880	AUGGUCAGAUUCUUCAAAUA	669-690	881	UUUUUUUGAAGAUUCUGACCAUUG	667-689
AD-81699.1	882	CAUGUGCACAUUGAAAACUGU	607-628	883	ACAGUUUUCAAUGUGCACAUGCG	605-627
AD-81743.1	884	AUUCAAAACUUGAAUAUUCUUA	124-144	885	UAAGAAUAUUAAGUUUUGAAUGA	122-144
AD-81700.1	886	CAUGUGCACAUUGAAAACUGU	607-628	887	ACAGUUUUCAAUGUGCACAUGCG	605-627

Example 2. *In Vitro* Screening of LECT2 siRNA**Experimental Methods****Cell culture and transfections:**

5 Cynomolgus monkey primary hepatocytes were transfected independently by adding 5 µl of Opti-MEM plus 0.1 µl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA. cat #13778-150) to 5.1 µl of siRNA duplexes per well into a 384-well plate and incubated at room temperature for 15 minutes. 40 µl of InVitroGRO CP Medium (BioIVT Cat # Z99029) containing 5×10^3 primary cynomolgus monkey hepatocytes were then added to the siRNA
10 mixture. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 10nM final duplex concentrations.

RNA isolation:

Total RNA was isolated using an automated protocol on a BioTek-EL406 platform using DYNABEADS (Invitrogen, Cat #61012). Briefly, 70 µl of Lysis/Binding Buffer and 10 µl of
15 lysis buffer containing 3 µl of magnetic beads were added to the plate with cells. Plates were incubated on an electromagnetic shaker for 10 minutes at room temperature and then magnetic beads were captured and the supernatant was removed. Bead-bound RNA was then washed 2 times with 150 µl Wash Buffer A and once with Wash Buffer B. Beads were then washed with 150 µl Elution Buffer, re-captured and supernatant removed.

cDNA synthesis:

20 cDNA was synthesized using ABI High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, Cat #4368813). 12µl of a master mix containing 1.2 µl 10X Buffer, 0.48 µl 25X dNTPs, 1.2 µl 10x Random primers, 0.6 µl Reverse Transcriptase, 0.6 µl RNase inhibitor and 7.92 µl of H₂O per reaction was added to RNA isolated above. Plates were sealed,
25 mixed, and incubated on an electromagnetic shaker for 10 minutes at room temperature, followed by 2h at 37°C.

Real time PCR:

2µl of cDNA were added to a master mix containing 0.5µl of GAPDH TaqMan Probe (Hs99999905), 0.5µl LECT2 probe and 5µl Lightcycler 480 probe master mix (Roche Cat #
30 04887301001) per well in a 384 well plates (Roche cat # 04887301001). Cynomolgus monkey primary hepatocytes qPCR was probed with a custom cynomolgus GAPDH probe and a

cynomolgus LECT2 probe (Mf02803673_m1). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche) using the $\Delta\Delta C_t$ (RQ) assay. Each duplex was tested in two independent transfections and data were normalized to cells transfected with a non-targeting control siRNA. To calculate relative fold change, real time data were analyzed using the $\Delta\Delta C_t$ method and normalized to assays performed with cells transfected with 20nM AD-1955, or mock transfected cells.

Results

The results of the single dose screen in primary monkey hepatocytes with two sets of exemplary LECT2 siRNAs are shown in Table 4A (correspond to siRNAs in Table 2A and Table 2B) and Table 4B (correspond to siRNAs in Table 3A and Table 3B). The single dose experiments were performed at 10nM final duplex concentration and the data are expressed as percent message remaining relative to AD-1955 non-targeting control.

Table 4A. Cynomolgus monkey LECT2 endogenous *in vitro* 10nM screen with one set of exemplary LECT2 siRNAs

Duplex Name	% of Cyno Message Remaining	STDEV
AD-133457.6	21.0	3.9
AD-454742.1	59.0	8.3
AD-454743.1	51.3	5.9
AD-454744.1	27.3	4.1
AD-397297.2	9.2	1.4
AD-454745.1	10.0	2.8
AD-397294.2	10.5	1.2
AD-454746.1	6.7	1.0
AD-454747.1	10.1	1.7
AD-133461.7	7.1	3.2
AD-454748.1	5.1	1.6
AD-454749.1	7.6	2.4
AD-454750.1	4.0	0.9
AD-397303.2	4.0	0.2
AD-454751.1	4.3	1.0
AD-397300.2	4.0	1.2
AD-454752.1	5.2	1.1
AD-454753.1	8.8	1.8
AD-397298.1	7.6	3.8

AD-454754.1	7.6	0.5
AD-454755.1	5.2	0.9
AD-454756.1	6.0	1.2
AD-454757.1	4.5	0.5
AD-454758.1	4.3	1.8
AD-454759.1	8.3	1.5
AD-454760.1	6.2	2.2
AD-454761.1	6.2	2.4
AD-81725.10	6.8	1.6
AD-454762.1	5.8	2.3
AD-454763.1	6.5	2.0
AD-454764.1	7.7	2.5
AD-454765.1	6.0	1.3
AD-454766.1	7.0	1.9
AD-454767.1	6.2	1.5
AD-454768.1	6.0	3.3
AD-454769.1	5.8	1.3
AD-454770.1	6.4	1.9
AD-454771.1	5.6	2.0
AD-454772.1	6.2	1.9
AD-454773.1	7.4	1.2
AD-454774.1	7.4	1.0
AD-454775.1	7.6	2.4
AD-454776.1	8.9	3.7
AD-454777.1	6.3	1.4
AD-454778.1	6.8	2.2
AD-454779.1	6.5	0.3
AD-454780.1	7.1	2.1
AD-454781.1	5.7	1.6
AD-454782.1	10.2	2.7
AD-454783.1	5.6	1.2
AD-454784.1	9.3	5.3
AD-454785.1	6.5	1.4
AD-454786.1	8.0	1.7
AD-454787.1	6.6	1.7
AD-454788.1	7.0	0.6
AD-454789.1	8.8	1.6
AD-454790.1	6.8	2.1
AD-454791.1	5.1	1.1

AD-454792.1	5.2	1.3
AD-454793.1	6.5	1.0
AD-454794.1	7.2	2.6
AD-81723.6	5.3	1.4
AD-454795.1	3.7	0.3
AD-454796.1	7.3	2.9
AD-454797.1	7.1	2.0
AD-454798.1	5.8	0.9
AD-454799.1	4.9	0.7
AD-454800.1	5.0	1.8
AD-454801.1	3.1	0.1
AD-454802.1	5.4	1.8
AD-454803.1	4.6	1.9
AD-454804.1	60.0	11.5
AD-454805.1	32.5	6.5
AD-454806.1	6.6	1.5
AD-454807.1	7.5	0.7
AD-454808.1	5.3	1.4
AD-454809.1	6.3	2.3
AD-454810.1	5.7	1.1
AD-454811.1	6.2	1.3
AD-454812.1	4.5	1.7
AD-454813.1	4.5	1.0
AD-454814.1	5.9	0.4
AD-454815.1	7.5	1.4
AD-454816.1	6.2	2.7
AD-454817.1	6.3	1.5
AD-454818.1	6.1	0.8
AD-454819.1	58.1	15.4
AD-454820.1	52.7	6.4
AD-454821.1	3.9	0.8
AD-454822.1	4.6	0.3
AD-454823.1	6.1	2.7

Table 4B. Cynomolgus monkey LECT2 endogenous *in vitro* 10nM screen with another set of exemplary LECT2 siRNAs

Duplex Name	% of Cyno Message Remaining	STDEV
AD-81680.1	0.3	0.2
AD-81708.1	0.3	0.4
AD-81679.1	0.4	0.3
AD-81715.1	0.4	0.5
AD-78150.5	0.4	0.3
AD-81696.1	0.4	0.5
AD-81728.1	0.4	0.6
AD-81690.2	0.4	0.3
AD-81723.1	0.5	0.3
AD-81690.1	0.5	0.3
AD-81707.2	0.5	0.5
AD-81707.1	0.5	0.5
AD-81736.1	0.6	0.9
AD-81714.1	0.6	0.4
AD-78140.4	0.6	0.5
AD-81721.1	0.6	0.5
AD-81724.1	0.6	0.5
AD-81710.1	0.6	0.4
AD-81711.1	0.7	0.5
AD-81722.1	0.7	0.6
AD-81708.2	0.7	0.5
AD-81681.1	0.7	0.6
AD-81678.2	0.8	0.6
AD-81725.1	0.8	0.5
AD-81720.1	0.8	0.6
AD-81678.1	0.8	0.7
AD-81691.1	0.8	0.7
AD-81709.1	0.9	0.7
AD-81713.1	0.9	0.8
AD-81712.1	0.9	0.8
AD-81682.1	0.9	0.7
AD-81693.1	1.0	0.8
AD-81720.2	1.0	0.8
AD-81745.1	1.0	0.9
AD-81719.1	1.0	0.8
AD-81692.1	1.1	0.8
AD-81692.2	1.1	0.7
AD-81742.1	1.1	0.8
AD-81693.2	1.1	0.8

AD-81718.1	1.1	0.8
AD-78153.4	1.1	0.8
AD-81705.2	1.2	1.0
AD-81727.1	1.3	0.9
AD-81705.1	1.3	1.0
AD-81694.1	1.4	1.3
AD-81683.1	1.4	1.1
AD-81677.2	1.8	1.7
AD-81716.1	1.9	1.4
AD-81717.1	1.9	1.6
AD-81735.1	2.2	1.5
AD-81695.1	2.4	2.6
AD-81706.1	2.6	1.8
AD-81737.1	2.7	2.0
AD-81744.1	2.8	1.9
AD-81677.1	2.8	2.1
AD-81697.1	3.6	2.8
AD-81686.1	3.6	2.6
AD-81684.1	3.7	2.6
AD-81732.1	3.7	2.8
AD-81740.1	3.9	3.0
AD-81738.1	4.0	2.9
AD-81698.1	4.8	3.6
AD-81703.1	5.0	5.7
AD-81731.1	5.0	3.7
AD-81739.1	5.1	5.1
AD-81730.1	5.1	4.1
AD-81748.1	5.7	3.8
AD-81734.1	6.4	4.4
AD-81746.1	6.4	4.3
AD-81729.1	6.6	4.9
AD-81688.1	6.8	4.8
AD-81733.1	7.1	4.8
AD-81701.1	8.8	5.9
AD-81704.1	9.5	9.3
AD-81702.1	9.7	6.5
AD-81741.1	10.1	7.7
AD-81747.1	10.6	7.5
AD-81687.1	11.8	8.0
AD-81726.1	12.2	8.6
AD-81689.1	25.5	19.5
AD-81685.1	27.4	18.2
AD-81699.1	27.7	19.1

AD-81743.1	37.9	27.0
AD-81700.1	55.5	40.6

Example 3. In Vivo Screening of LECT2 siRNA

Pharmacodynamics of three exemplary LECT2 siRNAs in rodent AAV models

The sequences and chemistry of the three exemplary LECT2 siRNAs, AD-454781, AD-1333461, and AD-454746, that were investigated in the rodent AAV models, are depicted in **FIG. 2**. Wildtype B6/C57 mice (Charles Rivers Laboratory) were intravenously injected with human LECT2 constructs under a liver-specific promoter, TBG, that were packaged in AAV8 viral particles (2×10^{11} gc/mouse). After two weeks, mice were injected subcutaneously with 2 mg/kg of one of the three LECT2 siRNAs shown in **FIG. 2**, or a PBS control. On day 14 post-treatment, livers were harvested for qPCR analysis (done as described in Example 2) with a probe specifically recognizing LECT2. Mouse GAPDH was used as normalization control. Relative levels of human LECT2 mRNA in the liver were calculated with the delta/delta Ct method, normalized to PBS control groups, and is depicted as percent LECT2 remaining on the Y-axis in **FIG. 3**. As seen in **FIG. 3**, administration of the AD-454746 siRNA led to approximately a 70% decrease in LECT2 liver mRNA; the AD-133461 siRNA led to a 60% decrease; and the AD454781 siRNA led to the greatest decrease, at ~80%.

Whole blood was also harvested from the mice treated either the siRNA or PBS control. Whole blood was collected in heparinized tubes both prior to treatment and at day 14 post-treatment in order to generate heparin plasma. The plasma was diluted 1:50-1:75 and run on a LECT2 specific ELISA to quantify circulating levels of the protein. To perform the ELISA, plates were pre-coated overnight at 4°C, with 100 µL of the mouse anti-human LECT2 capture antibody (R&D cat. # MAB722), which was diluted to a concentration of 1 µg/mL. Plates were washed with PBS-T, blocked for 1 hour with PBS/3% BSA at room temperature, and then washed an additional 5 times. The plasma samples (100 µL per well) were then added to plate and incubated for 1 hour at room temperature with shaking (~600 rpm). A human plasma standard (Abcam, Cat#ab188467, 500 ug/ml, Lot#GR3202526-3) was used as a control. The plate was then washed five times, the detection antibody (AbD31038.2 Anti-col_hLECT2, Fab-Max-FH BioRad) was added to the plate (100 µL per well), and the plate was then incubated at

room temperature for 1 hour with shaking (~600 rpm). Subsequently, the plate was washed 5 times, the human Anti-bacterial Alkaline Phosphatase:HRP antibody (Bio-Rad, Cat#HCA275P) was added to the wells (100 μ L per well), and the plate was then incubated at room temperature for 1 hour with shaking (~600 rpm). Plate was washed followed by addition of the TMB reagent (TMB Surmodics Cat# TMBS-0100-01) and a 10 minute incubation. This reaction was then quenched with 100 μ L of the sulfuric acid stop solution (Nova-Stop Solution, Surmodics Cat#ASTP-0100-01), and absorbance was measured at 450nm.

Using the values from the LECT2 specific ELISA, the relative levels of plasma LECT2 protein were calculated by normalization to protein levels prior to dosing, which is depicted as percent LECT2 remaining on the Y-axis in **FIG. 3**. As can be seen in **FIG. 3**, administration of the AD-454746 siRNA led to approximately a 75% decrease in LECT2 plasma protein levels; the AD-133461 siRNA led to a 70% decrease; and the AD454781 siRNA led to the greatest decrease, at ~80%.

Pharmacodynamics of three exemplary LECT2 siRNAs in cynomolgus monkeys

The three LECT2 siRNAs depicted in **FIG. 2** were injected subcutaneously into cynomolgus monkeys at increasing doses of 0.3 mg/kg, 1 mg/kg, and 3 mg/kg (**FIGS. 4A-4C**, respectively). Plasma was collected in heparinized tubes pre-treatment and at various timepoints post-treatment, which are depicted on the X-axis in **FIGS. 4A-4C**. Circulating levels of LECT2 plasma protein were quantified by ELISA. Relative levels of plasma LECT2 protein were calculated by normalization to protein levels prior to treatment, which is depicted as plasma LECT2 protein knockdown on the Y-axis in **FIGS. 4A-4C**. As can be seen in **FIGS. 4A-4C**, there was a dose-dependent increase in silencing, as the greatest knockdown in protein levels was observed when all three of the LECT2 siRNAs were administered at 3 mg/kg (**FIG. 4C**). However, administering as low as 0.3 mg/kg of each siRNA did result in some knockdown of the LECT2 protein (**FIG. 4A**). Additionally, across all three doses administered, the AD-454781 siRNA led to the greatest knockdown in protein levels at all timepoints post-treatment (**FIGS. 4A-4C** and Table 5). Plasma LECT2 protein knockdown quantified on day 29 post-treatment in the monkeys for each of the LECT2 siRNAs administered at either 1 mg/kg or 3 mg/kg is also summarized in Table 5 below.

Table 5. Efficacy and duration of three exemplary LECT2 siRNAs in cynomolgus monkeys as measured by percent knockdown of LECT2 plasma protein levels

siRNA	Potency and duration	
	Plasma LECT2 protein % knockdown	
	Day 29	
	1 mg/kg	3 mg/kg
AD-454781	90%	97%
AD-133461	77%	90%
AD-454746	50%	68%

Assessment of LECT2 knockdown in rodents with the AD-86459 and AD-86460

siRNAs

The LECT2 siRNAs, AD-86459 and AD-86460 (Tables 6 and 7), or a PBS control were injected subcutaneously into SD-1 rats (**FIG. 5A**) and CD-1 mice (**FIG. 5B**). The experimental and control treatments were administered monthly at 10 mg/kg. Livers were harvested at 3, 6, or 12 months post-first dosing. Liver RNA was isolated for qPCR analysis (done as described in Example 2) using primers and probes specific for murine/rat LECT2 and also murine/rat GAPDH, which was the normalization control. Relative levels of rodent LECT2 mRNA in the liver were calculated using the $\Delta\Delta C_t$ method, normalizing to the PBS controls, which is depicted as expression fold difference on the Y-axis of the graphs in **FIGS. 5A-5B**. Data are presented in **FIG. 5** with mean $\pm$ standard deviation and each point representing an individual rodent. In both rats (**FIG. 5A**) and mice (**FIG. 5B**), the AD-86459 siRNA and the AD-86460 siRNA led to almost complete knockdown of the LECT2 mRNA in the liver at all timepoints post-initial treatment that were sampled.

Table 6: LECT2 siRNA Modified Sequences

Duplex Name	Seq ID No: (sense)	Sense Seq	Seq ID No: (antisense)	Antisense Seq
AD-86459	889	cscsgaagAfaAfCfGfugcauucuaaL96	890	usUfsagaAfuGfCfacguUfuCfuucggsgsa
AD-86460	891	gsusgucaAfaAfUfuUfuuuacauuaL96	892	usAfsaugUfaGfAfaaaUfuUfgacacsasa

Table 7: LECT2 siRNA Unmodified Sequences

Duplex Name	Seq ID No: (sense)	Sense Seq	Seq ID No: (antisense)	Antisense Seq
AD-86459	893	CCGAAGAAACGUGCAUUCUAA	894	UUAGAAUGCACGUUUCUUCGGGA
AD-86460	895	GUGUCAAAAUUUUCUACAUUA	896	UAAUGUAGAAAAUUUUGACACAA

Assessment of LECT2 knockdown in cynomolgus monkeys with the AD-81725 siRNA

Cynomolgus monkeys were injected subcutaneously with the LECT2 siRNA, AD-81725, or a PBS control (**FIGS. 6A-6B**). The experimental and control treatments were administered monthly at 3 mg/kg. Livers were harvested at 6 months post-first dosing. Liver RNA was isolated for qPCR analysis (done as described in Example 2) using primers and probes specific for cynomolgus LECT2 and also cynomolgus GAPDH, which was the normalization control. Relative levels of cynomolgus LECT2 mRNA in the liver were calculated using the $\Delta\Delta C_t$ method, normalizing to the PBS controls, which is depicted as expression fold difference on the Y-axis in **FIG. 6A**. Data are presented in **FIG. 6A** with mean $\pm$ standard deviation and each point representing an individual monkey. The AD-81725 siRNA led to almost complete knockdown of the LECT2 mRNA in the liver of the monkeys at 6 months post-initial dosing.

Whole blood was also collected in heparinized tubes pre-treatment and each month for a six month duration post-initial treatment (**FIG. 6B**). Plasma was isolated and used to measure circulating levels of LECT2 protein by ELISA specific for human/cynomolgus LECT2 protein. Relative levels of LECT2 protein were calculated by normalizing to pre-treatment protein levels, which is depicted as plasma LECT2 protein remaining on the Y axis in **FIG. 6B**. The AD-81725

siRNA led to a >99% decrease in LECT2 plasma protein levels in the monkeys, which was observed at each timepoint sampled post-first dosing (**FIG. 6B**).

EQUIVALENTS


Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.

WE CLAIM:


1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, which antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from one of the antisense sequences listed in Tables 2A-2B, 3A-3B, 6 or 7, or a pharmaceutically acceptable salt thereof.
2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand that is 15-30 nucleotides in length and an antisense strand that is 15-30 nucleotides in length and the antisense strand is complementary to at least 15 contiguous nucleotides of a target sequence listed in Table 2A, 2B, 3A, 3B, 6, or 7, or a pharmaceutically acceptable salt thereof.
3. The dsRNA of claim 1 or 2, wherein said dsRNA comprises at least one modified nucleotide.
4. The dsRNA of any of the preceding claims, wherein the dsRNA comprises a duplex region that is 15-30 base pairs in length.
5. The dsRNA of claim 4, wherein the duplex region is 17-25 base pairs in length.
6. The dsRNA of claim 4 or 5, wherein the duplex region is 19-22 base pairs in length.
7. The dsRNA of any of claims 4-6, wherein the duplex region is 21 base pairs in length.
8. The dsRNA of any of claims 1 or 3-7, wherein the region of complementarity is at least 17 nucleotides in length.

9. The dsRNA of any of claims 1 or 3-8, wherein the region of complementarity is between 21 and 25 nucleotides in length.
10. The dsRNA of any of claims 1 or 3-9, wherein the region of complementarity is 23 nucleotides in length.
11. The dsRNA of any of the preceding claims, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide or 2 nucleotides.
12. The dsRNA of any of the preceding claims, wherein dsRNA comprises a blunt end.
13. The dsRNA of any of claims 3-12, wherein at least one of said modified nucleotides is chosen from the group consisting of: a 2'-O-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.
14. The dsRNA of any of claims 3-12, wherein at least one of said modified nucleotides is chosen from the group consisting of: a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleic acid (LNA), an acyclic nucleotide, an abasic nucleotide, a glycol nucleotide (GNA), 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.
15. The dsRNA of any of claims 3-12, wherein the modifications on the nucleotides are selected from the group consisting of a locked nucleic acid (LNA), an acyclic nucleotide, a hexitol or hexose nucleic acid (HNA), a cyclohexene nucleic acid (CeNA), a glycol nucleic acid (GNA), 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-deoxy, 2'-hydroxyl, and combinations thereof.
16. The dsRNA of any of claims 3-12, wherein the modifications on the nucleotides are 2'-O-methyl, 2'-fluoro, or both, and optionally GNA.

17. The dsRNA of any of the preceding claims wherein the sense strand is conjugated to at least one ligand.
18. The dsRNA of claim 17, wherein the ligand is attached to the 3' end of the sense strand.
19. The dsRNA of claim 17 or 18, wherein the ligand comprises a carbohydrate.
20. The dsRNA of any of claims 17-19, wherein the ligand is a GalNAc ligand.
21. The dsRNA of any of claims 17-20, wherein the ligand is



22. The dsRNA of any of claims 17-21, wherein the ligand is attached via a linker.
23. The dsRNA of claim 22, wherein the linker is a bivalent or trivalent branched linker.
24. The dsRNA of claim 22, wherein the ligand and linker are as shown in Formula XXIV:



25. The dsRNA of any of claims 17-24, wherein the ligand targets the dsRNA to hepatocytes.
26. The dsRNA of any of the preceding claims, wherein the region of complementarity consists of an antisense sequence selected from the antisense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7.
27. The dsRNA of any of the preceding claims, wherein the dsRNA comprises a sense strand consisting of a sense sequence selected from the sense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7, and an antisense strand consisting of an antisense sequence selected from the antisense sequences disclosed in Tables 2A-2B, 3A-3B, 6 or 7.
28. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the sense strand comprises the sequence and all of the modifications of ggsucagAfuCfUfUfcaaaaauaaL96 (SEQ ID NO: 143) and the antisense strand comprises the sequence and all of the modifications of asUfsuuaUfuUfUfgaagAfuCfugaccsgsg (SEQ ID NO: 144).
29. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the region of complementarity is substantially complementary to nucleotides 669-691 of SEQ ID NO: 1.
30. A cell containing the dsRNA of any of the preceding claims.
31. A pharmaceutical composition for inhibiting expression of a LECT2 gene, the composition comprising the dsRNA of any of claims 1-29.
32. The pharmaceutical composition of claim 31, wherein dsRNA is administered in an unbuffered solution.

33. The pharmaceutical composition of claim 32, wherein said unbuffered solution is saline or water.
34. The pharmaceutical composition of claim 31, wherein said dsRNA is administered with a buffer solution.
35. The pharmaceutical composition of claim 34, wherein said buffer solution comprises acetate, citrate, prolamine, carbonate, phosphate or any combination thereof.
36. The pharmaceutical composition of claim 34 or 35, wherein said buffer solution is phosphate buffered saline (PBS).
37. The pharmaceutical composition of any of claims 31-36, wherein said composition comprises a lipid formulation.
38. The pharmaceutical composition of claim 37, wherein the lipid formulation is an LNP formulation.
39. The pharmaceutical composition of claim 37 or 38, wherein the lipid formulation is an LNP11 formulation.
40. The pharmaceutical composition of any of claims 31-39, wherein the dsRNA is targeted to a liver cell or a hepatocyte.
41. The pharmaceutical composition of any of claims 31-40, wherein said composition is administered intravenously.
42. The pharmaceutical composition of any of claims 31-40, wherein said composition is administered subcutaneously.

43. The pharmaceutical composition of claim 41, wherein said composition comprises a lipid formulation and is administered intravenously.
44. The pharmaceutical composition of any of claims 31-43, wherein said composition comprises a dsRNA that is conjugated to a ligand chosen from a carbohydrate ligand or a GalNAc ligand.
45. A method of inhibiting LECT2 expression in a cell, the method comprising:
- (a) contacting, e.g., introducing into the cell the dsRNA of any of claims 1-29, and
 - (b) maintaining the cell of step (a) for a time sufficient to obtain degradation of the mRNA transcript of a LECT2 gene, thereby inhibiting expression of the LECT2 gene in the cell.
46. The method of claim 45, wherein the cell is treated *ex vivo*, *in vitro*, or *in vivo*.
47. The method of claim 45 or 46, wherein the cell is present in a subject in need of treatment, prevention and/or management of a disorder related to LECT2 expression.
48. The method of claim 47, wherein said disorder is amyloidosis.
49. The method of claim 48, wherein the amyloidosis is a LECT2 amyloidosis.
50. The method of any of claims 45-49, wherein the cell is a liver cell or a hepatocyte.
51. The method of any of claims 45-50, wherein the expression of LECT2 is inhibited by at least 20%.
52. The method of any of claims 45-51, wherein the expression of LECT2 is inhibited by at least 90%.

53. A method of treating a disorder related to LECT2 expression, comprising administering to a subject in need of such treatment a therapeutically effective amount of
- (i) the dsRNA of any of claims 1-29 or
 - (ii) the pharmaceutical composition of any of claims 31-44.
54. A method of treating LECT2 amyloidosis, comprising administering to a subject in need of such treatment a therapeutically effective amount of
- (i) the dsRNA of any of claims 1-29 or
 - (ii) the pharmaceutical composition of any of claims 31-44.
55. The method of claim 52 or 53, wherein the subject has amyloidosis or is at risk for developing amyloidosis.
56. The method of any of claims 53-55, wherein the amyloidosis is a LECT2 amyloidosis.
57. The method of any of claims 45-56, wherein the dsRNA or composition comprising the dsRNA is administered according to a dosing regimen.
58. The method of claim 57, wherein the dosing regimen is weekly, biweekly, or monthly.
59. The method of any of claims 45-58, wherein the method reduces LECT2 amyloid deposition.
60. A method of reducing LECT2 amyloid deposition in a subject having a LECT2 amyloidosis, the method comprising administering to the subject
- (i) the dsRNA of any of claims 1-29 or
 - (ii) the pharmaceutical composition of any of claims 31-44.
61. The method of any of claims 53-60, wherein the dsRNA is administered at a dose of 0.05-50 mg/kg.

62. The method of any of claims 53-61, wherein the dsRNA is administered at a concentration of 0.01 mg/kg to 5 mg/kg bodyweight of the subject.
63. The method of any of claims 53-62, wherein the dsRNA is formulated as an LNP formulation and is administered at a dose of 0.1 mg/kg to 0.5 mg/kg.
64. The method of any of claims 53-63, wherein the dsRNA is conjugated to a GalNAc ligand.
65. The method of any of claims 53-64, wherein the dsRNA is conjugated to a GalNAc ligand and is administered at a dose of 1 mg/kg to 10 mg/kg, optionally at a dose of 1 mg/kg or 3 mg/kg.
66. A vector encoding at least one strand of the dsRNA of any of claims 1-29.
67. A cell comprising the vector of claim 66.

1/8

```
1 aaatcaaata gctatccatg gaatattaga acttgacttg ctccatcctc ttaaactttt
61 tgtgtctcac actaaagaaa tgagagatgc agaattctaa ggctaaatag ctaggaaagta
121 ttcatattcaa cttgaatat cttcaaagag agtgtggggg caactctaata cagaggaaaga
181 aactaaagga agtaaaacca gatgttttcc accaaagccc tccttttggc tggctctgatt
241 tctaccgcac tggcagggcc atgggctaata atatgtgctg gcaagtcttc caatgagatc
301 cggacgtgtg accgccatgg ctgtggacag tactctgctc aaagaagtca gaggcctcac
361 cagggtgtgg acatcttgtg ctctgctgga tctactgtgt acgcaccatt cactggaatg
421 attgtgggcc aggagaaacc ttatcaaaac aagaatgcta tcaataatgg tgttcgaata
481 tctggaagag gtttttgtgt caaatgttc tacattaagc caattaagta taaaggctcct
541 attaagaagg gagaaaaact tggaaactcta ttgcccttgc agaaagtta tcctggcata
601 caatcgcacg tgcacattga aaactgtgac tcgagtgacc ctactgcata cctgtaaatc
661 gaaggccaat ggtcagatct tcaaaaataaa aagtcattctt aaaaacctgg atgcataccc
721 ttctcttcaa gaaatttgtg ttcacaaaagg aaaaatgcat gaagggatgg ataccccat
781 ttccatgaca tgattattac acattgcatg cctgtatcaa aacatctcac gtacctcata
841 aacatatata cctatgtacc cacaaaaatt ttttaattaa aaaaaggaaa tttagagttta
901 aatagaaaca tgataaatgc aagaaaagaaa acattttgat ttttaactcat tgtcactctg
961 atgttcatgt gaactgggtg cttcgggctc tttgatctgt cacctatgga atctgagtg
1021 ttttattttt tagatttctc agtcccaaa agtcaagata aataaacaag agaactt
```

SEQ ID NO:1

FIG. 1

**FIG. 2**




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

7/8




FIG. 5A






FIG. 5B

8/8

**FIG. 6A****FIG. 6B**

SEQUENCE LISTING

<110> ALNYLAM PHARMACEUTICALS, INC.

<120> COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

<130> A2038-7232W0

<140>

<141>

<150> 62/895,217

<151> 2019-09-03

<160> 906

<170> PatentIn version 3.5

<210> 1

<211> 1077

<212> DNA

<213> Homo sapiens

<400> 1

aaatcaaata gctatccatg gaatattaga acttgacttg ctccatcctc ttaaactttt	60
tgtgtctcac actaaagaaa tgagagatgc agaattctaa ggctaaatag ctaggaagta	120
ttcattcaaa cttgaatatt cttcaaagag agtgtggggg caactctaata cagaggaaga	180
aactaaagga agtaaaacca gatgttttcc accaaagccc tccttttggc tggcttgatt	240
tctaccgcac tggcagggcc atgggctaata atatgtgctg gcaagtcttc caatgagatc	300
cggacgtgtg accgccatgg ctgtggacag tactctgctc aaagaagtca gaggcctcac	360
cagggtgtgg acatcttgtg ctctgctgga tctactgtgt acgcaccatt cactggaatg	420
attgtgggcc aggagaaacc ttatcaaaac aagaatgcta tcaataatgg tggttcgaata	480
tctggaagag gtttttgtgt caaaatgttc tacattaagc caattaagta taaaggtcct	540
attaagaagg gagaaaaact tggaaactcta ttgcccttgc agaaagtta tcctggcata	600
caatcgcacg tgcacattga aaactgtgac tcgagtgcac ctactgcata cctgtaaatc	660
gaaggccaat ggtcagatct tcaaaataaa aagtcacatt aaaaacctgg atgcataccc	720
ttctcttcaa gaaatttgtg ttcacaaagg aaaaatgcat gaagggatgg atacccatt	780
ttccatgaca tgattattac acattgcatg cctgtatcaa aacatctcac gtacctcata	840
aacatataca cctatgtacc cacaaaaatt ttttaattaa aaaaaggaaa tttgagttta	900
aatagaaaca tgataaatgc aagaaagaaa acatcttgat ttttaactcat tgtcactctg	960
atgttcatgt gaactggttg cttcgggctc tttgatctgt cacctatgga atctgagtgg	1020
ttttattttt tagatttctc agtcccaaag atctaagata aataaacaag agaactt	1077

<210> 2

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2 caugugcaca uugaaaacug u	21
<210> 3 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 3 acaguutuca augugcacau gcg	23
<210> 4 <211> 23 <212> DNA <213> Homo sapiens	
<400> 4 cgcatgtgca cattgaaaac tgt	23
<210> 5 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 5 caugugcaca uugaaaacug u	21
<210> 6 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 6 acaguutuca augugcacau ggg	23

<210> 7
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 7
 cccatgtgca cattgaaaac tgt 23

 <210> 8
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 8
 caugugcaca uugaaaacug u 21

 <210> 9
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 9
 acaguutuca augugcacau ggu 23

 <210> 10
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 10
 accatgtgca cattgaaaac tgt 23

 <210> 11
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 11
 ugugcacauu gaaaacugu 19

 <210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 12
 acaguutuca augugcacau g 21

<210> 13
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 13
 catgtgcaca ttgaaaactg t 21

<210> 14
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 14
 caugugcaca uugaaaacug u 21

<210> 15
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 15
 acaguutuca augugcacau gcg 23

<210> 16
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 16
 cgcattgtgca cattgaaaac tgt 23

<210> 17
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 17
 caugugcaca uugaaaacug u 21

<210> 18
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 18
 acaguutuca augugcacau gcg 23

<210> 19
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 19
 cgcatgtgca cattgaaaac tgt 23

<210> 20
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 20
 caugugcaca uugaaaacug u 21

<210> 21
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 21

acaguutuca augugcacau gcg	23
<210> 22 <211> 23 <212> DNA <213> Homo sapiens	
<400> 22 cgcatgtgca cattgaaaac tgt	23
<210> 23 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 23 caugugcaca uugaaaacug u	21
<210> 24 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 24 acaguutuca augugcacau gcg	23
<210> 25 <211> 23 <212> DNA <213> Homo sapiens	
<400> 25 cgcatgtgca cattgaaaac tgt	23
<210> 26 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 26 caugugcaca uugaaaacug u	21
<210> 27	

<211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 27
 acaguutuca augugcacau gcg 23

 <210> 28
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 28
 cgcattgtgca cattgaaaac tgt 23

 <210> 29
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 29
 auggucagau cuucaaaaaua a 21

 <210> 30
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 30
 uuauuutgaa gaucugacca uug 23

 <210> 31
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 31
 caatgggtcag atcttcaaaa taa 23

<210> 32 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 32 auggucagau cuucaaaaaua a	21
<210> 33 <211> 23 <212> DNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide" <400> 33 uuauuutgaa gaucugacca ugg	23
<210> 34 <211> 23 <212> DNA <213> Homo sapiens <400> 34 ccatggtcag atcttcaaaa taa	23
<210> 35 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 35 auggucagau cuucaaaaaua a	21
<210> 36 <211> 23 <212> DNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic	

oligonucleotide"

<400> 36
uuauuutgaa gaucugacca ugu 23

<210> 37
<211> 23
<212> DNA
<213> Homo sapiens

<400> 37
acatggtcag atcttcaaaa taa 23

<210> 38
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 38
ggucagaucu ucaaaaaua 19

<210> 39
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 39
uuauuutgaa gaucugacca u 21

<210> 40
<211> 21
<212> DNA
<213> Homo sapiens

<400> 40
atggtcagat cttcaaaata a 21

<210> 41
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 41
auggucagau cuucaaaaaua a 21

<210> 42
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 42
 uuauuutgaa gaucugacca uug 23

 <210> 43
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 43
 caatggtcag atcttcaaaa taa 23

 <210> 44
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 44
 auggucagau cuucaaaa a 21

 <210> 45
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 45
 uuauuutgaa gaucugacca uug 23

 <210> 46
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 46

caatggtcag atcttcaaaa taa 23

<210> 47
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 47
auggucagau cuucaaaaaua a 21

<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 48
uuauuutgaa gaucugacca uug 23

<210> 49
<211> 23
<212> DNA
<213> Homo sapiens

<400> 49
caatggtcag atcttcaaaa taa 23

<210> 50
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 50
auggucagau cuucaaaaaua a 21

<210> 51
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 51
 uuauuutgaa gaucugacca uug 23

 <210> 52
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 52
 caatggtcag atcttcaaaa taa 23

 <210> 53
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 53
 auggucagau cuucaaaaaua a 21

 <210> 54
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 54
 uuauuutgaa gaucugacca uug 23

 <210> 55
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 55
 caatggtcag atcttcaaaa taa 23

 <210> 56
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 56 auggucagau cuucaaaaaua u	21
<210> 57 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 57 auauuutgaa gaucugacca uug	23
<210> 58 <211> 23 <212> DNA <213> Homo sapiens	
<400> 58 caatggtcag atcttcaaaa tat	23
<210> 59 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 59 auggucagau cuucaaaaaua u	21
<210> 60 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 60 auauuutgaa gaucugacca ugg	23
<210> 61 <211> 23 <212> DNA	

<213> Homo sapiens

<400> 61
ccatggtcag atcttcaaaa tat 23

<210> 62
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 62
auggucagau cuucaaaaaua u 21

<210> 63
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 63
auauuutgaa gaucugacca ugu 23

<210> 64
<211> 23
<212> DNA
<213> Homo sapiens

<400> 64
acatggtcag atcttcaaaa tat 23

<210> 65
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 65
ggucagaucu ucaaaaauau 19

<210> 66
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 66
 auauuutgaa gaucugacca u 21

<210> 67
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 67
 atggtcagat cttcaaaata t 21

<210> 68
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 68
 auggucagau cuucaaaaaua u 21

<210> 69
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 69
 auauuutgaa gaucugacca uug 23

<210> 70
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 70
 caatggtcag atcttcaaaa tat 23

<210> 71
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 71
 auggucagau cuucaaaaaua u 21

<210> 72
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 72
 auauuutgaa gaucugacca uug 23

<210> 73
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 73
 caatggtcag atcttcaaaa tat 23

<210> 74
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 74
 auggucagau cuucaaaaaua u 21

<210> 75
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 75
 auauuutgaa gaucugacca uug 23

<210> 76
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 76
 caatggtcag atcttcaaaa tat 23

 <210> 77
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 77
 auggucagau cuucaaaaaua u 21

 <210> 78
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 78
 auauuutgaa gaucugacca uug 23

 <210> 79
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 79
 caatggtcag atcttcaaaa tat 23

 <210> 80
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 80
 auggucagau cuucaaaaaua u 21

 <210> 81
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 81
 auauuutgaa gaucugacca uug 23

<210> 82
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 82
 caatggtcag atcttcaaaa tat 23

<210> 83
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 83
 ggucagaucu ucaaaaauaaa a 21

<210> 84
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 84
 uuuuauuuug aagaucugac cau 23

<210> 85
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 85
 atggtcagat cttcaaaata aaa 23

<210> 86
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 86
ggucagaucu ucaaaaauaaa a 21

<210> 87
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 87
uuuuuuuuug aagaucugac cgu 23

<210> 88
<211> 23
<212> DNA
<213> Homo sapiens

<400> 88
acggtcagat cttcaaaata aaa 23

<210> 89
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 89
ggucagaucu ucaaaaauaaa a 21

<210> 90
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 90
uuuuuuuuug aagaucugac ccu 23

<210> 91
<211> 23
<212> DNA
<213> Homo sapiens

<400> 91
agggtcagat cttcaaaata aaa 23

<210> 92
<211> 21
<212> RNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 92
 ggucagaucu ucaaaauaaa a 21

<210> 93
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 93
 uuuuauuuug aagaucugac cgg 23

<210> 94
 <211> 23
 <212> DNA
 <213> Homo sapiens
 <400> 94
 ccggtcagat cttcaaaata aaa 23

<210> 95
 <211> 19
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 95
 ucagaucuuc aaaauaaaa 19

<210> 96
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 96
 uuuuauuuug aagaucugac c 21

<210> 97
 <211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 97
 ggtcagatct tcaaaataaa a 21

<210> 98	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 98	
ggucagaucu ucaaaaauaaa a	21
<210> 99	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 99	
uuuuuuuuug aagaucugac cau	23
<210> 100	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 100	
atggtcagat cttcaaaata aaa	23
<210> 101	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 101	
ggucagaucu ucaaaaauaaa a	21
<210> 102	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 102	
uuuuuuuuug aagaucugac cau	23
<210> 103	
<211> 23	

<212> DNA
 <213> Homo sapiens

 <400> 103
 atggtcagat cttcaaaata aaa 23

 <210> 104
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 104
 ggucagaucu ucaaaaauaaa a 21

 <210> 105
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 105
 uuuuauuuug aagaucugac cau 23

 <210> 106
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 106
 atggtcagat cttcaaaata aaa 23

 <210> 107
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 107
 ggucagaucu ucaaaaauaaa a 21

 <210> 108
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 108

uuuuuuuuug aagaucugac cau 23

<210> 109
<211> 23
<212> DNA
<213> Homo sapiens

<400> 109
atggtcagat cttcaaaata aaa 23

<210> 110
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 110
ggucagaucu ucaaaaauaaa a 21

<210> 111
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 111
uuuuuuuuug aagaucugac cau 23

<210> 112
<211> 23
<212> DNA
<213> Homo sapiens

<400> 112
atggtcagat cttcaaaata aaa 23

<210> 113
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 113
ggucagaucu ucaaaaauaaa a 21

<210> 114
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 114
 uuuuauuuug aagaucugac cau 23

<210> 115
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 115
 atggtcagat cttcaaaata aaa 23

<210> 116
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 116
 ggucagaucu ucaaaaauaaa a 21

<210> 117
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 117
 uuuuauuuug aagaucugac cau 23

<210> 118
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 118
 atggtcagat cttcaaaata aaa 23

<210> 119
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 119
 ggucagaucu ucaaaaauaaa a 21

<210> 120

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 120
 uuuuauuuug aagaucugac cau 23

 <210> 121
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 121
 atggtcagat cttcaaaata aaa 23

 <210> 122
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 122
 ggucagaucu ucaaaauaaa a 21

 <210> 123
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 123
 uuuuauuuug aagaucugac cgu 23

 <210> 124
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 124
 acggtcagat cttcaaaata aaa 23

 <210> 125
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 125
ggucagaucu ucaaaauaaa a 21

<210> 126
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 126
uuuuuuuuug aagaucugac ccu 23

<210> 127
<211> 23
<212> DNA
<213> Homo sapiens

<400> 127
agggtcagat cttcaaaata aaa 23

<210> 128
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 128
ggucagaucu ucaaaauaaa a 21

<210> 129
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 129
uuuuuuuuug aagaucugac cgg 23

<210> 130
<211> 23
<212> DNA
<213> Homo sapiens

<400> 130
ccggtcagat cttcaaaata aaa 23

<210> 131
<211> 19
<212> RNA
<213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 131 ucagaucuuc aaaauaaaa	19
<210> 132 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 132 uuuuuuuuug aagaucugac c	21
<210> 133 <211> 21 <212> DNA <213> Homo sapiens	
<400> 133 ggtcagatct tcaaaataaa a	21
<210> 134 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 134 ggucagaucu ucaaaaauaaa u	21
<210> 135 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 135 auuuuuuuug aagaucugac cau	23
<210> 136 <211> 23 <212> DNA <213> Homo sapiens	
<400> 136 atggtcagat cttcaaaata aat	23

<210> 137
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 137
 ggucagaucu ucaaaaauaaa u 21

 <210> 138
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 138
 auuuauuuug aagaucugac cgu 23

 <210> 139
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 139
 acggtcagat cttcaaaata aat 23

 <210> 140
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 140
 ggucagaucu ucaaaaauaaa u 21

 <210> 141
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 141
 auuuauuuug aagaucugac ccu 23

 <210> 142
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 142 agggtcagat cttcaaaata aat	23
<210> 143 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 143 ggucagaucu ucaaaaauaaa u	21
<210> 144 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 144 auuuauuuug aagaucugac cgg	23
<210> 145 <211> 23 <212> DNA <213> Homo sapiens	
<400> 145 ccggtcagat cttcaaaata aat	23
<210> 146 <211> 19 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 146 ucagaucuuc aaaaauaaau	19
<210> 147 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 147 auuuauuuug aagaucugac c	21

<210> 148
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 148
 ggtcagatct tcaaaataaa t 21

 <210> 149
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 149
 ggucagaucu ucaaaauaaa u 21

 <210> 150
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 150
 auuuuuuuug aagaucugac cau 23

 <210> 151
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 151
 atggtcagat cttcaaaata aat 23

 <210> 152
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 152
 ggucagaucu ucaaaauaaa u 21

 <210> 153
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 153
auuuuuuuug aagaucugac cau 23

<210> 154
<211> 23
<212> DNA
<213> Homo sapiens

<400> 154
atggtcagat cttcaaaata aat 23

<210> 155
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 155
ggucagaucu ucaaaaauaaa u 21

<210> 156
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 156
auuuuuuuug aagaucugac cau 23

<210> 157
<211> 23
<212> DNA
<213> Homo sapiens

<400> 157
atggtcagat cttcaaaata aat 23

<210> 158
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 158
ggucagaucu ucaaaaauaaa u 21

<210> 159
<211> 23
<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 159
 auuuauuuug aagaucugac cau 23

<210> 160
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 160
 atggtcagat cttcaaaata aat 23

<210> 161
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 161
 ggucagaucu ucaaaaauaaa u 21

<210> 162
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 162
 auuuauuuug aagaucugac cau 23

<210> 163
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 163
 atggtcagat cttcaaaata aat 23

<210> 164
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 164
 ggucagaucu ucaaaaauaaa u 21

<210> 165
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 165
 auuuuuuuug aagaucugac cau 23

 <210> 166
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 166
 atggtcagat cttcaaaata aat 23

 <210> 167
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 167
 ggucagaucu ucaaaaauaaa u 21

 <210> 168
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 168
 auuuuuuuug aagaucugac cau 23

 <210> 169
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 169
 atggtcagat cttcaaaata aat 23

 <210> 170
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"		
<400> 170 ggucagaucu ucaaaaauaaa u		21
<210> 171 <211> 23 <212> RNA <213> Artificial Sequence		
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"		
<400> 171 auuuauuuug aagaucugac cau		23
<210> 172 <211> 23 <212> DNA <213> Homo sapiens		
<400> 172 atggtcagat cttcaaaata aat		23
<210> 173 <211> 21 <212> RNA <213> Artificial Sequence		
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"		
<400> 173 ggucagaucu ucaaaaauaaa u		21
<210> 174 <211> 23 <212> RNA <213> Artificial Sequence		
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"		
<400> 174 auuuauuuug aagaucugac cgu		23
<210> 175 <211> 23 <212> DNA <213> Homo sapiens		
<400> 175 acggtcagat cttcaaaata aat		23
<210> 176 <211> 21		

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 176
 ggucagaucu ucaaaauaaa u 21

 <210> 177
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 177
 auuuauuuug aagaucugac ccu 23

 <210> 178
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 178
 agggtcagat cttcaaaata aat 23

 <210> 179
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 179
 ggucagaucu ucaaaauaaa u 21

 <210> 180
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 180
 auuuauuuug aagaucugac cgg 23

 <210> 181
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 181

ccggtcagat cttcaaaata aat 23

<210> 182
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 182
ucagaucuuc aaaauaaau 19

<210> 183
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 183
auuuauuuug aagaucugac c 21

<210> 184
<211> 21
<212> DNA
<213> Homo sapiens

<400> 184
ggtcagatct tcaaaataaa t 21

<210> 185
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 185
aauggucaga ucuucaaaau a 21

<210> 186
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 186
uauuuugaag aucugaccou ugg 23

<210> 187

<211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 187
 ccaatggtca gatcttcaaa ata 23

 <210> 188
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 188
 aauggucaga ucucaaaaau a 21

 <210> 189
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 189
 uauuuugaag aucugaccuu ugu 23

 <210> 190
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 190
 acaatggtca gatcttcaaa ata 23

 <210> 191
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 191
 aauggucaga ucucaaaaau a 21

 <210> 192
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 192 uauuuugaag aucugacc <u>au</u> ucu	23
<210> 193 <211> 23 <212> DNA <213> Homo sapiens	
<400> 193 agaatggtca gatcttcaaa ata	23
<210> 194 <211> 19 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 194 uggucagau <u>c</u> uucaaaa <u>ua</u>	19
<210> 195 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 195 uauuuugaag aucugacc <u>au</u> u	21
<210> 196 <211> 21 <212> DNA <213> Homo sapiens	
<400> 196 aatggtcaga tcttcaaaat a	21
<210> 197 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 197 aauggucaga ucuucaaaa <u>u</u> a	21
<210> 198 <211> 23 <212> RNA <213> Artificial Sequence	

<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 198	
uauuuugaag aucugacc <u>au</u> ugg	23
<210> 199	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 199	
ccaatggtca gatcttcaaa ata	23
<210> 200	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 200	
aauggucaga ucuucaaaa <u>u</u> a	21
<210> 201	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 201	
uauuuugaag aucugacc <u>au</u> ugg	23
<210> 202	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 202	
ccaatggtca gatcttcaaa ata	23
<210> 203	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 203	
aauggucaga ucuucaaaa <u>u</u> a	21

<210> 204
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 204
 uauuuugaag aucugaccu ugg 23

 <210> 205
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 205
 ccaatggtca gatcttcaaa ata 23

 <210> 206
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 206
 aauggucaga ucucaaaa a 21

 <210> 207
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 207
 uauuuugaag aucugaccu ugg 23

 <210> 208
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 208
 ccaatggtca gatcttcaaa ata 23

 <210> 209
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 209 aauggucaga ucucaaaaau a	21
<210> 210 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 210 uauuuugaag aucugaccu ugg	23
<210> 211 <211> 23 <212> DNA <213> Homo sapiens	
<400> 211 ccaatggtca gatcttcaaa ata	23
<210> 212 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 212 aauggucaga ucucaaaaau a	21
<210> 213 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 213 uauuuugaag aucugaccu ugg	23
<210> 214 <211> 23 <212> DNA <213> Homo sapiens	
<400> 214 ccaatggtca gatcttcaaa ata	23
<210> 215 <211> 21 <212> RNA <213> Artificial Sequence	

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 215
 aauggucaga ucuucaaaaau a 21

 <210> 216
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 216
 uauuuugaag aucugaccu ugg 23

 <210> 217

 <400> 217
 000

 <210> 218
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 218
 ccaatggtca gatcttcaaa ata 23

 <210> 219
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 219
 aauggucaga ucuucaaaaau a 21

 <210> 220
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 220
 uauuuugaag aucugaccu ugg 23

 <210> 221
 <211> 23

<212> DNA
 <213> Homo sapiens

 <400> 221
 ccaatggtca gatcttcaaa ata 23

 <210> 222
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 222
 aauggucaga ucucaaaaau a 21

 <210> 223
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 223
 uauuuugaag aucugaccuu ugu 23

 <210> 224
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 224
 acaatggtca gatcttcaaa ata 23

 <210> 225
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 225
 aauggucaga ucucaaaaau a 21

 <210> 226
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 226

uauuuugaag aucugaccu ucu 23

<210> 227
<211> 23
<212> DNA
<213> Homo sapiens

<400> 227
agaatggtca gatcttcaaa ata 23

<210> 228
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 228
uggucagau uucaaaaau 19

<210> 229
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 229
uauuuugaag aucugaccu u 21

<210> 230
<211> 21
<212> DNA
<213> Homo sapiens

<400> 230
aatggtcaga tcttcaaaat a 21

<210> 231
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 231
aauggucaga ucuucaaaa u 21

<210> 232
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 232
 aaauuugaag aucugaccu ugg 23

<210> 233
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 233
 ccaatggtca gatcttcaaa att 23

<210> 234
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 234
 aauggucaga ucucaaaaau u 21

<210> 235
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 235
 aaauuugaag aucugaccu ugu 23

<210> 236
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 236
 acaatggtca gatcttcaaa att 23

<210> 237
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 237
 aauggucaga ucucaaaaau u 21

<210> 238

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 238
 aaauuugaag aucugaccau ucu 23

 <210> 239
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 239
 agaatggtca gatcttcaaa att 23

 <210> 240
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 240
 uggucagauc uucaaaaau 19

 <210> 241
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 241
 aaauuugaag aucugaccau u 21

 <210> 242
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 242
 aatggtcaga tcttcaaaat t 21

 <210> 243
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 243
aauggucaga ucuucaaaaau u 21

<210> 244
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 244
aaauuugaag aucugaccou ugg 23

<210> 245
<211> 23
<212> DNA
<213> Homo sapiens

<400> 245
ccaatggtca gatcttcaaa att 23

<210> 246
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 246
aauggucaga ucuucaaaaau u 21

<210> 247
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 247
aaauuugaag aucugaccou ugg 23

<210> 248
<211> 23
<212> DNA
<213> Homo sapiens

<400> 248
ccaatggtca gatcttcaaa att 23

<210> 249
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 249
 aauggucaga ucuucaaaa u 21

 <210> 250
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 250
 aauuuugaag aucugacc au ugg 23

 <210> 251
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 251
 ccaatggtca gatcttcaaa att 23

 <210> 252
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 252
 aauggucaga ucuucaaaa u 21

 <210> 253
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 253
 aauuuugaag aucugacc au ugg 23

 <210> 254
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 254
 ccaatggtca gatcttcaaa att 23

<210> 255
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 255
 aauggucaga ucuucaaaaau u 21

 <210> 256
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 256
 aaauuugaag aucugaccu ugg 23

 <210> 257
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 257
 ccaatggtca gatcttcaaa att 23

 <210> 258
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 258
 aauggucaga ucuucaaaaau u 21

 <210> 259
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 259
 aaauuugaag aucugaccu ugg 23

 <210> 260
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 260 ccaatggtca gatcttcaaa att	23
<210> 261 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 261 aauggucaga ucuucaaaaau u	21
<210> 262 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 262 aaauuugaag aucugaccu ugg	23
<210> 263 <211> 23 <212> DNA <213> Homo sapiens	
<400> 263 ccaatggtca gatcttcaaa att	23
<210> 264 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 264 aauggucaga ucuucaaaaau u	21
<210> 265 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 265 aaauuugaag aucugaccu ugg	23

<210> 266
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 266
 ccaatggtca gatcttcaaa att 23

 <210> 267
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 267
 aauggucaga ucuucaaaaau u 21

 <210> 268
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 268
 aaauuugaag aucugaccu ugu 23

 <210> 269
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 269
 acaatggtca gatcttcaaa att 23

 <210> 270
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 270
 aauggucaga ucuucaaaaau u 21

 <210> 271
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 271
aauuuugaag aucugaccu ucu 23

<210> 272
<211> 23
<212> DNA
<213> Homo sapiens

<400> 272
agaatggtca gatcttcaaa att 23

<210> 273
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 273
uggucagau uucaaaaau 19

<210> 274
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 274
aauuuugaag aucugaccu u 21

<210> 275
<211> 21
<212> DNA
<213> Homo sapiens

<400> 275
aatggtcaga tcttcaaaat t 21

<210> 276
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 276
cauggcaca uugaaaacug u 21

<210> 277
<211> 23
<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 277
 acaguutuca augugcacau gcg 23

<210> 278
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 278
 caugugcaca uugaaaacug u 21

<210> 279
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 279
 acaguutuca augugcacau ggg 23

<210> 280
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 280
 caugugcaca uugaaaacug u 21

<210> 281
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 281
 acaguutuca augugcacau ggu 23

<210> 282
 <211> 19
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 282
 ugugcacauu gaaaacugu 19

<210> 283
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 283
 acaguutuca augugcacau g 21

<210> 284
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 284
 caugugcaca uugaaaacug u 21

<210> 285
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 285
 acaguutuca augugcacau gcg 23

 <210> 286
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 286
 caugugcaca uugaaaacug u 21

 <210> 287
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 287
 acaguutuca augugcacau gcg 23

 <210> 288
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 288
 caugugcaca uugaaaacug u 21

 <210> 289
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 289

acaguutuca augugcacau gcg

23

<210> 290

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 290

caugugcaca uugaaaacug u

21

<210> 291

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 291

acaguutuca augugcacau gcg

23

<210> 292

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 292

caugugcaca uugaaaacug u

21

<210> 293

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 293
acaguutuca augugcacau gcg 23

<210> 294
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 294
auggucagau cuucaaaaaua a 21

<210> 295
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 295
uuauuutgaa gaucugacca uug 23

<210> 296
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 296
auggucagau cuucaaaaaua a 21

<210> 297
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 297
uuauuutgaa gaucugacca ugg 23

<210> 298
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 298
 auggucagau cuucaaaaaua a 21

<210> 299
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 299
 uuauuutgaa gaucugacca ugu 23

<210> 300
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 300
 ggucagaucu ucaaaaaua 19

<210> 301
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 301
 uuauuutgaa gaucugacca u 21

<210> 302
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 302
 auggucagau cuucaaaaaua a 21

 <210> 303
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 303
 uuauuutgaa gaucugacca uug 23

 <210> 304
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 304
 auggucagau cuucaaaaaua a 21

 <210> 305
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 305
 uuauuutgaa gaucugacca uug 23

 <210> 306
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 306
auggucagau cuucaaaaaua a 21

<210> 307
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 307
uuauuutgaa gaucugacca uug 23

<210> 308
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 308
auggucagau cuucaaaaaua a 21

<210> 309
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 309
uuauuutgaa gaucugacca uug 23

<210> 310
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 310
auggucagau cuucaaaaaua a 21

<210> 311
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 311
uuauuutgaa gaucugacca uug 23

<210> 312
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 312
auggucagau cuucaaaaaua u 21

<210> 313
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 313
auauuutgaa gaucugacca uug 23

<210> 314
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 314

auggucagau cuucaaaaaua u 21

<210> 315
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 315
auauuutgaa gaucugacca ugg 23

<210> 316
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 316
auggucagau cuucaaaaaua u 21

<210> 317
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 317
auauuutgaa gaucugacca ugu 23

<210> 318
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 318
ggucagaucu ucaaaaauau 19

<210> 319
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 319
 auauuutgaa gaucugacca u 21

 <210> 320
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 320
 auggucagau cuucaaaaaua u 21

 <210> 321
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 321
 auauuutgaa gaucugacca uug 23

 <210> 322
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 322
 auggucagau cuucaaaaaua u 21

 <210> 323
 <211> 23
 <212> DNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"
 <400> 323
 auauuutgaa gaucugacca uug 23
 <210> 324
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 324
 auggucagau cuucaaaaaua u 21
 <210> 325
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"
 <400> 325
 auauuutgaa gaucugacca uug 23
 <210> 326
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 326
 auggucagau cuucaaaaaua u 21
 <210> 327
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 327
 auauuutgaa gaucugacca uug 23

<210> 328
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 328
 auggucagau cuucaaaaaua u 21

<210> 329
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 329
 auauuutgaa gaucugacca uug 23

<210> 330
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 330
 ggucagaucu ucaaaaauaaa a 21

<210> 331
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 331 uuuuuuuuug aagaucugac cau	23
<210> 332 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 332 ggucagaucu ucaaaaauaaa a	21
<210> 333 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 333 uuuuuuuuug aagaucugac cgu	23
<210> 334 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 334 ggucagaucu ucaaaaauaaa a	21
<210> 335 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 335 uuuuuuuuug aagaucugac ccu	23
<210> 336 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic	

oligonucleotide"

<400> 336
ggucagaucu ucaaaaauaaa a 21

<210> 337
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 337
uuuuuuuuug aagaucugac cgg 23

<210> 338
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 338
ucagaucuuc aaaaauaaa 19

<210> 339
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 339
uuuuuuuuug aagaucugac c 21

<210> 340
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 340
ggucagaucu ucaaaaauaaa a 21

<210> 341
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 341 uuuuuuuuug aagaucugac cau	23
<210> 342 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 342 ggucagaucu ucaaaaauaaa a	21
<210> 343 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 343 uuuuuuuuug aagaucugac cau	23
<210> 344 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 344 ggucagaucu ucaaaaauaaa a	21
<210> 345 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 345 uuuuuuuuug aagaucugac cau	23
<210> 346 <211> 21 <212> RNA <213> Artificial Sequence	
<220>	

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 346
 ggucagaucu ucaaaaauaaa a 21

<210> 347
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 347
 uuuuuuuuug aagaucugac cau 23

<210> 348
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 348
 ggucagaucu ucaaaaauaaa a 21

<210> 349
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 349
 uuuuuuuuug aagaucugac cau 23

<210> 350
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 350
 ggucagaucu ucaaaaauaaa a 21

<210> 351
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 351 uuuuuuuuug aagaucugac cau	23
<210> 352 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 352 ggucagaucu ucaaaaauaaa a	21
<210> 353 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 353 uuuuuuuuug aagaucugac cau	23
<210> 354 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 354 ggucagaucu ucaaaaauaaa a	21
<210> 355 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 355 uuuuuuuuug aagaucugac cau	23
<210> 356 <211> 21 <212> RNA <213> Artificial Sequence	

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 356
 ggucagaucu ucaaaauaaa a 21

 <210> 357
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 357
 uuuuauuuug aagaucugac cgu 23

 <210> 358
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 358
 ggucagaucu ucaaaauaaa a 21

 <210> 359
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 359
 uuuuauuuug aagaucugac ccu 23

 <210> 360
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 360
 ggucagaucu ucaaaauaaa a 21

 <210> 361
 <211> 23
 <212> RNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 361
 uuuuauuuug aagaucugac cgg 23
 <210> 362
 <211> 19
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 362
 ucagaucuuc aaaauaaaa 19
 <210> 363
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 363
 uuuuauuuug aagaucugac c 21
 <210> 364
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 364
 ggucagaucu ucaaaauaaa u 21
 <210> 365
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 365
 auuuauuuug aagaucugac cau 23
 <210> 366
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 366
 ggucagaucu ucaaaauaaa u 21

 <210> 367
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 367
 auuuauuuug aagaucugac cgu 23

 <210> 368
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 368
 ggucagaucu ucaaaauaaa u 21

 <210> 369
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 369
 auuuauuuug aagaucugac ccu 23

 <210> 370
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 370
 ggucagaucu ucaaaauaaa u 21

 <210> 371

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 371
 auuuauuuug aagaucugac cgg 23

 <210> 372
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 372
 ucagaucuuc aaaauaaau 19

 <210> 373
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 373
 auuuauuuug aagaucugac c 21

 <210> 374
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 374
 ggucagaucu ucaaaaauaaa u 21

 <210> 375
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 375
 auuuauuuug aagaucugac cau 23

<210> 376 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 376 ggucagaucu ucaaaaauaaa u	21
<210> 377 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 377 auuuauuuug aagaucugac cau	23
<210> 378 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 378 ggucagaucu ucaaaaauaaa u	21
<210> 379 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 379 auuuauuuug aagaucugac cau	23
<210> 380 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 380 ggucagaucu ucaaaaauaaa u	21

<210> 381	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 381	
auuuauuuug aagaucugac cau	23
<210> 382	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 382	
ggucagaucu ucaaaaauaaa u	21
<210> 383	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 383	
auuuauuuug aagaucugac cau	23
<210> 384	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 384	
ggucagaucu ucaaaaauaaa u	21
<210> 385	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 385	
auuuauuuug aagaucugac cau	23

<210> 386
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 386
 ggucagaucu ucaaaauaaa u 21

 <210> 387
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 387
 auuuauuuug aagaucugac cau 23

 <210> 388
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 388
 ggucagaucu ucaaaauaaa u 21

 <210> 389
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 389
 auuuauuuug aagaucugac cau 23

 <210> 390
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 390

ggucagaucu ucaaaauaaa u 21

<210> 391
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 391
auuuauuuug aagaucugac cgu 23

<210> 392
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 392
ggucagaucu ucaaaauaaa u 21

<210> 393
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 393
auuuauuuug aagaucugac ccu 23

<210> 394
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 394
ggucagaucu ucaaaauaaa u 21

<210> 395
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 395
auuuuuuuug aagaucugac cgg 23

<210> 396
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 396
ucagaucuuc aaaauaaau 19

<210> 397
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 397
auuuuuuuug aagaucugac c 21

<210> 398
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 398
aauggucaga ucuucaaaau a 21

<210> 399
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 399
uauuuugaag aucugaccu ugg 23

<210> 400
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 400
aauggucaga ucuucaaaau a 21

<210> 401
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 401
uauuuugaag aucugaccou ugu 23

<210> 402
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 402
aauggucaga ucuucaaaau a 21

<210> 403
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 403
uauuuugaag aucugaccou ucu 23

<210> 404
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 404
uggucagau ucaaaaau 19

<210> 405
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 405
uauuuugaag aucugaccau u 21

<210> 406
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 406
aauggucaga ucuucaaaau a 21

<210> 407
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 407
uauuuugaag aucugaccau ugg 23

<210> 408
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 408
aauggucaga ucuucaaaau a 21

<210> 409
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 409
uauuuugaag aucugaccau ugg 23

<210> 410
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 410 aauggucaga ucuucaaaaau a	21
<210> 411 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 411 uauuuugaag aucugaccu ugg	23
<210> 412 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 412 aauggucaga ucuucaaaaau a	21
<210> 413 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 413 uauuuugaag aucugaccu ugg	23
<210> 414 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 414 aauggucaga ucuucaaaaau a	21
<210> 415 <211> 23 <212> RNA <213> Artificial Sequence	
<220>	

<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 415	
uauuuugaag aucugaccu ugg	23
<210> 416	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 416	
aauggucaga ucucaaaaau a	21
<210> 417	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 417	
uauuuugaag aucugaccu ugg	23
<210> 418	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 418	
aauggucaga ucucaaaaau a	21
<210> 419	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 419	
uauuuugaag aucugaccu ugg	23
<210> 420	
<211> 21	
<212> RNA	
<213> Artificial Sequence	

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 420
 aauggucaga ucuucaaaaau a 21

 <210> 421
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 421
 uauuuugaag aucugaccu ugg 23

 <210> 422
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 422
 aauggucaga ucuucaaaaau a 21

 <210> 423
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 423
 uauuuugaag aucugaccu ugu 23

 <210> 424
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 424
 aauggucaga ucuucaaaaau a 21

 <210> 425
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 425
 uauuuugaag aucugaccu ucu 23

 <210> 426
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 426
 uggucagau uucaaaaua 19

 <210> 427
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 427
 uauuuugaag aucugaccu u 21

 <210> 428
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 428
 aauggucaga ucucaaaau u 21

 <210> 429
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 429
 aaauuugaag aucugaccu ugg 23

 <210> 430
 <211> 21
 <212> RNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 430
 aauggucaga ucuucaaaaau u 21

<210> 431
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 431
 aaauuugaag aucugaccu ugu 23

<210> 432
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 432
 aauggucaga ucuucaaaaau u 21

<210> 433
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 433
 aaauuugaag aucugaccu ucu 23

<210> 434
 <211> 19
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 434
 uggucagau ucaaaaau 19

<210> 435
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 435
 aaauuugaag aucugaccu u 21

 <210> 436
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 436
 aauggucaga ucucaaaa u 21

 <210> 437
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 437
 aaauuugaag aucugaccu ugg 23

 <210> 438
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 438
 aauggucaga ucucaaaa u 21

 <210> 439
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 439
 aaauuugaag aucugaccu ugg 23

 <210> 440

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 440
 aauggucaga ucuucaaaaau u 21

 <210> 441
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 441
 aaauuugaag aucugaccu ugg 23

 <210> 442
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 442
 aauggucaga ucuucaaaaau u 21

 <210> 443
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 443
 aaauuugaag aucugaccu ugg 23

 <210> 444
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 444
 aauggucaga ucuucaaaaau u 21

<210> 445 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 445 aauuuugaag aucugaccu ugg	23
<210> 446 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 446 aauggucaga ucucaaaa u	21
<210> 447 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 447 aauuuugaag aucugaccu ugg	23
<210> 448 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 448 aauggucaga ucucaaaa u	21
<210> 449 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 449 aauuuugaag aucugaccu ugg	23

<210> 450 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 450 aauggucaga ucuucaaaaau u	21
<210> 451 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 451 aaauuugaag aucugaccu ugg	23
<210> 452 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 452 aauggucaga ucuucaaaaau u	21
<210> 453 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 453 aaauuugaag aucugaccu ugu	23
<210> 454 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 454 aauggucaga ucuucaaaaau u	21

<210> 455 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 455 aauuuugaag aucugacc <u>au</u> ucu	23
<210> 456 <211> 19 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 456 uggucagau <u>c</u> uucaaaa <u>uu</u>	19
<210> 457 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 457 aauuuugaag aucugacc <u>au</u> u	21
<210> 458 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 458 auggucagau cuucaaaa <u>ua</u> a	21
<210> 459 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 459	

uuauuuugaa gaucugacca uug 23

<210> 460
<211> 23
<212> DNA
<213> Homo sapiens

<400> 460
caatggtcag atcttcaaaa taa 23

<210> 461
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 461
uugugucaaa auguucuaca u 21

<210> 462
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 462
auguagaaca uuuugacaca aaa 23

<210> 463
<211> 23
<212> DNA
<213> Homo sapiens

<400> 463
ttttgtgtca aaatgttcta cat 23

<210> 464
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 464
auggucagau cuucaaaaaua a 21

<210> 465
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 465
 uuauuuugaa gaucugacca uug 23

<210> 466
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 466
 caatggtcag atcttcaaaa taa 23

<210> 467
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 467
 uugugucaaa auguucuaca u 21

<210> 468
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 468
 auguagaaca uuuugacaca aaa 23

<210> 469
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 469
 ttttgtgtca aaatgttcta cat 23

<210> 470
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 470
 auggucagau cuucaaaaaua a 21

<210> 471

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 471
 uuauuuugaa gaucugacca uug 23

 <210> 472
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 472
 caatggtcag atcttcaaaa taa 23

 <210> 473
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 473
 caugugcaca uugaaaacug u 21

 <210> 474
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 474
 acaguuuua augugcacau gcg 23

 <210> 475
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 475
 cgcatgtgca cattgaaaac tgt 23

 <210> 476
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 476
aaccagaugu uuuccaccaa a 21

<210> 477
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 477
uuugguggaa acaucuggu uuu 23

<210> 478
<211> 23
<212> DNA
<213> Homo sapiens

<400> 478
aaaaccagat gttttccacc aaa 23

<210> 479
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 479
auggucagau cuucaaaaaua a 21

<210> 480
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 480
uuauuuugaa gaucugacca uug 23

<210> 481
<211> 23
<212> DNA
<213> Homo sapiens

<400> 481
caatggtcag atcttcaaaa taa 23

<210> 482
<211> 21
<212> RNA
<213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 482 aauggucaga ucuucaaaa a	21
<210> 483 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 483 uauuuugaag aucugacc au ugg	23
<210> 484 <211> 23 <212> DNA <213> Homo sapiens	
<400> 484 ccaatggtca gatcttcaaa ata	23
<210> 485 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 485 auggucagau cuucaaaa a	21
<210> 486 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 486 uuauuuugaa gaucugacca uug	23
<210> 487 <211> 23 <212> DNA <213> Homo sapiens	
<400> 487 caatggtcag atcttcaaaa taa	23

<210> 488
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 488
 uugugucaaa auguucuaca u 21

 <210> 489
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 489
 auguagaaca uuuugacaca aaa 23

 <210> 490
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 490
 ttttgtgtca aaatgttcta cat 23

 <210> 491
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 491
 uugugucaaa auguucuaca u 21

 <210> 492
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 492
 auguagaaca uuuugacaca aaa 23

 <210> 493
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 493 ttttgtgtca aaatgttcta cat	23
<210> 494 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 494 gcuaggaagu auucauucaa a	21
<210> 495 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 495 uuugaaugaa uacuuccuag cua	23
<210> 496 <211> 23 <212> DNA <213> Homo sapiens	
<400> 496 tagctaggaa gtattcattc aaa	23
<210> 497 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 497 uugugucaaa auguucuaca u	21
<210> 498 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 498 auguagaaca uuuugacaca aaa	23

<210> 499	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 499	
ttttgtgtca aaatgttcta cat	23
<210> 500	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 500	
caugugcaca uugaaaacug u	21
<210> 501	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 501	
acaguuuuca augugcacau gcg	23
<210> 502	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 502	
cgcatgtgca cattgaaaac tgt	23
<210> 503	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 503	
uugugucaaa auguucuaca u	21
<210> 504	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic	

oligonucleotide"

<400> 504
auguagaaca uuuugacaca aaa 23

<210> 505
<211> 23
<212> DNA
<213> Homo sapiens

<400> 505
ttttgtgtca aaatgttcta cat 23

<210> 506
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 506
uggucagauc uucaaaaaua a 21

<210> 507
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 507
uuuauuuuga agaucugacc auu 23

<210> 508
<211> 23
<212> DNA
<213> Homo sapiens

<400> 508
aatggtcaga tcttcaaaat aaa 23

<210> 509
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 509
uugugucaaa auguucuaca u 21

<210> 510
<211> 23
<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 510
 auguagaaca uuuugacaca aaa 23

<210> 511
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 511
 ttttgtgtca aaatgttcta cat 23

<210> 512
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 512
 uugugucaaa auguucuaca u 21

<210> 513
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 513
 auguagaaca uuuugacaca aaa 23

<210> 514
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 514
 ttttgtgtca aaatgttcta cat 23

<210> 515
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 515
 caauggucag aucuucaaaa u 21

<210> 516	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 516	
auuuugaaga ucugaccauu ggc	23
<210> 517	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 517	
gccaatggtc agatcttcaa aat	23
<210> 518	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 518	
uugugucaaa auguucuaca u	21
<210> 519	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 519	
auguagaaca uuuugacaca aaa	23
<210> 520	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 520	
ttttgtgtca aaatgttcta cat	23
<210> 521	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 521 auggucagau cuucaaaaaua a	21
<210> 522 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 522 uuauuuugaa gaucugacca uug	23
<210> 523 <211> 23 <212> DNA <213> Homo sapiens	
<400> 523 caatggtcag atcttcaaaa taa	23
<210> 524 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 524 auggucagau cuucaaaaaua a	21
<210> 525 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 525 uuauuuugaa gaucugacca uug	23
<210> 526 <211> 23 <212> DNA <213> Homo sapiens	
<400> 526 caatggtcag atcttcaaaa taa	23
<210> 527 <211> 21	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 527
 ggucagaucu ucaaaauaaa a 21

 <210> 528
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 528
 uuuuauuuug aagaucugac cau 23

 <210> 529
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 529
 atggtcagat cttcaaaata aaa 23

 <210> 530
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 530
 uugugucaaa auguucuaca u 21

 <210> 531
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 531
 auguagaaca uuuugacaca aaa 23

 <210> 532
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 532

ttttgtgtca aaatgttcta cat 23

<210> 533
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 533
auggucagau cuucaaaaaua a 21

<210> 534
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 534
uuauuuugaa gaucugacca uug 23

<210> 535
<211> 23
<212> DNA
<213> Homo sapiens

<400> 535
caatggtcag atcttcaaaa taa 23

<210> 536
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 536
auggucagau cuucaaaaaua a 21

<210> 537
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 537
uuauuuugaa gaucugacca uug 23

<210> 538

<211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 538
 caatggtcag atcttcaaaa taa 23

 <210> 539
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 539
 uugugucaaa auguucuaca u 21

 <210> 540
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 540
 auguagaaca uuuugacaca aaa 23

 <210> 541
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 541
 ttttgtgtca aaatgttcta cat 23

 <210> 542
 <211> 20
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 542
 uugugucaaa auguucuaca 20

 <210> 543
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 543 auguagaaca uuuugacaca aaa	23
<210> 544 <211> 23 <212> DNA <213> Homo sapiens	
<400> 544 ttttgtgtca aaatgttcta cat	23
<210> 545 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 545 uugugucaaa auguucuaca u	21
<210> 546 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 546 auguagaaca uuuugacaca aaa	23
<210> 547 <211> 23 <212> DNA <213> Homo sapiens	
<400> 547 ttttgtgtca aaatgttcta cat	23
<210> 548 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 548 auggucagau cuucaaaaaua a	21
<210> 549 <211> 23 <212> RNA <213> Artificial Sequence	

<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 549	
uuauuuugaa gaucugacca uug	23
<210> 550	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 550	
caatggtcag atcttcaaaa taa	23
<210> 551	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 551	
caugugcaca uugaaaacug u	21
<210> 552	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 552	
acaguuuua augugcacau gcg	23
<210> 553	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 553	
cgcatgtgca cattgaaaac tgt	23
<210> 554	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 554	
uugugucaaa auguucuaca u	21

<210> 555 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 555 auguagaaca uuuugacaca aaa	23
<210> 556 <211> 23 <212> DNA <213> Homo sapiens <400> 556 ttttgtgtca aaatgttcta cat	23
<210> 557 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 557 ucaaacuuga auauucuuca a	21
<210> 558 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 558 uugaagaaua uucaaguug aau	23
<210> 559 <211> 23 <212> DNA <213> Homo sapiens <400> 559 attcaaactt gaatattctt caa	23
<210> 560 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

<400> 560 uugugucaaa auguucuaca u	21
<210> 561 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 561 auguagaaca uuuugacaca aaa	23
<210> 562 <211> 23 <212> DNA <213> Homo sapiens	
<400> 562 ttttgtgtca aaatgttcta cat	23
<210> 563 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 563 caugugcaca uugaaaacug u	21
<210> 564 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 564 acaguuuua augugcacau gcg	23
<210> 565 <211> 23 <212> DNA <213> Homo sapiens	
<400> 565 cgcatgtgca cattgaaaac tgt	23
<210> 566 <211> 21 <212> RNA <213> Artificial Sequence	

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 566 caugugcaca uugaaaacug u	21
<210> 567 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 567 acaguuuuca augugcacau gcg	23
<210> 568 <211> 23 <212> DNA <213> Homo sapiens	
<400> 568 cgcatgtgca cattgaaaac tgt	23
<210> 569 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 569 uucauucaaa cuugaauuu a	21
<210> 570 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 570 uaauauucaa guuugaauga aua	23
<210> 571 <211> 23 <212> DNA <213> Homo sapiens	
<400> 571 tattcattca aacttgaata tta	23

<210> 572 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 572 caugugcaca uugaaaacug u	21
<210> 573 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 573 acaguuuua augugcacau gcg	23
<210> 574 <211> 23 <212> DNA <213> Homo sapiens <400> 574 cgcatgtgca cattgaaaac tgt	23
<210> 575 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 575 uuguguaaa auguucuaca u	21
<210> 576 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 576 auguagaaca uuuugacaca aaa	23
<210> 577 <211> 23 <212> DNA	

<213> Homo sapiens	
<400> 577 ttttgtgtca aaatgttcta cat	23
<210> 578 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 578 uuguguaaaa auguucuaca u	21
<210> 579 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 579 auguagaaca uuuugacaca aaa	23
<210> 580 <211> 23 <212> DNA <213> Homo sapiens	
<400> 580 ttttgtgtca aaatgttcta cat	23
<210> 581 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 581 caugugcaca uugaaaacug u	21
<210> 582 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 582 acaguuuua augugcacau gcg	23

<210> 583
<211> 23
<212> DNA
<213> Homo sapiens

<400> 583
cgcatgtgca cattgaaaac tgt 23

<210> 584
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 584
ugugucaaaa uguucuacau u 21

<210> 585
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 585
aauguagaac auuuugacac aaa 23

<210> 586
<211> 23
<212> DNA
<213> Homo sapiens

<400> 586
tttgtgtcaa aatgttctac att 23

<210> 587
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 587
caugugcaca uugaaaacug u 21

<210> 588
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 588 acaguuuua augugcacau gcg	23
<210> 589 <211> 23 <212> DNA <213> Homo sapiens	
<400> 589 cgcatgtgca cattgaaaac tgt	23
<210> 590 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 590 caugugcaca uugaaaacug u	21
<210> 591 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 591 acaguuuua augugcacau gcg	23
<210> 592 <211> 23 <212> DNA <213> Homo sapiens	
<400> 592 cgcatgtgca cattgaaaac tgt	23
<210> 593 <211> 20 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 593 auggucagau cuucaaaaaua	20
<210> 594 <211> 23	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 594
 uuauuuugaa gaucugacca uug 23

 <210> 595
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 595
 caatgggtcag atcttcaaaa taa 23

 <210> 596
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 596
 auggucagau cuucaaaaaua a 21

 <210> 597
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 597
 uuauuuugaa gaucugacca uug 23

 <210> 598
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 598
 caatgggtcag atcttcaaaa taa 23

 <210> 599
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 599

uugugucaaa auguucuaca u 21

<210> 600
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 600
auguagaaca uuuugacaca aaa 23

<210> 601
<211> 23
<212> DNA
<213> Homo sapiens

<400> 601
ttttgtgtca aaatgttcta cat 23

<210> 602
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 602
uugugucaaa auguucuaca u 21

<210> 603
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 603
auguagaaca uuuugacaca aaa 23

<210> 604
<211> 23
<212> DNA
<213> Homo sapiens

<400> 604
ttttgtgtca aaatgttcta cat 23

<210> 605
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 605
 agcuaggaag uauucauuc a 21

<210> 606
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 606
 uugaaugaau acuuccuagc uau 23

<210> 607
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 607
 atagctagga agtattcatt caa 23

<210> 608
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 608
 caugugcaca uugaaaacug u 21

<210> 609
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 609
 acaguuuua augugcacau gcg 23

<210> 610
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 610
 cgcatgtgca cattgaaaac tgt 23

<210> 611

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 611
 caugugcaca uugaaaacug u 21

 <210> 612
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 612
 acaguuuua augugcaca u gcg 23

 <210> 613
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 613
 cgcatgtgca cattgaaaac tgt 23

 <210> 614
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 614
 cuaggaagua uucauucaaa a 21

 <210> 615
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 615
 uuuugaauga auacuuccua gcu 23

 <210> 616
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 616 agctaggaag tattcattca aaa	23
<210> 617 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 617 uucaaacuug aaauuucuuc a	21
<210> 618 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 618 ugaagaauau ucaaguuuga aug	23
<210> 619 <211> 23 <212> DNA <213> Homo sapiens	
<400> 619 cattcaaact tgaatattct tca	23
<210> 620 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 620 auggucagau cuucaaaaaua a	21
<210> 621 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 621 uuauuuugaa gaucugacca uug	23

<210> 622
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 622
 caatggtcag atcttcaaaa taa 23

<210> 623
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 623
 caugugcaca uugaaaacug u 21

<210> 624
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 624
 acaguuuua augugcacau gcg 23

<210> 625
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 625
 cgcatgtgca cattgaaaac tgt 23

<210> 626
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 626
 auggucagau cuucaaaaaua a 21

<210> 627
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 627
 uuauutugaa gaucugacca uug 23

 <210> 628
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 628
 caatggtcag atcttcaaaa taa 23

 <210> 629
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 629
 auggucagau cuucaaaaaua a 21

 <210> 630
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 630
 uuauuuugaa gaucugacca uug 23

 <210> 631
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 631
 caatggtcag atcttcaaaa taa 23

 <210> 632
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 632
 aaagcuagg aaguaucau u 21

<210> 633	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 633	
aaugaauacu uccuagcuau uua	23
<210> 634	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 634	
taaatagcta ggaagtattc att	23
<210> 635	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 635	
aguauucauu caaacuugaa u	21
<210> 636	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 636	
auucaaguuu gaaugaauac uuc	23
<210> 637	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 637	
gaagtattca ttcaaacttg aat	23
<210> 638	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic	

oligonucleotide"	
<400> 638 aggaaguauu caucaaaacu u	21
<210> 639 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 639 aaguuugaau gaauacuucc uag	23
<210> 640 <211> 23 <212> DNA <213> Homo sapiens	
<400> 640 ctaggaagta ttcattcaaa ctt	23
<210> 641 <211> 20 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 641 caugugcaca uugaaaacug	20
<210> 642 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 642 acaguuuuca augugcacau gcg	23
<210> 643 <211> 23 <212> DNA <213> Homo sapiens	
<400> 643 cgcatgtgca cattgaaaac tgt	23
<210> 644 <211> 21 <212> RNA	

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 644
 caugugcaca uugaaaacug u 21

<210> 645
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"
 <400> 645
 acaguutuca augugcacau gcg 23

<210> 646
 <211> 23
 <212> DNA
 <213> Homo sapiens
 <400> 646
 cgcatgtgca cattgaaaac tgt 23

<210> 647
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 647
 ggcuaaaauag cuaggaagua u 21

<210> 648
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 648
 auacuuccua gcuaauuagc cuu 23

<210> 649
 <211> 23

<212> DNA
 <213> Homo sapiens

 <400> 649
 aaggctaaat agctaggaag tat 23

 <210> 650
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 650
 aaguaaucau ucaaacuuga a 21

 <210> 651
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 651
 uucaaguuug aaugaauacu ucc 23

 <210> 652
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 652
 ggaagtattc attcaaactt gaa 23

 <210> 653
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 653
 aaauucuaagg cuaaaauagcu a 21

 <210> 654
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 654

uagcuauuuu gccuuagaau ucu 23

<210> 655
<211> 23
<212> DNA
<213> Homo sapiens

<400> 655
agaattctaa ggctaaatag cta 23

<210> 656
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 656
uugaauauuc uucaaagaga a 21

<210> 657
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 657
uucucuuga agaauauuca agu 23

<210> 658
<211> 23
<212> DNA
<213> Homo sapiens

<400> 658
acttgaatat tcttcaaaga gaa 23

<210> 659
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 659
uagcuaggaa guauucauuc a 21

<210> 660
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 660
 ugaaugaaua cuuccuagcu auu 23

<210> 661
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 661
 aatagctagg aagtattcat tca 23

<210> 662
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 662
 aacuugaaua uucucaaag a 21

<210> 663
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 663
 ucuuugaaga auauucaagu uug 23

<210> 664
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 664
 caaacttgaa tattcttcaa aga 23

<210> 665
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 665
 gaauucuaag gcuaaaauagc u 21

<210> 666

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 666
agcuauuuag ccuugaauu cug 23

<210> 667
<211> 23
<212> DNA
<213> Homo sapiens

<400> 667
cagaattcta aggctaaata gct 23

<210> 668

<400> 668
000

<210> 669

<400> 669
000

<210> 670

<400> 670
000

<210> 671

<400> 671
000

<210> 672

<400> 672
000

<210> 673

<400> 673
000

<210> 674

<400> 674
000

<210> 675

<400> 675
000

<210> 676

<400> 676
000

<210> 677

<400> 677
000

<210> 678
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 678
auggucagau cuucaaaaaua a 21

<210> 679
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 679
uuauuutgaa gaucugacca uug 23

<210> 680
<211> 23
<212> DNA
<213> Homo sapiens

<400> 680
caatggtcag atcttcaaaa taa 23

<210> 681
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 681
auagcuagga aguauucauu a 21

<210> 682
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 682
 uaaugaaauac uuccuagcua uuu 23

 <210> 683
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 683
 aaatagctag gaagtattca tta 23

 <210> 684
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 684
 caugugcaca uugaaaacug u 21

 <210> 685
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 685
 acagutuuca augugcacau gcg 23

 <210> 686
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 686
 cgcatgtgca cattgaaaac tgt 23

 <210> 687
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 687 caugugcaca uugaaaacug u	21
<210> 688 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 688 acaguuutca augugcacau gcg	23
<210> 689 <211> 23 <212> DNA <213> Homo sapiens	
<400> 689 cgcatgtgca cattgaaaac tgt	23
<210> 690 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 690 caugugcaca uugaaaacug u	21
<210> 691 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 691 acaguutuca augugcacau gcg	23

<210> 692
<211> 23
<212> DNA
<213> Homo sapiens

<400> 692
cgcatgtgca cattgaaaac tgt 23

<210> 693
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 693
auucauucaa acuugaauau u 21

<210> 694
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 694
aauauucaag uuugaaugaa uac 23

<210> 695
<211> 23
<212> DNA
<213> Homo sapiens

<400> 695
gtattcattc aaacttgaat att 23

<210> 696
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 696
acuugaauau ucuucaaaaga a 21

<210> 697
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 697 uucuuugaag aaauucaag uuu	23
<210> 698 <211> 23 <212> DNA <213> Homo sapiens	
<400> 698 aaacttgaat attcttcaaa gaa	23
<210> 699 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 699 auggucagau cuucaaaaaua a	21
<210> 700 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 700 uuauuutgaa gaucugacca uug	23
<210> 701 <211> 23 <212> DNA <213> Homo sapiens	
<400> 701 caatggtcag atcttcaaaa taa	23
<210> 702 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 702	

augugcacau ugaaaacugu a 21

<210> 703
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 703
uacaguuuuc aaugugcaca ugc 23

<210> 704
<211> 23
<212> DNA
<213> Homo sapiens

<400> 704
gcatgtgcac attgaaaact gta 23

<210> 705
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 705
auggucagau cuucaaaaaua a 21

<210> 706
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 706
uuauuuugaa gaucugacca uug 23

<210> 707
<211> 23
<212> DNA
<213> Homo sapiens

<400> 707
caatggtcag atcttcaaaa taa 23

<210> 708
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 708
 auggucagau cuucaaaaaua a 21

<210> 709
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 709
 uuauuuugaa gaucugacca uug 23

<210> 710
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 710
 caatggtcag atcttcaaaa taa 23

<210> 711
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 711
 caugugcaca uugaaaacug u 21

<210> 712
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 712
 acaguuuua augugcacau gcg 23

<210> 713
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 713
 cgcatgtgca cattgaaaac tgt 23

<210> 714

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 714
 auucaaacu gaauauucu a 21

 <210> 715
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 715
 uaagaauuu caaguuugaa uga 23

 <210> 716
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 716
 tcatccaac ttgaatattc tta 23

 <210> 717
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 717
 cauggcaca uugaaaacug u 21

 <210> 718
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 718
 acaguuuua augugcaca gcg 23

 <210> 719
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 719
cgcatgtgca cattgaaaac tgt 23

<210> 720
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 720
auggucagau cuucaaaaaua a 21

<210> 721
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 721
uuauuuugaa gaucugacca uug 23

<210> 722
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 722
uugugucaaa auguucuaca u 21

<210> 723
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 723
auguagaaca uuuugacaca aaa 23

<210> 724
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 724
auggucagau cuucaaaaaua a 21

<210> 725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 725
uuauuuugaa gaucugacca uug 23

<210> 726
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 726
uugugucaaa auguucuaca u 21

<210> 727
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 727
auguagaaca uuuugacaca aaa 23

<210> 728
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 728
auggucagau cuucaaaaaua a 21

<210> 729
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 729

uuauuuugaa gaucugacca uug

23

<210> 730

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 730

caugugcaca uugaaaacug u

21

<210> 731

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 731

acaguuuuca augugcacau gcg

23

<210> 732

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 732

aaccagaugu uuuccaccaa a

21

<210> 733

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 733

uuugguggaa aacaucuggu uuu

23

<210> 734

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 734 auggucagau cuucaaaaaua a	21
<210> 735 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 735 uuauuuugaa gaucugacca uug	23
<210> 736 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 736 aauggucaga ucucaaaaau a	21
<210> 737 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 737 uauuuugaag aucugaccu ugg	23
<210> 738 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 738 auggucagau cuucaaaaaua a	21
<210> 739 <211> 23 <212> RNA <213> Artificial Sequence	
<220>	

<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 739	
uuauuuugaa gaucugacca uug	23
<210> 740	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 740	
uugugucaaa auguucuaca u	21
<210> 741	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 741	
auguagaaca uuuugacaca aaa	23
<210> 742	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 742	
uugugucaaa auguucuaca u	21
<210> 743	
<211> 23	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 743	
auguagaaca uuuugacaca aaa	23
<210> 744	
<211> 21	
<212> RNA	
<213> Artificial Sequence	

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 744
 gcuaaggaagu auucauucaa a 21

 <210> 745
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 745
 uuugaaugaa uacuuccuag cua 23

 <210> 746
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 746
 uugugucaaa auguucuaca u 21

 <210> 747
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 747
 auguagaaca uuuugacaca aaa 23

 <210> 748
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 748
 caugugcaca uugaaaacug u 21

 <210> 749
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 749
 acaguuuua augugcaca gcg 23

 <210> 750
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 750
 uuguguaaa auguucuaca u 21

 <210> 751
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 751
 auguagaaca uuugacaca aaa 23

 <210> 752
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 752
 uggucagauc uucaaaaaua a 21

 <210> 753
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 753
 uuuaauuuga agaucugacc auu 23

 <210> 754
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 754
 uugugucaaa auguucuaca u 21

<210> 755
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 755
 auguagaaca uuuugacaca aaa 23

<210> 756
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 756
 uugugucaaa auguucuaca u 21

<210> 757
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 757
 auguagaaca uuuugacaca aaa 23

<210> 758
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 758
 caauggucag aucuucaaaa u 21

<210> 759
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 759
 auuuugaaga ucugaccau ggc 23

 <210> 760
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 760
 uugugucaaa auguucuaca u 21

 <210> 761
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 761
 auguagaaca uuuugacaca aaa 23

 <210> 762
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 762
 auggucagau cuucaaaaaua a 21

 <210> 763
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 763
 uuauuuugaa gaucugacca uug 23

 <210> 764

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 764
 auggucagau cuucaaaaaua a 21

 <210> 765
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 765
 uuauuuugaa gaucugacca uug 23

 <210> 766
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 766
 ggucagaucu ucaaaaauaaa a 21

 <210> 767
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 767
 uuuuuuuug aagaucugac cau 23

 <210> 768
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 768
 uugugucaaa auguucuaca u 21

<210> 769 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 769 auguagaaca uuuugacaca aaa	23
<210> 770 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 770 auggucagau cuucaaaaaua a	21
<210> 771 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 771 uuauuuugaa gaucugacca uug	23
<210> 772 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 772 auggucagau cuucaaaaaua a	21
<210> 773 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 773 uuauuuugaa gaucugacca uug	23

<210> 774
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 774
 uugugucaaa auguucuaca u 21

<210> 775
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 775
 auguagaaca uuuugacaca aaa 23

<210> 776
 <211> 20
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 776
 uugugucaaa auguucuaca 20

<210> 777
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 777
 auguagaaca uuuugacaca aaa 23

<210> 778
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 778
 uugugucaaa auguucuaca u 21

<210> 779
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 779
 auguagaaca uuuugacaca aaa 23

 <210> 780
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 780
 auggucagau cuucaaaaaua a 21

 <210> 781
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 781
 uuauuuugaa gaucugacca uug 23

 <210> 782
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 782
 cauggcaca uugaaaacug u 21

 <210> 783
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 783

acaguuuuca augugcaca u gcg 23

<210> 784
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 784
uugugucaaa auguucuaca u 21

<210> 785
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 785
auguagaaca uuuugacaca aaa 23

<210> 786
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 786
ucaaacuuga auauucuua a 21

<210> 787
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 787
uugaagaaua uucaaguug aa u 23

<210> 788
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 788
uugugucaaa auguucuaca u 21

<210> 789
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 789
auguagaaca uuuugacaca aaa 23

<210> 790
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 790
caugugcaca uugaaaacug u 21

<210> 791
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 791
acaguuuua augugcacau gcg 23

<210> 792
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 792
caugugcaca uugaaaacug u 21

<210> 793
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 793
acaguuuua augugacau gcg 23

<210> 794
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 794
uucuucaaa cuugaauuu a 21

<210> 795
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 795
uaauuucaa guuugaauga aua 23

<210> 796
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 796
caugucaca uugaaaacug u 21

<210> 797
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 797
acaguuuua augugacau gcg 23

<210> 798
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 798
uugugucaaa auguucuaca u 21

<210> 799
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 799
auguagaaca uuuugacaca aaa 23

<210> 800
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 800
uugugucaaa auguucuaca u 21

<210> 801
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 801
auguagaaca uuuugacaca aaa 23

<210> 802
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 802
caugugcaca uugaaaacug u 21

<210> 803
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 803 acaguuuuca augugcacau gcg	23
<210> 804 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 804 ugugucaaaa uguucuacau u	21
<210> 805 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 805 aauguagaac auuuugacac aaa	23
<210> 806 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 806 caugugcaca uugaaaacug u	21
<210> 807 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 807 acaguuuuca augugcacau gcg	23
<210> 808 <211> 21 <212> RNA <213> Artificial Sequence	
<220>	

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 808
 caugugcaca uugaaaacug u 21

<210> 809
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 809
 acaguuuuca augugcacau gcg 23

<210> 810
 <211> 20
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 810
 auggucagau cuucaaaaaua 20

<210> 811
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 811
 uuauuuugaa gaucugacca uug 23

<210> 812
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 812
 auggucagau cuucaaaaaua a 21

<210> 813
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 813 uuauuuugaa gaucugacca uug	23
<210> 814 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 814 uugugucaaa auguucuaca u	21
<210> 815 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 815 auguagaaca uuuugacaca aaa	23
<210> 816 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 816 uugugucaaa auguucuaca u	21
<210> 817 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 817 auguagaaca uuuugacaca aaa	23
<210> 818 <211> 21 <212> RNA <213> Artificial Sequence	

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 818
 agcuaggaag uauucauuc a 21

 <210> 819
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 819
 uugaaugaau acuuccuagc uau 23

 <210> 820
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 820
 cauggcaca uugaaaacug u 21

 <210> 821
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 821
 acaguuuua augugcacau gcg 23

 <210> 822
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 822
 cauggcaca uugaaaacug u 21

 <210> 823
 <211> 23
 <212> RNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 823
 acaguuuua augugcaca gcg 23

<210> 824
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 824
 cuaggaagua uucauucaaa a 21

<210> 825
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 825
 uuuugaauga auacuuccua gcu 23

<210> 826
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 826
 uucaaacuug aauauucuuc a 21

<210> 827
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 827
 ugaagaauau ucaaguuuga aug 23

<210> 828
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 828
 auggucagau cuucaaaaaua a 21

 <210> 829
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 829
 uuauuuugaa gaucugacca uug 23

 <210> 830
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 830
 caugugcaca uugaaaacug u 21

 <210> 831
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 831
 acaguuuua augugcacau gcg 23

 <210> 832
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 832
 auggucagau cuucaaaaaua a 21

 <210> 833

<211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 833
 uuauutugaa gaucugacca uug 23

 <210> 834
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 834
 auggucagau cuucaaaaaua a 21

 <210> 835
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 835
 uuauuuugaa gaucugacca uug 23

 <210> 836
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 836
 aauagcuagg aaguauucau u 21

 <210> 837
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 837
aaugaauacu uccuagcuau uua 23

<210> 838
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 838
aguauucauu caaacuugaa u 21

<210> 839
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 839
auucaaguuu gaaugaauac uuc 23

<210> 840
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 840
aggaaguauu cauucaaacu u 21

<210> 841
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 841
aaguuugaau gaauacuucc uag 23

<210> 842
<211> 20
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 842

caugugcaca uugaaaacug

20

<210> 843

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 843

acaguuuuca augugcacau gcg

23

<210> 844

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 844

caugugcaca uugaaaacug u

21

<210> 845

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 845

acaguutuca augugcacau gcg

23

<210> 846

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 846

ggcuaaaauag cuaggaagua u

21

<210> 847

<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 847
 auacuuccua gcuaauuagc cuu 23

 <210> 848
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 848
 aaguauucau ucaaacuuga a 21

 <210> 849
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 849
 uucaaguuug aaugaauacu ucc 23

 <210> 850
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 850
 aaucuaagg cuaaauagcu a 21

 <210> 851
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 851
 uagcuauuua gccuuagaau ucu 23

 <210> 852

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 852
 uugaauauuc uucaaagaga a 21

 <210> 853
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 853
 uucucuuuga agaauauuca agu 23

 <210> 854
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 854
 uagcuaggaa guauucauuc a 21

 <210> 855
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 855
 ugaaugaaua cuuccuagcu auu 23

 <210> 856
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 856
 aacuugaaua uucuucaaag a 21

<210> 857
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 857
 ucuuugaaga auauucaagu uug 23

 <210> 858
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 858
 gaauucuaag gcuaaaauagc u 21

 <210> 859
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 859
 agcuauuuag ccuuagaauu cug 23

 <210> 860
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 860
 auggucagau cuucaaaaaua a 21

 <210> 861
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 861
uuauuutgaa gaucugacca uug 23

<210> 862
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 862
auagcuagga aguauucauu a 21

<210> 863
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 863
uaaugaauc uuccuagcua uuu 23

<210> 864
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 864
caugugcaca uugaaaacug u 21

<210> 865
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 865
acagutuuca augugcacau gcg 23

<210> 866
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 866
 caugugcaca uugaaaacug u 21

 <210> 867
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 867
 acaguuutca augugcacau gcg 23

 <210> 868
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 868
 caugugcaca uugaaaacug u 21

 <210> 869
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 869
 acaguutuca augugcacau gcg 23

 <210> 870
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 870
 auucauucaa acuugaauau u 21

 <210> 871
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 871
 aauauucaag uuugaaugaa uac 23

 <210> 872
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 872
 acuugaauau ucuucaaaga a 21

 <210> 873
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 873
 uucuuugaag aauauucaag uuu 23

 <210> 874
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 874
 auggucagau cuucaaaaaua a 21

 <210> 875
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"	
<400> 875 uuauuutgaa gaucugacca uug	23
<210> 876 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 876 augugcacau ugaaaacugu a	21
<210> 877 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 877 uacaguuuuc aaugugcaca ugc	23
<210> 878 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 878 auggucagau cuucaaaaaua a	21
<210> 879 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 879 uuauuuugaa gaucugacca uug	23

<210> 880
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 880
 auggucagau cuucaaaaaua a 21

 <210> 881
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 881
 uuauuuugaa gaucugacca uug 23

 <210> 882
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 882
 caugucaca uugaaaacug u 21

 <210> 883
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 883
 acaguuuua augugacau gcg 23

 <210> 884
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 884

auucaaaacuu gaauauucuu a 21

<210> 885
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 885
uaagaauauu caaguugaa uga 23

<210> 886
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 886
caugugcaca uugaaaacug u 21

<210> 887
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 887
acaguuuua augugcaca u gcg 23

<210> 888

<400> 888
000

<210> 889
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 889
ccgaagaaac gugcauucua a 21

<210> 890
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 890
 uuagaaugca cguuucuucg gga 23

 <210> 891
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 891
 gugucaaaau uuucuacauu a 21

 <210> 892
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 892
 uaauguagaa aauuuugaca caa 23

 <210> 893
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 893
 ccgaagaaac gugcauucua a 21

 <210> 894
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 894
 uuagaaugca cguuucuucg gga 23

 <210> 895
 <211> 21
 <212> RNA

<213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 895
 gugucaaaau uuucuacauu a 21

<210> 896
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 896
 uaauguagaa aauuuugaca caa 23

<210> 897
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 897
 ggucagaucu ucaaaaauaaa u 21

<210> 898
 <211> 23
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 898
 auuuuuuuug aagaucugac cgg 23

<210> 899
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"
 <400> 899
 auggucagau cuucaaaaaua a 21

<210> 900
 <211> 23

<212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 900
 uuauuutgaa gaucugacca uug 23

<210> 901
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 901
 caugugcaca uugaaaacug u 21

<210> 902
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 902
 acaguutuca augugcacau gcg 23

<210> 903
 <211> 16
 <212> PRT
 <213> Unknown

 <220>
 <221> source
 <223> /note="Description of Unknown:
 RFGF peptide"

 <400> 903
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

<210> 904
 <211> 11
 <212> PRT
 <213> Unknown

<220>

<221> source

<223> /note="Description of Unknown:
RFGF analogue peptide"

<400> 904

Ala Ala Leu Leu Pro Val Leu Leu Ala Ala Pro
1 5 10

<210> 905

<211> 13

<212> PRT

<213> Human immunodeficiency virus

<400> 905

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
1 5 10

<210> 906

<211> 16

<212> PRT

<213> Drosophila sp.

<400> 906

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15